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ABSTRACT 
 
 
 
Artemisinin-based combination therapy (ACT) is currently the most effective treatment 
strategy against Plasmodium falciparum malaria. There have been reports from Southeast 
Asia of parasite resistance to artemisinin and its derivatives, and there are fears that resistance 
to this class of drugs will spread to Africa. Artemisinin resistance is recognised by a 
relatively slow parasite clearance rate in patients receiving an ACT or artemisinin. In-vitro 
or ex-vivo methods are conventionally used to determine the EC50 value – the effective 
concentration of drug that inhibits parasite growth by 50% for parasite lines in the laboratory. 
To date, there have been no consistent correlations between the estimated in-vivo half-life 
of P. falciparum treated with artemisinin in-vivo and in-vitro EC50 estimates from standard 
48hr artemisinin susceptibility assays. 
 
This study investigates alternative methods of assaying artemisinin resistance by in 
vitro exposure to dihydroartemisin (DHA) - the major metabolite of all artemisinins. DHA 
has a short half-life (1-2hr) in-vivo and so short drug pulses were applied to parasites in an 
effort to better mimic in-vivo conditions. A 6hr drug pulse assay and a standard 48hr assay 
were used to observe any differences that may exist in EC50 values among field isolates from 
Kenya (HL1204), Ghana (HL1210) and Nigeria (HL1212).  In all three isolates tested, the 
mean DHA EC50 values for the 6hr pulse assays were higher than estimates from standard 
48hr assays. This trend was seen as an elevated EC50 value in the dose response curve, 
allowing discrimination of DHA  EC50 6hr values among the isolates. Field isolates from 
Ghana (6 fold higher than 3D7 lab strain) and Nigeria (3.4 fold higher) showed elevated 
mean DHA EC50 6hr value compared to that from Kenya (1.7 fold higher than 3D7). 
 
When this assay was applied to parasites from Cambodia with known PfK13-
determined artemisinin resistance, an elevated EC50 value in the 6hr pulse assay was again 
observed, but discrimination between Cambodian resistant and sensitive isolates was not 
achieved. We present results from a new DHA in vitro susceptibility assay format we have 
devised to overcome this problem. Experiments suggest this format can identify both PfK13-
dependent Asian phenotypes and PfK13-independent phenotypes in African parasites. 
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Susceptibility to partner drugs lumefantrine and piperaquine was assessed with standard 48hr 
assays for all isolates. 
 
The genetic basis of the susceptibility phenotypes observed was explored by whole 
genome sequencing for each African isolate. Mutations present in 11 genes of interests for 
drug resistance loci were identified. As these isolates are multiclonal, all haplotypes present 
in selected genes of interests for every isolate were described. Implications of this work for 
continuing studies of parasite susceptibility of ACT in Africa are considered. This includes a 
new method that can be used to monitor and control the spread of drug resistance on the 
African continent.  
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1.1 Malaria: A brief history 
Malaria is one of the world’s most deadly diseases affecting approximately 5% of the world’s 
population. Although the disease has been eradicated in most temperate regions, it continues 
to be endemic throughout much of the tropics and subtropics. In 2015, 95 countries and 
territories had ongoing malaria transmission and it was estimated that about 3.2 billion people 
are at risk of malaria (WHO, 2015).  
Malaria is a highly preventable and treatable disease with children and pregnant women 
bearing the greatest burden. However, increased efforts are reducing the burden of the 
disease. Between the year 2000 and 2015, it was estimated that the incidence of malaria 
amongst at risk populations fell by 37% globally and the death rate among at risk populations 
fell by 65% globally amongst children under the ages of 5 and by 60% among all age groups 
(WHO, 2015). At present 90% of cases and deaths occur in Africa (Figure 1.1) and 85% of 
malaria-related deaths occur in children under 5 years of age. According to the WHO, malaria 
is both a disease of poverty and a cause of poverty (www.who.com) 
 
 
 
 
Figure 1.1 Areas at risk of Plasmodium falciparum malaria transmission in 2013. 
Graph shows percentage population at risk (World malaria report, 2013). 
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Malaria has been described since antiquity and Hippocrates, amongst occidental writers, is 
usually accredited with the first clear description. He differentiated patterns of fever in 
epidemics and he described the regular paroxysms of intermittent in his aphorisms. Seasonal 
periodic fevers were particularly common in marshy areas of Europe and were often referred 
to as ‘paludial’ (Bruce-Chwatt, 1988). Italian writers thought malaria was caused by the 
offensive vapours emanating from the tiberian marshes. The cause of the seasonal periodic 
fevers remained a continuous source of debate until the late nineteenth century. The work of 
Meckel, Frerich and Virchow showed that the pigment observed in the blood of some patients 
that had periodic fever resulted from the destruction of red blood corpuscles. The same 
pigment was also found to cause the characteristic grey discolouration of the internal organs 
in patients that were dying from the disease (Foster et al., 1965).  In 1880, Charles Alphonse 
Laveran identified moving bodies whilst examining the blood of a patient with ague and he 
deduced correctly these were parasites of red blood cells (Laveran, 1880). The 
transmissibility of the infection in blood was proven by Gerhardt four years later and, by the 
next decades the route of natural infection was discovered (Bruce-Chwatt, 1988). 
 
In 1897, Ronald Ross started investigating the possibility that malaria could be transmitted by 
mosquitoes. He then reported the presence of pigmented bodies in the gut of a species of 
mosquito after many months of failure. This mosquito had fed on patients with malaria so he 
suggested the pigmented bodies might represent the parasite stage in the mosquito. After 
many years of study, Ross characterized the complete lifecycle. He also identified the 
anopheles mosquito as the vector of human malaria (Ross, 1897). Both Ross and Laveran 
received Nobel Prizes for their respective discoveries in malaria. 
 
The understanding of the biology of malaria was further advanced by the Viennese 
psychiatrist Julius Wagner-Jauregg, who won the third Nobel Prize for his discovery. He 
became interested in the relationship between fever and mental illness and, between 1888 and 
1917 he experimented on a few methods to induce fever to treat patients with general 
paralysis of the insane, which is a form of neurosyphilis. In 1917, he inoculated blood from a 
malaria infected soldier into two patients that had neurosyphillis and from then on, began the 
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era of malaria therapy of neurosyphillis. This therapy became the standard practice for 
treating neurosyphllis all over the world until the introduction of penicillin thirty years later 
(Bruce-Chwatt, 1988). 
 
Until the 19
th
 century, Malaria was found in northern Europe, North America and Russia. 
There was also intense transmission in South America. It has been eradicated from many of 
these areas since then and the number of cases in China, India and the Middle East has 
significantly reduced (Bruce-Chwatt, 1988). However, in Africa, malaria continues with 
much morbidity and mortality. In recent times, due to interventions like insecticide treated 
bed nets and indoor residual spraying, coupled with effective case management, morbidity 
and mortality of malaria have been significantly reduced.  
 
 
1.2 Phylogeny 
 
Malaria is caused by protozoan parasites of the genus Plasmodium, which are inoculated into 
humans by biting female Anopheles mosquitoes. There are six known human malaria 
parasites namely Plasmodium falciparum, Plasmodium vivax, Plasmodium malariaie, 
Plasmodium ovalecurtisi, Plasmodium ovale wallikeri, and Plasmodium knowlesi (Singh et 
al., 2004; Cox-Singh et al., 2008; Sutherland et al., 2010; WHO 2013c). Of all the strains, P. 
falciparum is the most virulent causing about 85% of all malaria cases in humans and almost 
all mortality (Rich et al., 2009). It has been suggested that the relative pathogenicity of P. 
falciparum is as a result of recently being acquired by transfer from a non-human host (Rich 
et al., 2009). Molecular phylogenies carried out a few years ago, were consistent with this 
hypothesis as they showed that P. falciparum was more closely related to Plasmodium 
gallinaceum, a chicken parasite, than it was to other human parasite species (Waters et al., 
1991). A considered explanation was that P. falciparum evolved from an avian parasite 
through a horizontal transfer, probably through the Neolithic domestication of chickens (Rich 
et al., 2009). However, with the increasing availability of genomic DNA sequence data, the 
closest relative of P. falciparum was shown to be P. reichenowi, a malaria parasite found in 
chimpanzees which was not included in earlier studies (Escalante and Ayala, 1994).  
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There are differences in the morphology, immunology and geographic distribution of these 
species. There are also differences in drug response and the ability to relapse (Greenwood et 
al. 2005). 
 
 
1.3 Geographical aspects 
 
 
1.3.1 Distribution 
 
Malaria was eradicated in the United States in the 1940s after widespread spraying of 
dichlorodiphenyltrichloroethane. Europe, Central and South America and other parts of the 
world have been successful in eradicating malaria but the tropics still bear the burden. P. 
falciparum is common in areas like Africa, Haiti, and Papua New Guinea while P. vivax is 
predominant in North Africa, the Middle East, central and parts of South America and the 
Indian subcontinent. In South America, Oceania and East Asia, the prevalence of both species 
is approximately equal. P. vivax is very rare in sub-Saharan Africa while P. ovale spp. are 
uncommon outside the tropical belt of Africa. P. malariae is less common outside Africa but 
is found in most areas. In China and neighbouring countries, P. vivax strains are very much 
present with long incubation periods (White, 2011). 
 
1.3.2 The vector 
 
Certain species of Anopheline mosquitoes are responsible for the transmission of malaria. 
Transmission does not occur at temperatures below 16ºC or above 33ºC, it also doesn’t occur 
at altitudes greater than 2000m above sea level. This is because development in the mosquito 
(sporogony) cannot take place. High humidity and an ambient temperature between 20ºC and 
30ºC are optimum conditions for transmission to take place. Rainfall provides mosquitoes 
with breeding sites but also, too much rainfall may wash mosquito larvae and pupae away 
(Gillies et al., 1998). 
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Malaria epidemiology may vary considerably even within small geographic areas. The 
transmission of malaria to humans is dependent on many interrelated factors but the most 
important concerns the anopheline mosquito vector and its longevity. The development of the 
sporozoite parasites in the vector (sporogony) takes over a week and this is dependent on 
ambient temperature. If malaria is to be transmitted, the mosquito must survive for longer 
than this after feeding on a gametocyte-carrying human (Mollineaux et al., 1988). 
 
 
1.4 The human host 
 
There has to be an accessible human reservoir of viable gametocytes to transmit malaria 
infection. As a result, the behaviour of humans also plays an important role in malaria 
epidemiology. Infants and young children are more susceptible to malaria in areas of high 
transmission rates than the more immune older children and adults. In these areas, the 
densities of parasites are higher and the presence of gametocytes in the blood of children is 
detected more frequently. Traditionally, the endemicity of malaria has been defined in terms 
of the spleen rates or the rate of parasite clearance in children aged between 2 and 9 years 
(Mollineaux et al., 1988). 
Areas like tropical Africa or coastal New Guinea are holoendemic or hyperendemic for P. 
falciparum and people are repeatedly infected throughout their lives. A lot of morbidity and 
mortality occurs during childhood. For example, in the Gambia, where people were infected 
once each year on average, which is a relatively low figure for the African continent (Marsh 
K et al., 1999), malaria has been estimated to cause 25% of deaths in children between 1 and 
4 years of age (Greenwood et al, 1987). If the child survives eventually, a state of 
‘premunition’ is achieved where infections cause little or no problems in the (Baird et al., 
1991; Perignon & Druilhe, 1994). This means a form of immunity develops which becomes 
sufficient enough to control the infection but not to prevent it. Premunition occurs at a slow 
rate and acquisition of this state is age dependent. Non- immune adults entering an area of 
intense transmission acquire premunition much faster than children (Aponte et al., 2007; 
Baird et al., 1991). 
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1.5 Life cycle 
 
The life cycle of Plasmodium falciparum is a complex one that involves transmission 
between a mosquito vector and a human host, and sexual and asexual stages of development 
(Fig 1.2). The injection of haploid sporozoites into the human host by an infected female 
Anopheles mosquito during a blood meal begins the lifecycle. Sporozoites are motile forms 
of the parasite which gain access to the liver through the blood stream. In the liver, it 
undergoes asexual multiplication that results in tens of thousands of merozoites. This pre-
erythrocytic parasite development stage is short and the release of merozoites from the 
hepatocyte (hepatic stage) to the bloodstream occurs after 6-8 days (Hermsen et al., 2004) 
where red blood cell (erythrocytes) invasion occurs. Once merozoites are in the erythrocyte 
(erythrocytic stage), P. falciparum develops into a ring stage, a trophozoite stage which has 
high metabolic activity and finally, into schizonts where asexual replication occurs. In the 
schizont, new merozoites are formed and released into the blood stream when erythrocytes 
erupt. This is the stage where the clinical symptoms of malaria (e.g. fever) are manifested. 
Free merozoites go on to invade new erythrocytes which then develop into schizonts and 
continue the asexual life cycle. However, a fraction of released merozoites produce sexual 
gametocytes, which are the forms transmitted from humans to the mosquito. This occurs after 
differentiation into haploid male and female gametocytes occur. Gametocyte maturation in P. 
falciparum occurs in the bone marrow and requires 10-12 days (Eichner et al., 2001) and 
mature gametocytes (stage V) appear and persist in the peripheral blood with a mean 
circulation time of 3.4-6.5 days per gametocyte (Eichner et al., 2001; Bousema et al., 2010). 
Immature gametocytes (stages I-IV) sequester in the bone marrow (Drakeley et al., 2006). 
 
When a human host is bitten by a female anopheline mosquito, the macro and micro 
gametocytes are taken up during a blood meal. Gametocytes develop into gametes and sexual 
reproduction occurs in the midgut of the mosquito. These forms are motile and long lived and 
the process (gametocytogenesis) takes about 7-10 days in P. falciparum. The male 
gametocyte undergoes rapid nuclear division and each of the nuclei formed is associated with 
a flagellum that is approximately 20-25um long. Fusion and meiosis (sexual reproduction) 
takes place after the motile male microgamete seeks the female macrogametes (Read et al, 
1992). This sexual reproduction stage is diploid and allows recombination of genetic material 
to take place. The diploid zygote matures into an ookinete and then develops in an oocyst 
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after penetrating the midgut epithelium cell wall (Fig 1.2). Each oocyst produces haploid 
sporozoites that migrate to the salivary gland of the mosquito to await inoculation into the 
next human host during a blood meal thereby completing the life cycle. The development of 
the parasite in the mosquito is known as sporogony and this usually takes between 8 and 35 
days depending on the species of mosquito and parasite and also the ambient temperature. 
(Stone et al., 2013; Miurhead-Thomas, 1954). 
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Figure 1.2 The life cycle of P. falciparum (adapted from (Rosenthal 2008). The 
parasite cycle involves both an anopheline mosquito and a human host with sexual 
reproduction taking place in the mosquito and asexual reproduction takes place in the 
human host. 
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1.6 Genetic complexity of P. falciparum infections 
 
1.6.1 Estimation of multiplicity of infection (MOI) 
 
In malaria endemic areas, MOI can be a useful indicator of the transmission level, where the 
latter is positively correlated with the average number of malaria parasite strains in an 
individual (Babiker et al., 1994). The merozoite surface proteins (MSPs (MSP1, MSP2) in 
plasmodium falciparum are involved in invasion of erythrocytes. Genotyping of the MSP1 
and MSP2 genes is a method used to asses MOI in P. falciaprum because both genes are 
highly polymorphic in sequence and in length (Ntoumi et al., 1995). MSP genotyping can 
distinguish between infections and clones by detecting the presence of different alleles at a 
polymorphic marker (Snounou et al., 1999). 
 
Malaria clinical isolates are made up of a mixture of different parasite strains (and species) in 
the form of multiple haploid clones. An individual can simultaneously be parasitized by many 
genetically distinct infections and the multiplicity of such infections in a host may be related 
to malaria endemicity, the risk of clinical malaria and the degree of immunity against P. 
falciparum. Different parasite clones may vary significantly in immune-avoidance 
mechanisms, immunogenicity, and drug susceptibility (Meyer et al., 2002; Nsobya et al., 
2008). 
 
1.6.2 Genetics of Plasmodium 
 
In the human host, the malaria parasite is haploid and an individual may be infected with a 
multiplicity of genetically diverse clones (Barbiker et al., 1994). The zygote (ookinete) phase 
is the only diploid phase in the parasite lifecycle and is produced through fertilization of the 
micro and macro gamete in the midgut. After zygote formation, meiosis occurs rapidly which 
gives rise to haploid nuclei in the ookinete. In eukaryotic organisms, meiosis creates diversity 
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by genetic recombination, gene re-assortment on different chromosomes and by cross-over 
events.   
During mosquito tranmission, the gametes of a single haploid parasite clone taken up in the 
mosquito midgut undergoes self-mating to produce homozygous zygotes which contain 
identical alleles at all loci (Freitas-Junior et al., 2000). Heterozygotes are expected if 
gametocytes of two or more genetically distinct clones are taken up into the mosquito and 
then a cross over event or selfing event occurs amongst gametes. This recombination (during 
meiosis) gives rise to parasites with novel gene combination among the haploid progeny 
(Babiker et al., 1993; Walliker et al., 1987). 
1.6.2 Genetic recombination 
 
Figure 1.3: The process of genetic recombination in malaria parasites when 2 clones 
undergo cross-mating in mosquitoes. A and a are alleles of one gene, and B and b are 
alleles of a second gene. One parent clone has genotype AB and the other ab; both produce 
gametocytes, capable of infecting mosquitoes, between which mating occur. 
Recombinants Ab and aB are produced following meiosis of diploid zygotes AaBb (Beale 
et al., 1978; Walliker et al., 1987; Babiker et al., 1999). The diagram was drawn from 
findings from the three published papers. 
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1.7 Antimalarial drugs 
 
1.7.1 Quinine 
 
Quinine is an alkaloid which was first isolated by French chemists Pierre Pelletier and Joseph 
Caventou in 1820 (Greenwood 1992; Meshnick and Dobson, 2001). It was isolated from the 
bark of a cinchona tree and has been used in Western medicine since the early 17
th
 century 
for its medical properties, together with related alkaloids (WHO 1986; Meshnick and Dobson 
2001). 
The need to treat soldiers infected with malaria during World War I gave rise to chemical 
research on antimalarial compounds and resulted in the synthesis of quinine. In 1920, 
Plasmoquine (8-aminoquinoline pamaquine) was the first drug synthesized; it was active 
against the liver stage parasites (hypnozoites) of P. ovale and P. vivax infections but use was 
discontinued as it was found to be very toxic (Greenwood, 1995; Sa et al., 2011). 
Quinine has a half-life range of 11-18 hours and is active against the Schizont stage of 
malaria parasites (Jamaludin et al, 1988). It was used to treat severe malaria until research 
published from the AQUAMAT and SEAQUAMAT study trials showed that the use of 
artesunate was effective in treating severe malaria (Dondorp et al., 2010). Quinine was later 
replaced with artesunate for treatment of severe malaria under the recommendation of the 
WHO, although the use of quinine is recommended in places where artesunate is unavailable 
(WHO 2010). 
 
1.7.2 Chloroquine (CQ) 
 
A 4- aminoquinoline compound called resoquine was developed in Germany in 1934 but was 
not used due to concerns about toxicity (Loeb, 1946). The interest in resoquine was later 
sparked during World War II when a modified compound, santoquine, was captured from the 
Germans. In 1946, resoquine was renamed to chloroquine (Loeb, 1946) and is one of the 
most successful drugs ever produced. Chloroquine was the most widely used antimalarial 
drug until recently. It is easy to administer, inexpensive and well tolerated and kills all blood 
stages of malaria parasite (WHO 1986, Meshnick and Dobson 2001; Sa et al., 2011). In the 
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1990s, its use was replaced with other regimens as a result of parasite resistance (White, 
1998), which is thought to have led to the increase in disease burden on the African continent 
in the 1980s (Trape et al., 1998).  
Chloroquine works by interfering with hematin detoxification of plasmodium, which is a 
toxic by-product of haemoglobin degradation in the food vacuole of Plasmodium. 
Chloroquine is no longer recommended for the treatment of P. falciparum however, it is still 
used to treat infections caused by P.vivax and P.ovale which are less severe forms of malaria 
(Ratcliffe et al., 2007). It is recommended for P.vivax infections in combination with 
primaquine due to the fact that resistance has not fully developed (Price et al., 2009; WHO 
2010). 
 
1.7.3 Amodiaquine 
 
American scientists carried out a screening programme of antimalarials which led to the 
discovery of amodiaquine, a synthetic 4-aminoquinoline (Greenwood, 1995), but its use was 
discontinued after reports of long term prophylaxis side effects like hepatotoxicity (Ringwald 
et al, 1998; Taylor and White, 2004). It is highly efficacious in treating cases involving 
chloroquine resistance and was very potent in some African countries where chloroquine had 
failed. Although it is more active than chloroquine, it rapidly metabolizes to 
desethylamodiaquine and shows cross resistance to chloroquine. 
Currently, amodiaquine is used in combination with artesunate as first line treatment of 
uncomplicated P.falciparum because the side effects do not occur when shorter treatment 
courses are given (Olliaro et al., 1996). 
 
1.7.4 Pyronaridine 
 
Pyronaridine has been used to treat malaria in China for more than 30 years (Croft et al., 
2012). It was first synthesized in the Chinese Institute of Parasitic Diseases in 1970 (Zheng et 
al., 1979) and has a similar structure to chloroquine. It is active against erythrocytic stages of 
P. falciparum (Ringwald et al., 1996; Vivas et al., 2008) and has been shown in clinical 
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studies to be less toxic when compared to chloroquine (Chang et al., 1992). In cases of 
chloroquine resistance, pyronaridine is highly effective (Ringwald et al., 1996) and is 
combined with artesunate in the treatment of uncomplicated P.falciparum malaria (Croft et 
al., 2012; Rueangweerayut et al., 2012). 
 
1.7.5 Primaquine 
 
Primaquine was used during the Korean War and is still used today (Greenwood, 1995; Baird 
and Hoffman, 2004). It is used in the treatment of P. vivax and P. ovale hypnozoites and is 
also used as prophylaxis in regions that are endemic (Vale et al., 2009). Primaquine is fully 
effective against all stages of gametocytes and was discovered when an alternative to 
pamaquine was sought after, specifically, an alternative drug that could prevent relapse. 
However, it causes haemolysis in patients who are glucose-6-phosphate dehydrogenase 
(G6PD) enzyme deficient (Howes et al., 2013). According to the WHO, a single low dose of 
primaquine (0.25 mg base/kg) is administered to patients with uncomplicated P. falciparum 
malaria and this dose is effective in patients who have G6PD deficiency (WHO, 2012). 
 
1.7.6 Piperaquine 
 
First synthesized in the 1960s, piperaquine was developed in China where it was used as 
prophylaxis and treatment of malaria (O’Neill et al., 2012). It consists of two 4-
aminoquinoline moieties (bisoquinoline) and is very active against chloroquine resistant 
P.falciparum.  Piperaquine is relatively inexpensive, has low toxicity when compared to the 
other quinolone based compounds and is classified as safe and tolerable (Raynes, 1999; 
O’Neill et al., 2012). It is used as a partner drug in combination therapy (dihydroartemisinin-
piperaquine) by the recommendation of the WHO because it has a long elimination half-life 
(Davis et al., 2005; WHO 2010). Reports of dihydroartemisinin-piperaquine treatment failure 
have emerged (Leang et al., 2013; Saunders et al., 2014; Spring et al., 2015; Amaratunga et 
al., 2016) in Cambodia, Vietnam, China, Mynamar, Thailand and Indonesia, areas where 
artemisinin resistance has emerged and spread (Dondorp et al., 2009; Ariey et al., 2014; 
Ashley et al., 2014; Takala-Harrison et al., 2015). 
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1.7.7 Mefloquine 
 
During the Vietnam War, the United States Army Antimalarial Drug Development Program 
discovered new chemical groups that were used as prototypes to develop new antimalarial 
compounds and mefloquine was one of such (Kitchen et al., 2006). It is a 4- 
quinolinemethanol that was introduced in the mid-1970s (WHO, 1986) but was approved for 
use in 1989 (Shanks, 1994). As a result of its long half-life, it’s used as prophylaxis with 
doses given once a week. It is also used in combination therapy with artesunate as first line 
treatment of uncomplicated P. falciparum (WHO 2010; Biamonte et al., 2013). 
Unfortunately, reports of neurotoxicity and the emergence of drug resistance limits its use 
and so other less toxic and safer antimalarial drug are favoured (Overbosch et al., 2001; 
Croft, 2007). 
 
1.7.8 Lumefantrine 
 
Lumefantrine, previously called benflumetol, was synthesized by the Beijing Academy of 
Military Medical Sciences in the 1970s (Bickii et al., 1998). Earlier studies of the 
combination therapy using artemether and lumefantrine showed both drugs had synergistic 
activity and were highly efficacious (Hassan et al., 1999). The WHO recommended 
artemether-lumefantrine (AL) in combination as the firs fixed-dose artemisinin based 
combination therapy for the treatment of uncomplicated P. falciparum malaria (Nosten and 
white, 2007). It was earlier suggested that since lumefantrine had never been used as 
monotherapy prior to its combination with artemether, there will be a low risk of resistance 
emerging when compared to other drugs used in combination therapies (Premji, 2009). 
However, a recent study has shown artemether-lumefantrine failure in parasites isolates of 
African origin imported into the U.K (Sutherland et al., 2016); although findings would have 
been strengthened if full regimen compliance was observed and if post-treatment 
lumefantrine levels were measured to rule out malabsorption (Laloo et al., 2016). Another 
recent study showed evidence of increasing treatment failure with artemether-lumefantrine 
among malaria patients in Zambia (Cardol et al., 2016). 
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1.7.9 Atovaquone 
 
Atovaquone is a 2-hydroxynapthoquinone currently used in combination with proguanil 
(Meshnick and Dobson, 2001). It is used as prophylaxis in travellers because it readily clears 
liver schizonts, and is used in the treatment of uncomplicated P. falciparum malaria (Hudson, 
1993; Biamonte et al, 2013). 
 
1.7.10 Antifolates 
 
In the early 1950s, British chemists synthesized antifolates which are derivatives of 
pyrimidine targeting the folate metabolism pathway (Schiltzer, 2007). One of such 
compounds is proguanil, which inspired further investigation on antifolates (WHO, 1986; 
Nzila, 2006) and pyrimethamine, a compound active against blood forms of malaria was 
found (Falco et al., 1951). Other examples of antitfolates discovered include sulfadoxine, 
dapsone and sulfone. These drugs are used in combination and have a synergistic effect. 
In 1971, two antifolate compounds, sulfadoxine and pyrimethamine (Fansidar 
TM
) were the 
first available combination therapies. Sulfadoxine-pyrimethamine (SP) is affordable, 
effective, has a good compliance with a long half-life and can be taken in a single dose 
(Basco et al., 1998). SP replaced chloroquine as first line treatment in many countries due to 
the emergence and spread of chloroquine resistance (White, 2004). 
SP was changed as first line treatment of uncomplicated P.falciparum when resistance 
emerged in South America (Gregson and Plowe, 2005), and Southeast Asia (WHO 2001). 
Currently, artemisinin combination therapies (ACTs) are used as first line treatment of 
malaria. As a result, SP in combination with artesunate is recommended (WHO, 2010), 
although SP alone is used in areas where ACT cannot be accessed (Thriemer et al, 2006; 
Mkulama et al., 2008). 
An advantage of SP is that it has a good safety profile and as a result, it is recommended for 
preventative use in pregnant women and in children in Africa. It is also used in intermittent 
preventative therapy (IPT) programmes in areas that  have low drug resistance and moderate 
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to high malaria transmission setting (Peters et al., 2007; WHO, 2013; Beshir et al., 2013). In 
children, SP in combination with amodiaquine is used as seasonal malaria chemoprevention 
(SMC) to reduce mortality caused by malaria infection in the Sahel sub-region of Africa 
(WHO, 2013). 
The combination of pyrimethamine and sulfadoxine, have played a significant role in malaria 
therapy.  However, development of resistance by mutations in dihydrofolate reductase gene 
has compromised the use of pyrimethamine. Likewise, mutations in dihydropteroate synthase 
gene have caused reduced sensitivity to sulfadoxine (Warhurst, 1998). 
 
 
1. 8 Antimalarial drug resistance 
 
Antimalarial drug resistance has been defined as ‘the ability of a parasite strain to survive and 
/or multiply regardless of the administration and absorption of a drug given in doses equal to 
or higher than those usually recommended but within tolerance of the subject’ (Bruce-Chwatt  
et al., 1986). It is usual to also specify that the particular drug in question must be in contact 
with the parasite or the infected red blood cell for the duration of the time necessary for its 
normal action (Bruce-Chwatt et al., 1986; WHO, 2010). This is often interpreted as referring 
only to the parasite’s persistence after treatment doses of an antimalarial rather than failure of 
prophylaxis (Lobel et al., 1986). It is worth mentioning that the definition of drug resistance 
with regards artemisinins has been controversial particularly because of its mode of action. 
This will be discussed further in section 1.9.2 
Antimalarial drug resistance could sometimes be mistaken for failure to clear malarial 
parasiteamia or failure to resolve the disease after treatment with an antimalarial drug. While 
it is true that drug resistance can cause treatment failure, not all treatment failure is as a result 
of drug resistance (Boland, 2001). It is worth mentioning that there are several other factors 
that can contribute to treatment failure including misdiagnosis, poor drug quality, incorrect 
dosing, non-compliance with duration of dosing regimen, poor absorption, and drug 
interactions (Boland, 2001). Each of these factors that contribute to treatment failure may 
enhance development of true drug resistance by increasing the exposure of parasites exposure 
to drug levels thereby increasing the chances of resistant parasites to emerge (White, 1998). 
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Antimalarial drugs are one of the most important tools in the fight against malaria and the 
emergence of drug resistance threatens malaria control and eradication programmes 
especially in Africa. Case in point was the emergence of chloroquine drug resistance in 
Africa in the 1980s, which was considered responsible for the dramatic increase in child 
morbidity and mortality (Trape, 2001). Currently, there have been reports on resistance to 
almost all antimalarial compounds established. In the last few years, ACTs have been used as 
first line treatment for malaria treatment (Dondorp et al., 2011) and there are currently no 
alternative antimalarials with the same level of tolerability and efficacy (WHO, 2013). 
Unfortunately, resistance to ACTs have been reported in areas of South-East Asia and there 
are fears drug resistance will spread to Africa or rise de-novo (Dondorp et al., 2009; Ariey et 
al., 2014; Ashley et al., 2014; Takala-Harrison et al., 2015). This could affect malaria 
eradication and elimination efforts. ACT drug resistance will be discussed in more detail in 
section 1.9.2 
 
1.8.1 Mechanism of malaria resistance 
 
Resistance occurs through mutations that are spontaneous and confer reduced sensitivity to a 
particular drug or class of drugs (Thaithong S, 1983). A single point mutation is needed to 
confer resistance for some drugs while multiple mutations or copy number polymorphisms 
are required for other (White and Pongtavornpinyo, 2003).  
Genetically determined resistance that occurs in a pathogen under drug pressure develops 
through de-novo emergence of new genotype and the subsequent spread of the new genotypes 
through the parasite population. Emergence of de-novo mutation is thought to be independent 
of drug selection pressure and is also thought to be a rare event (White and Pongtavornpinyo, 
2003). Parasites with mutation can survive and expand in numbers in the presence of a drug 
to give rise to gametocyte densities sufficient for subsequent spread through the population 
(Barnes and White, 2005; Hastings, 2006). It is thought that drug pressure gives a selective 
advantage to resistant parasites by increasing their frequency in the population, thereby 
enabling transmission in mosquitoes and subsequently to the human population (Olliaro and 
Taylor, 2004). 
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After genetic recombination (as shown in figure 1.3), which takes place in the mosquito 
through fertilization of mosquito stages, a formation or breakdown of mutagenic resistance 
can take place (Barnes and White, 2005). This occurs if a mosquito infects a host carrying 
multiple parasite genotype or two hosts carrying different gametocyte (Barnes and White, 
2005). Selection occurs in the parasite mutant alleles when antimalarial drug concentration 
are enough to repress susceptible parasites developing or not enough to inhibit new mutants, 
a phenomenon called ‘drug selection’ (White, 1998). The spread of resistance is difficult to 
avoid once drug resistant malaria parasites have emerged. 
 
 
1.9 Resistance to chloroquine and ACT 
 
This section focuses on drug resistance to both chloroquine and ACT as both drugs are of 
interest in the work carried out in this thesis, particularly the latter. This is because the work 
carried out in Chapter 4 used chloroquine (see method section in Chapter 3), and the work 
carried out in both Chapters 4 and 5 made extensive use of dihydro-artemisinin. 
 
1.9.1 Chloroquine resistance 
 
Chloroquine is classified as a diprotic weak base, which moves between the digestive 
vacuole, which is acidic and the extracellular matrix through diffusion. Once in the vacuole, 
protonation of CQ takes place which causes the CQ molecule to become trapped as the 
membranes are not permeable to charged species (Homewood et al., 1972; Ferrari and Cutler, 
1991). CQ accumulation occurs inside the digestive vacuole as a result of the ion-trapping 
(Hawley et al., 1996). CQ binds to haem in the digestive vacuole which then leads to the 
inhibition of haemozoin polymerization, causing an accumulation of toxic free haem, 
membrane damage and oxidative stress in the parasite (Sullivan et al., 1998; Warhust et al., 
2007; Roepe, 2009). 
There has been a history of improper use of chloroquine, despite this; there was 
approximately a 20 year lag between the initial introduction in the 1950s and the eventual 
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spread of resistance (Peters, 1987). As a result, it was suggested that CQ had a complex 
resistant mechanism that involved several genes and multiple mutations (Wernsdorfer, 1991). 
In the 1960s, the first CQ resistant case was reported in South America, specifically, Brazil, 
Venezuela and Columbia followed by reports in Southeast Asia, specifically Kampuchea and 
Thailand (Wernsdorfer, 1991). In the late 1970s, it was reported through epidemiological 
studies that CQ resistance had spread to Africa from Southeast Asia, where its emergence 
was reported in Tanzania and Kenya (Fogh et al, 1979; Campbell et al, 1979). 
When a parasite becomes resistant to CQ, there is reduced accumulation in the digestive 
vacuole compared to a parasite sensitive to CQ (Saliba et al, 1998). As a result, the drug 
concentration in the digestive vacuole is kept below toxic levels (Saliba et al., 1998; Bray et 
al., 2005). Genetic cross studies carried out between Dd2 (CQ resistant) and HB3 (CQ 
sensitive) strains demonstrated that drug resistance occurs due to selection of a mutant pfcrt 
protein (Wellems et al., 1991; Su et al., 1997; Fidock et al., 2000), which is located in the 
parasites digestive vacuole where it can control chloroquine access to haem (Fidock et al., 
2000; Cooper et al., 2002). Pfcrt belongs to the drug transporter superfamily (Martin and 
Kirk, 2004). The function of this protein is not well known however, it was proposed that it 
either allows protonated CQ to leave the digestive vacuole by acting as a channel, or it 
functions as an active transporter protein (Warhurst et al., 2002; Sanchez et al., 2007). 
Linkage studies carried out by Fidock et al., (2000) showed that an association between an 
amino acid substitution of lysine to threonine at position 76 (K76T) causes CQ resistance. 
This mutation results in a loss of positive charge within the channel which alters the 
selectivity of the channel, causing it to transport the positively charged CQ and allowing it 
exit the digest vacuole thereby inhibiting it from its site of action (Warhurst et al, 2002; 
Lehane and Kirk, 2008). 
Other mutations which have different drug resistant phenotypes and different geographic 
distributions also exist in combination with K76T (Bray et al., 2005; Sa et al., 2009). These 
mutations play a compensatory role for the unfavourable changes of the normal function of 
Pfcrt (Hyde, 2007). Parasites that are CQ resistant are classified based on mutation at amino 
acid position 72-76, with mutations CVMNK being a sensitive haplotype, CVIET and 
SVMNT being a resistant haplotype (Cooper et al., 2005; Summers et al., 2012). 
In Africa, CVIET is the most dominant haplotype but it’s also found in South America and 
South East Asia while the  SVMNT haplotype is more dominant in areas like the Philippines 
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(Chen et al., 2005), Papua New Guinea (Mehlotra et al., 2001) and  South America (Fidock 
et al., 2000; Cooper et al., 2005; Gama et al., 2010). 
Other genes have been associated with CQ resistance such as Pfmdr1, a homologue of 
mammalian multidrug resistance gene (mdr1) called P-glycoprotein homolog 1 (Pgh1) (Foote 
et al, 1990). This gene is discussed in more detail in section 1.16.1 
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1.9.2 Artemisinin 
 
Artemisinins are derived from Artemisia annua and have been used in traditional Chinese 
medicine for centuries (Peters, 1987; Hsu, 2006; Cui and Su, 2009). The antimalarial 
properties of artemisinins were discovered by Chinese scientists in 1971 and are well 
established for the treatment of malaria, including drug resistant strains (Meshnick and 
Dobson, 2001).  Through a collaborative effort known as ‘project 523’, the Chinese prepared 
dihydroartemisinin (DHA), artemether and artesunate (generically known as artemisinins) 
and these have had major contribution to the management of malaria (White, 2008).  
Chemically, artemisinin is a sesquiterpene lactone containing a peroxide bridge which is 
believed to be responsible for the drugs mechanism of action. The active metabolite, DHA 
retains the potent activity of the parent compound against the erythrocytic stages of the 
parasite life cycle (Cui and Su, 2009). ART and its derivatives are an important class of 
antimalarials that have a number of advantages over other antimalarial compounds. These 
include its suitability for the treatment of severe malaria and the fact that it can be 
administered through several routes (Dondorp et al., 2010). 
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Figure 1.4: Artemisinin derivatives: Chemical structure of artemisinin, dihydroartemisinin, 
artemether, arteether, artesunate and artemisone. 
 
1.9.2.1 Pharmacological properties 
 
Artemisinins kill nearly all of the asexual stages of a parasite development in the blood 
(Kuile et al., 1993). Artemisinin is active against early and late ring forms, trophozoites, 
schizonts as well as early gametocytes (Krishna et al., 2004). There are debates regarding 
artemisinin antimalarial action and although the endoperoxide bridge lies at the heart of 
antiparasitic activity, the chemical nature of this interaction is not fully understood. Ion- 
dependent alkylation of cellular proteins has been proposed as a likely mode of action 
because cations catalyse in-vitro reactions of some artemisinins, including their 
decomposition in aqueous solutions (Ter Kuile et al., 1993). 
Artemisinins have a broad stage specificity of antimalarial action that has two therapeutic 
consequences. First, the drug kills all young circulating ring-stage parasites in P. falciparum 
infections which give rise to a more rapid parasiteamia reduction compared to other class of 
antimalarials (Hien and White, 1993; White, 1997). Secondly, artemisinins reduce the 
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number of parasites that grow to mature stages and sequester in and block venules and 
capillaries of the host (Krishna et al., 2004). Additionally, an advantage of artemisinin being 
active against early ring forms is that it can interrupt parasite transmission rates at a 
population level because inhibition of early ring forms can inhibit gametocyte development 
(Price et al., 1996). Artemisinin is eliminated by metabolic bi-transformation, predominantly 
by CYP 2B6, to inactive metabolites (Kuile et al., 1993). 
Artemisinin derivatives are administered through various routes. Artemisinin, 
dihydroartemisinin, artemether (Intramuscular injections) and artesunate can be administered 
orally. For severe malaria, artesunate is used intravenously. Artesunate, arteether and 
artemether are metabolized in-vivo into dihydroartemisinin, which is the biologically active 
form of the drug (White, 1999). Artemisinin derivatives are most active against late rings to 
early trophozoite stages of P. falicparum, and they clear parasites faster than any other 
antimalarial medicines (McIntosh et al., 1999; White N, 1999).  
Within a single host, multiple stages may coexist and due to the fact artemisinin derivatives 
have a short half-life, short treatment regimens with artemisinins are inefficient in clearing all 
the parasites (White, 1999). This is why artemisinin monotherapy has very high 
recrudescence rate unless given for 7 days and is recommended that artemisinin derivatives 
be used in conjunction with other antimalarials with longer half-lives such as mefloquine or 
lumefantrine (White, 1998). Artemisinin derivatives are administered in the first day or two 
and rapidly decrease parasite biomass. Then the partner drug e.g. mefloquine is co-
administered because it maintains therapeutic blood concentrations for several days (White, 
1999). This allows the drug to kill the few remaining parasites that escape killing by 
artemisinin derivative. Artemisinin combination therapy (ACT) has an advantage over 
artemisinin monotherapy as it delays the appearance of resistance (White, 2008) 
 
1.9.2.2 Toxicity 
 
 In a prospective study carried out in Thailand, adverse events were rare in 3500 patients 
treated with artemisinin derivatives (oral artesunate) (Price et al., 1999). The drug was 
reported to be safe in pregnant women (McGready et al., 1999), however, another study 
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showed embryotoxicity of artemisinins in pregnant women in their first trimester (Clark et 
al., 2009). 
Several animal studies have shown however, that artemisinin derivatives cause neurotoxicity 
when given at high doses (Brewer et al., 1998). There were two cases of patients who 
suffered from neurological conditions after receiving artemisinin treatments (Elias et al., 
1999), however, these two cases were isolated and could have been unrelated to the 
treatments received by the patients. Another study showed teratogenicity in rats (Chen, 
1984). When compared to the very large number of patients treated safely with artemisinin’s, 
the adverse neurotoxic effects could be said to be quite rare (Dayan, 1998). 
 
 
1.9.2.3 Molecular targets of artemisinin’s 
 
There has been continuous debate about the mode of artemisinin in Plasmodium and 
questions about being either a single or multiple targets.  Artemisinin has as 1, 2, 4-trioxane 
core incorporating an endoperoxide bridge that is essential for activity (Avery et al., 1993; 
Meshnick, 2002; Golenser et al., 2006) (Figure 1.4). Some studies suggest that artemisinins 
become activated (Krishna et al., 2004) inside the parasite, which leads to radical 
intermediates that reacts with parasite targets that are susceptible (Posner et al., 1995; Olliaro 
et al., 2001; O’Neill et al., 2010). However, it is still not clear what the origin and nature of 
the artemisinin activator is. Some studies have proposed that parasite uptake of haemoglobin 
through haemoglobin derived haem or ferrous iron is important for artemisinin activity 
(O’Neill, 2004) while other studies have proposed a metal independent activation of 
artemisinins (Haynes et al., 2010). Another hypothesis is that artemisinin works by directly 
binding to calcium ATPase (Pfatpase6), in a way that is haeme-independent and analogous to 
the inhibition of the sarco/endoplasmic reticulum calcium ATPase by thapsigargin (Krishna 
et al., 2010). It is important to understand the mechanism of action of artemisinin so that the 
development of drug resistance by parasites can be fully elucidated. Proposed mechanisms of 
artemisinin action are discussed in more detail in section 1.14. 
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1.9.2.4 Artemisinin combination treatment 
 
P. falciparum has developed resistance to almost all classes of antimalarial compound 
(WHO, 2010). The WHO recommended artemisinin-based combination therapy (ACT) as 
first line treatment after P. falciparum developed resistance not only to chloroquine, but also 
to mefloquine, sulphodoxine-pyrimethamine, and other used antimalarial drugs. ACT is the 
combination of an artemisinin derivative such as arthemeter, artesunate or dihydroartemisin 
and a partner drug like mefloquine, piperaquine, amodiaquine or lumefantrine which have a 
longer half life in the bloodstream than artemisinin. 
A 7 day regimen is required to maximize cure rates when artemisinins are given alone. There 
are issues with adhering to a 7 day treatment course and so a combination partner in ACT 
which has slower elimination allows a complete treatment to be given in 3 days (Nyunt et al., 
2007). Although a 3 day regimen of artemisinin reduces the parasite biomass, the longer 
acting drug, which is also less potent, kills any remaining parasites over a 1-2 week period. In 
order to avoid losing the potency of artemisinins to resistance development, the use of 
combined regimens was recommended for uncomplicated malaria. However, the use of 
artemisinin monotherapy continues to be common practice in areas that are malaria endemic 
(WHO, 2010). Unfortunately, impaired parasite response to artemisinin monotherapy has 
emerged and is very well established in the Thailand-Cambodia border region which is a 
historical epicentre for the development and spread of antimalarial resistance (Noedl et al., 
2008). 
As a result of reduced sensitivity to artemisinin, the ACT partner drug becomes more 
vulnerable to the development of resistance (Spring et al., 2015; Amaratunga et al., 2016). 
Once resistance develops, current ACT regimens will begin to fail especially as previous 
emergence of parasite resistance to all currently used partner drugs have already developed 
(Leang et al., 2013; Saunders et al., 2014; Spring et al., 2015; Amaratunga et al., 2016). 
There is a current fear that resistance will either spread to Africa from Southeast Asia or 
independently arise and so it is crucial to fill in the current gaps in the understanding of how 
artemisinin resistance has emerged and also on the mode of action of the drug.  
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1.9.2.5 Artemisinin resistance: Definition 
 
The WHO has working definitions of resistance in human populations which is based on 
clinical and parasitological outcomes observed during in vivo studies of ACTs or artesunate 
monotherapy (WHO, 2014). 
Suspected resistance occurs when >10% of patients still have parasitaemia at least 72 hours 
after treatment initiation. This is during a standard oral regimen of ACT directly administered 
over 3 consecutive days. Parasiteamia is detected by examining a thick blood film of asexual 
stage P. falciparum parasites (WHO, 2011). Confirmed resistance occurs when standard oral 
regimens of artemisinin monotherapy (2-4mg/kg/day) are administered over 7 consecutive 
days, and adequate levels of drug are documented in plasma, the WHO confirms resistance if 
parasites are still present on day 7 (i.e, at 168 hours), or if parasites are present at 72 hours 
and then recrudesce i.e. initially clear but then reappear as late as day 42 (WHO, 2011). 
For in-vitro studies, there are conventional invitro tests that provide a quantitative measure of 
intrinsic susceptibility of P. falciparum parasites to antimalarial drugs (WHO, 2001). These 
were originally devised for monitoring CQ resistance. This is usually expressed as IC50, the 
concentration of drug that inhibits the growth of parasite by 50% (as determined by 
quantifying parasite DNA replication by radioisotope methods, monitoring the maturation of 
ring to schizont stage parasites by microscopy or flow cytometry, counting new ring stage 
parasites after one cycle of parasite growth and re-invasion, or quantifying the level of 
parasite specific proteins) (WHO, 2011). 
Molecular marker studies can be more standardized and deployable compared to in vivo and 
in vitro studies and are very useful for large scale surveillance studies for monitoring 
antimalarial resistance (Plowe et al., 2007). When molecular markers are identified, they 
reveal insight into the mode of action of artemisinin and drug resistance. The majority of 
studies in this area have deployed a candidate gene approach which focuses on genes that are 
known to play a role in parasite resistance, or to genes involved with proposed mechanism of 
drug action (Sisowath et al., 2007; Humphreys et al., 2007; Henriques et al., 2014). Some 
other studies have focused on gene expression following exposure to high doses of artesunate 
(Deplaine et al., 2011). 
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1.10 Parasite clearance 
 
Antimalarial treatment reduces parasitaemia in patients and is essential for recovery from 
symptomatic malaria. A rapid decline is parasite density is expected provided a potent 
regimen is given in appropriate doses. The parasite clearance time is the frequently quoted 
measure of therapeutic response but it is an imprecise measure dependent on pre-treatment 
parasite density and parasitaemia (White, 2011). It is also worth mentioning that adequate 
clinical and parasitological response (ACRP) at day 28 and day 42 after treatment was the 
classic method used before parasite clearance times were used (WHO, 2006). 
After the start of an anti-malarial treatment, the graphic plot of parasite densities that follows 
is known as the parasite clearance curve. This curve measures the therapeutic response of a 
drug (White, 2011). In a P. falciparum infection, the higher the initial parasite density, the 
longer counts will take to become undetectable (parasite clearance time). Factors which affect 
the parasite clearance time includes frequency of sampling, parasitaemia estimate, stage of 
parasite development, drug effects and host defences (White , 2011). 
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Figure 1.5: Graph showing the log therapeutic responses of two P. falciparum infections 
illustrating that parasite clearance time is dependent on pre-treatment parasite density, but 
for sensitive parasites, the slope is independent of the starting parasitaemia (White, 2011). 
 
 
Artemisinin derivatives clear parasitaemia more rapidly than other malaria drugs and that is 
its pharmacological hallmark. In addition to this effect, they change the shape of the parasite 
clearance curve qualitatively, due to that, little or no initial plateau phase is visible and a log-
linear decline in parasiteamia is reached almost as soon as parasiticidal drug concentrations 
are reached (White, 1999). Artemisinins create a steeper slope of the log-linear segment of 
the parasite clearance curve compared to any other antimalarial drug. This happens as a result 
of the killing of ring stage parasites, in addition to other stages which are then removed from 
circulation (Chotivanich et al, 2000). These parasites therefore do not mature or sequester 
(Udomsangpetch et al, 1996) and this explains the immediate rapid decline in parasitaemia 
observed consistently in all studies with artemisinin derivatives. The emergence of 
artemisinin resistance in P. falciparum in western Cambodia is manifest by marked slow 
parasite clearance in-vivo (Dondorp et al, 2009). Unfortunately, this in-vivo phenotype has 
not been reliably predicted ex-vivo and conventional in-vitro testing showed little difference 
in drug susceptibility between sensitive and resistant parasites (Dondorp et al, 2009).  
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Figure 1.6: The proportion of patients with severe falciparum malaria (defined by clinical 
or laboratory evidence of vital organ dysfunction) remaining parasitaemic after receiving 
rectal artemisinins or parenteral quinine in a series of randomized trials (Gomes et al., 
2008).   
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Figure 1.7: Normalized P. falciparum parasite clearance curves showing the fraction of 
initial parasitaemia versus time in patients treated with artesunate in Western Cambodia and 
Western Thailand. Parasite clearance was significantly slower in Western Cambodia very 
similar to clearance of quinine in figure 1.6 (Dondorp et al., 2009). 
 
Although most P. falciparum infections still eventually clear after treatment with artemisinin-
based combination therapies in Cambodia, resistant parasites usually take 3 or 4 days to clear 
compared to 2 days for parasites which are artemisinin-sensitive. It has been suggested that 
this delayed clearance could be a step towards high level resistance and treatment failure 
(Dondorp et al., 2011).  The loss of potency to artemisinins renders the more slowly 
eliminated drugs which are part of the combination therapies, vulnerable to the development 
of resistance. This threat would have a huge impact on malaria eradication efforts worldwide 
and as such, an ambitious program was launched to contain artemisinin resistance under the 
guidance of the World Health Organisation (WHO). 
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1.11 In-vitro artemisinin drug response 
 
Reduced artemisinin susceptibility in the greater Mekong sub-region is characterised by slow 
parasite clearance (Noedl et al., 2008; Dondorp et al., 2009) and for so long, there had been 
no consensus on the mechanism by which these phenomena occur. Mathematical modelling 
done Saralamba et al (2011) predicted that ring stage parasites in slow clearing infections had 
a reduced susceptibility to artemisinin. To explore genetic changes that could lead to 
resistance, Witkowski et al (2013) performed in-vitro experiments with artemisinin resistant 
parasites isolated from the F32- Tanzania clone and showed that parasites which were 
exposed to high doses of artemisinin undergo quiescence at ring stage. This was not 
considered to be responsible for resistance as evidence shows that artemisinin sensitive lines 
are also able to go into dormancy and this is dependent on the genetic background of the 
parasite (Tucker et al., 2010). It was proposed that parasites that are resistant to artemisinin 
are able to tolerate more drugs by recovering from dormancy and resuming normal growth at 
a much greater rate than parental strains susceptible to artemisinin. This means that resistant 
lines which become dormant have a higher survival rate after dormancy (Tucker et al., 2010). 
A study which investigated the link between dormancy and parasite resistance of a semi-
synthetic derivative of artemisinin, artelinic acid (AL), showed the association between AL 
resistant parasites and a decreased sensitivity of mature-stage parasites, a decreased 
sensitivity of the ring stage to induce dormancy, and a faster recovery from dormancy 
(Teuscher et al., 2012). Another study also reported that mature stage of artemisinin resistant 
laboratory lines had reduced sensitivity to artemisinin which also occurred in trophozoite and 
schizont stages and not only ring stages (Cui et al., 2012). These findings are different from 
the artemisinin resistant F32-Tanzania mature stages, which are killed by artemisinin 
derivatives (Witkowski et al., 2010). 
To find out how these findings relate to reduced susceptibility of field isolates in Cambodia, 
P. falciparum field isolates from Pailin and Ratanakiri, which are areas of artemisinin 
resistance and susceptibility respectively (two geographically distant areas), were culture 
adapted and in-vitro susceptibility to DHA investigated using a ring stage survival assay 
(RSA) and a mature stage survival assay (MSA) (Witkowski et al., 2013). The study showed 
that P. falciaprum at ring stage from Pailin is able to withstand artemisinin toxicity through 
developmental arrest or quiescence, while mature stages are fully susceptible. 
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Artemisinin resistance has spread rapidly throughout Southeast Asia. Resistance has become 
prevalent in other Cambodian provinces (Amaratunga et al., 2012; Ariey et al., 2012), 
Southern Vietnam (Ashley et al., 2014; Hien et al., 2012), Thailand-Myanmar border areas 
(Ashley et al., 2014; Phyo et al., 2012) and is emerging in Southern Laos (Ashley et al., 
2014).  
 
1.12 Candidate molecular markers for Artemisinin resistance 
 
Molecular markers of resistance are very useful tools that help monitor the evolution and 
spread of resistance, which could enable the establishment of national treatment policies and 
to design drug combinations that could delay drug resistance from evolving. For this, 
powerful new tools emerging from the fast growing field of genomics are being used to 
address this problem. Whole genome sequencing technology and computational methods 
which allow parasite genome variation to be studied are being utilised.  
Until 2014, in P. falciparum there were no universally validated and accepted molecular 
markers of artemisinin resistance in the field. Amplification of the gene encoding for the 
multidrug resistance protein, Pfmdr1 (Reed et al., 2000; Sidhu et al., 2006) and 
polymorphisms in pfatpase6 (Jambou et al., 2005) have been investigated but there was no 
correlation found between variants of these genes and in-vivo responses to artemisinin 
derivatives in the first study which described resistance along the Thai/Cambodian border. 
Experimental studies have also been done to elucidate an area of the genome that could be 
associated with artemisinin resistance. For example, parasites resistant to artemisinins have 
been generated in-vitro and Pfmdr1 duplications were identified (Chavchich et al., 2010). 
The phenotypes and genetic changes associated with it have been shown to be unstable in the 
absence of drugs (Beez et al, 2011; Hunt et al., 2007). Another study carried out a genetic 
linkage analysis of the experimental P. falciaprum Hb2 x Dd2 cross and showed that three 
loci, Pfmdr1 and two on chromosome 12 and 13 (Beez et al., 2011), were associated with 
artemisinin response and had the potential to evolve to artemisinin resistance. However, 
neither of these parental parasite lines had a distinct artemisinin resistant phenotype. 
Another candidate from P. chaubaudi Pcubp1, which encodes ubiquitin carboxyl-terminal 
hydrolase 1, and Pcap2mu, encoding clathrin vesicle-associated adaptor 2, µ subunit, have 
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both been implicates in laboratory-derived artemisinin resistance in the rodent parasite P. 
chaubaudi. Both genes have polymorphic homologues in P.falciparum (Hunt et al., 2007; 
Henriques et al., 2013). These polymorphisms have not yet been completely validated in-vivo 
as markers in parasites that have been established to have reduced artemisinin sensitivity. 
Although a study in Kenya using genome wide association study, found an association 
between Pfubp1 variant, E1528D and reduced artemisinin susceptibility in-vitro (Borrmann 
et al., 2013). 
 
Genome wide single nucleotide polymorphism (SNP) typing of P. falciaprum parasites from 
Thailand, Laos and Cambodia was used for analysis of genetic haplotype variation and 
conservation and also geographic differentiation of parasites. Resistance to artemisinin had 
started emerging when candidate regions associated with slow parasite clearance rates after 
drug treatment was found in the chromosome 13 region (Cheeseman et al., 2012). Since then, 
the Kelch propeller region has been identified as the candidate gene that influences 
artemisinin response (Ariey et al., 2014). 
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1.12.1 Artemisinin resistance associated mutations in the Pf Kelch13 propeller region 
 
Genome wide association studies of slow clearing and fully susceptible parasites from the 
tracking resistance to artemisisin collaboration (TRAC) study (Ashley et al., 2014) were used 
to identify a region on P. falciparum chromosome 13 associated with artemisinin resistance 
(Takala-Harrison et al., 2013). Resistance was independently linked with multiple SNPs in a 
gene known as kelch13 (K13) which is found in the β-propeller domain of the encoded kelch-
like protein, PF3D7_1343700 (Ariey et al., 2014). K13 propeller domain mediates diverse 
cellular function, including ubiquitin-regulated protein degradation and oxidative stress 
responses (Adams et al., 2000). A mutation in K13 was observed in the Tanzanian F32 
parasite line that was exposed to escalating concentrations of artemisinin over a period of 5 
years. This mutation known as M476I, gave rise to the F32-ART line which had other 
mutations (Witkowski et al., 2010). Analysis of Cambodian isolates through genome analysis 
identified four prevalent K-13 mutations, I543T, Y493H, R539T and C580Y, which were 
also associated with long parasite clearance half-lives (>5 hours) in patients and high RSA
0-3h 
survival rates in vitro (Ariey et al.,  2014; Amaratunga et al.,  2014). 
A recent study deployed genome editing techniques to ascertain if K13-propeller mutations 
confer ART resistance in clinical isolates (Straimer et al., 2014). Zing finger nucleases 
(Straimer et al., 2012; Lee and Fidock, 2014) were developed to target genetic engineering of 
K13 into both older established reference lines and newly culture adapted Cambodian 
isolates. Plasmids were created to contain either wild type K13 allele or one of several 
already identified mutations found in F32-ART or ART-resistant Cambodian isolates. 
A series of clones which had individual K13 mutations removed from ART resistant 
Cambodian isolates were generated using donor plasmids which contained a wild-type K13-
propeller sequence and silent binding site mutations (Straimer et al., 2014). One of such 
isolates, (Cam3.II) was a slow clearer following ART monotherapy and had an in-vivo half-
life of 6 hours. The study showed that parental Cambodian lines Cam3.I
R539T
 and 
Cam3.II
R539T
, both harbouring the R539T mutation had a survival rate of 40%-49% on the 
RSA0-3h assay while the edited Cam3.I
rev 
and Cam3.II
rev
 clones which had the reverted wild-
type alleles only had 0.3%-0.7% survival rate (Straimer et al., 2014).  This experiment 
highlighted the importance of the mutation R539T in mediating in vitro artemisinin resistance 
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in Cambodian isolates. The same study also showed a similar trend in other resistant lines. 
The RSA
0-3h 
survival rate was also reduced when the mutation I543T was removed. The 
parental line Cam5
I543T
 had a survival rate of 43% compared to 0.3% of the revertant Cam5
rev 
(Straimer et al., 2014). Similarly, the mutation C580Y had a 13% survival rate in the parental 
line Cam2
C580Y
 compared 2.4% in the revertant line Cam2
rev
. 
The impact of introducing K13 mutations into a fast clearing line was also investigated. The 
survival rates of the edited clones in the RSA were higher compared to the parental wild-type 
lines (Straimer et al., 2014). Using an alternative method of genome editing, the CRISPR-
CAS9 system, Ghorbal et al (2013) generated trasngenic, P. falciparum 3D7 parasites with 
enhanced RSA
0-3h  
survival due to engineered to expression of K13 C580Y. 
The contribution of individual mutation to artemisinin resistance was investigated. Using the 
Dd2 reference line, it was found that the introduction of mutations M476I, I543T or R539T 
conferred higher levels of resistance compared to mutations Y493H and C580Y (10-30% 
compared to 2-4% survival). Of all the mutations, the C580Y mutation has rapidly become 
the predominant allele in western Cambodia (Ashley et al., 2014). K13 mutations have also 
been observed in African isolates but none of the mutations observed are similar to the most 
prevalent mutations found in Southeast Asia. These data do not support the use of K-
13propeller mutant genotypes as a marker for reduced parasite susceptibility to artemisinins. 
 
 
 
1.13 Geographical distribution and spread of artemisinin resistance 
 
1.13.1 Southeast Asia 
Artemisinin resistance defined by in-vivo slow parasite clearance and RSA (marker 
prevalence) has spread rapidly throughout Southeast Asia. Resistance has become prevalent 
in other Cambodian provinces (Amaratunga et al., 2012; Ariey et al., 2012), Southern 
Vietnam (Ashley et al., 2014; Hien et al., 2012), Thailand-Myanmar border areas (Ashley et 
al., 2014; Phyo et al., 2012) and is emerging in Southern Laos (Ashley et al., 2014).  
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1.13.2 Africa 
 
Although none of the K13 mutations found in Africa correspond to the most prevalent 
mutations present in Cambodia, artemisinin and artemisinin combination treatments are still 
very efficacious in Africa (Ashley et al., 2014; Menard et al., 2016; Muwanguzi et al., 2016). 
Taylor et al carried out deep sequencing study of the K13 propeller domain in over 1,110 P. 
falciparum infections which were retrieved from 14 sites across sub-Saharan Africa and 
found a large reservoir of naturally occurring K13 propeller variations. The study identified 
one rare mutation, P553L which was previously found in Cambodia. Other mutations were 
also found such as A578S, which is close to known resistance-causing mutations in the 
propeller domain (Taylor et al., 2014). 
A study done in Dakar, Senegal analysed the K13 gene sequences of 138 malaria patient 
samples. Only two mutations, T149S (6.3%), and K189T (42.2%) were detected (Torrentino-
Madamet et al., 2014). However, when a subsequent study was done in the region from 
samples that were collected from patients in 2013 and 2014, the N554H, Q613H, and V637I 
mutations were identified in the propeller region of K13 in 92 (5.5%) isolates (Boussaroque 
et al., 2016). Again, none of the polymorphisms associated with artemisinin resistance in 
Southeast Asia was detected in Dakar. 
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Table 1.1: Polymorphisms observed in the K13-propeller domain 
Codon 
Position 
Amino acid 
reference 
sequence 
Nucleotide 
reference 
sequence 
Amino Acid 
mutant-type 
sequence 
Nucleotide mutant-
type sequence 
449 G ggt A gCt 
458 N aat Y Tat 
474 T aca I aCa 
476 M atg I atA 
481 A gct V gTt 
493 Y tac H Tac 
508 T act N aCt 
527 P cct T Act 
533 G ggt S Agt 
537 N aat I aTt 
539 R aga 
T 
 
aCa 
543 I att T aCt 
553 P ccg L cTg 
561 R cgt H cAt 
568 V gtg G gGg 
574 P cct L cTt 
580 C tgt Y tAt 
584 D gat V gTt 
612 E gaa D gaT 
623 S agt C Tgt 
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1.14 New proposed molecular mechanism of artemisinin resistance 
 
Parasite genetic loci associated with artemisinin resistance have been revealed through 
genome wide association studies (Takala-Harrison et al., 2013; Ariey et al., 2014). Although 
there has not been any consensus on molecular targets of artemisinin, a study has provided 
biochemical and cellular evidence that artemisinins are potent inhibitors of P. falciparum 
phospatidylinositol-3-kinase (PfP13K) (Mbengue et al., 2015). In strains that are artemisinin 
resistant, increased PfP13K levels are associated with the C580Y mutation in PfKelch13 
(Mbengue et al., 2015). 
 
 
 
Figure 1.8: Crystal model of the K13-propeller domain of Plasmodium falciparum. The data 
that feeds into the model was retrieved from rcsb.org and assembled using deep view 
software with direction from Prof. David Warhurst.  
 
 
 
 
Blade I 
Blade II 
Blade III Blade IV 
Blade V 
Blade VI 
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1.15 Current gaps in artemisinin efficacy and resistance 
 
1.15.1 In-vivo studies 
 
There are a few limitations with in-vivo classification of artemisinin resistance. Three doses 
of artemisinin in ACT therapy reduces parasite density to 10
4
 fold. Resistance based on a 
parasite clearance time (PCT) to 0 by 72 hours will have limitations in situations where there 
are very high parasite densities eg >100,000/uL of whole blood. This means the drug may not 
effectively clear parasites. Another limitation would arise in areas of high endemicity where 
the immune system plays a role in acquired immunity by clearing parasites relatively fast 
compared to areas like Southeast Asia. In this instance, a delay in clearance time from 24-48 
hours over time may indicate a decline in susceptibility of parasites to artemisinin  and it may 
not meet the WHO standard 72 hours delayed clearance definition (Fairhurst et al., 2012). 
With the reduction in malaria transmission intensity in various regionites of Africa, and with 
changes in the rate of acquired immunity (O’Meara et al., 2010; Barnes et al., 2009), PCT 
trends are difficult to interpret (Borrmann et al., 2011). Parasite clearance dynamics have to 
be monitored in detail after ACT is given to determine if parasite susceptibility to ACT is 
changing. In-vivo clearance dynamics can be analysed as parasite half life with blood 
obtained per day after treatment (Dondorp et al., 2009; Amaratunga et al., 2012), or by the 
absence or presence of parasite at a single time point after treatment initiation (Stepniewska 
et al., 2010). These involve so much bleeding from patient and a lot of microscopy readouts. 
A simple duplex quantitative polymerase chain reaction (qPCR) method has been proposed as 
an alternative and sensitive method that involves analysing sequentially collected filter paper 
blood samples to detect and quantify parasites below the microscopic threshold of detection 
(Beshir et al., 2010). 
 
1.15.2 In-vitro studies 
 
The standard in-vitro assays have produced IC50 values that have weak or no correlation to 
parasite clearance rate which is the current in-vivo parasite resistance phenotype. This means 
that a new type of in-vitro test, which can be validated, is needed. Two modified in vitro 
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assays have been used to assess resistance with some success with both assessing reduced 
susceptibility at the ring stage of development in erythrocytes (Tucker et al., 2012; 
Witkowski et al., 2013), however, these assays have not been validated elsewhere. These are 
the T0 [
3
H] hypoxanthine assay and a ring stage survival assay. The latter assesses the 
survival of ring stage parasites exposed to a single 6-hour pulse of 700nM DHA.  The 
percentage of normal parasites counted in blood smears stained with Giemsa at 72 hours is 
the endpoint. The RSA can be associated with clinical resistance due to a statistically 
significant correlation with in vivo clearance in the Greater Mekong region and with mutation 
in the K13 propeller domain (Ashley et al., 2014; Ariey et al., 2014). 
 
 
 
1.15.3 Molecular markers 
 
Previous studies using genome wide association identified genetic loci associated with in- 
vitro susceptibility of P. falciparum to artemisinins; none of these loci were associated with 
slow parasite clearance in malaria infected patients (Mok et al, 2011). Delay in parasite 
clearance time usually correlates with an increase in IC50 and putative molecular markers 
such as pfmdr1, pfatpase6, pfcrt, and pfubp-1. However Dondorp et al (2009) found no 
correlation between delayed clearance time and IC50 and found no associated molecular 
markers (Dondorp et al., 2009). More recent studies however showed that multiple point 
mutations in the propeller domain of Pf3D7_1343700, the kelch gene on chromosome 13 
(K13), have been associated with delayed parasite clearance phenotype in vivo and have 
provided a molecular marker for tracking the spread of artemisinin resistance (Straimer et al., 
2015; Ariey et al., 2014). 
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1.16 Genetic molecular markers of P. falciparum drug resistance 
 
1.16.1 Multidrug resistance protein 1 (Pfmdr1) 
 
The P. falciparum multidrug resistance protein 1 (Pfmdr1) gene encodes a transmembrane 
protein present in the digestive vacuole of the parasite. It has a nucleotide binding fold region 
that binds ATP and thus belongs to the ATP-binding cassette (ABC) superfamily. It has a 
molecular mass of 162.25 KDa, an exon encoding for P-glycoprotein homolog 1 protein 
which comprises of 1419 amino acid (Duraisingh and Cowman, 2005). Variation in Pfmdr1 
mRNA expression level, Pfmdr1 gene amplification and sequence polymorphism have all  
been involved in various antimalarial resistance and played a role in the emergence of 
multidrug resistance parasites (Duraisingh and Cowman, 2005). 
Mutations in positions (N86Y, Y184F, S1034C, N1042D and D1246Y) of the Pfmdr1 gene 
have been reported to be associated with drug susceptibility to quinine, chloroquine, 
amodiaquine, halofantrine, mefloquine, lumefantrine and artemisinin (Sidhu et al.,, 2005; 
Humphreys et al., 2005). Mutations at positions N86Y and N1042D are also associated with 
amodiaquine resistance (Sa et al., 2009). Mutations in positions N86Y of pfmdr1 gene 
together with mutations in K76T and A220S of the pfcrt gene have been associated with high 
resistance to chloroquine in field isolates (Sidhu et al., 2006). Copy number variation present 
in Pfmdr1 gene has been linked to quinine resistance, lumefantrine, mefloquime, 
halofantrine, and also resistance in artemisinin (Sidhu et al., 2006). 
 
1.16.2 Multidrug resistance-associated protein (Pfmrp) 
 
P. falciparum multidrug resistance-associated protein is a transmembrane protein located in 
the plasma membrane of the parasite. It encodes 1822 amino acid with a molecular mass of 
214.44 kDa and has two nucleotide binding domains and two membrane-spanning domain 
with each made up of 6 helical transmembrane domains. Pfmrp belongs to the ABC 
transporter family, located on chromosome 1 (Raj et al., 2009). The function of MRP is to 
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transport organic anionic substrates such as glutathione and is also involved in drug transport 
(Klokouzas et al., 2004). Mutations at positions Y191H and A437S in Pfmrp are associated 
with resistance in quinine and chloroquine (Mu et al., 2003). A high sensitivity to various 
antimalarial drugs such as artemisinin, piperaquine, chloroquine and quinine were obtained 
when a genetic knockout of Pfmrp gene in resistant parasite was carried out (Raj et al., 2009). 
As a result, Pfmrp is involved in changing the antimalarials response to drug resistance but 
not in determining the resistance in itself. It was hypothesized that Pfmrp pumps out various 
drugs and metabolites out of the parasite with the help of other transporters (Raj et al., 2009). 
 
 
1.16.3 Plasmodium falciparum sodium hydrogen exchanger (Pfnhe1) 
 
Pfnhe1 is a transmembrane protein made up of 12 transmembrane domains and has a 
molecular weight of 226 kDA.  It is located on chromosome 13 and has two exons that code 
for sodium hydrogen exchanger (Na +/H+ exchanger or pfnhe) protein which has been 
reported to be associated with resistance in quinine (Ferdig et al., 2004).  Pfnhe1 is localised 
in the plasma membrane of the parasite and is hypothesized to be involved in active efflux of 
protons to maintain a PH of 7.4 within the parasite as a result of a response to acidification by 
anaerobic glycolysis which is the main energy source for the parasite (Bosia et al., 1993). 
In-vitro culture studies have shown that polymorphisms in the microsatellite ms470 region 
showed a decrease in quinine susceptibility with an increase in DNNND repeat motif 
(Briolant, 2011). Subsequently, an increase in quinine susceptibility was observed with a rise 
in NHNDNHNNDDD motif (Briolant, 2011). Therefore, repeat polymorphisms present in 
Pfnhe1 gene has been proposed as a useful genetic marker in determining quinine resistance 
in certain regions as well as resistance to quinine mediated by other genetic markers such as 
Pfmdr1, Pfmrp, and Pfcrt (Ekland and Fidock, 2007) 
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1.16.4 P. falciparum bifunctional dihydrofolate reductase-thymidylae synthase 
 
The Pfdhfr-ts gene is located on chromosome 4 and encodes the Pfdhfr-ts protein. It is 608 
amino acids long and has a molecular weight of 71.73kDa, a bifunctional enzyzme involved 
in two main folate metabolic activity namely, the reduction of dihydrofolate into 
tetrahydrofolate by dihydrofolate reductase activity and the biosynthesis of dTMP by 
thymidylate synthase activity (Foote and Cowman, 1994).  Pfdhfr is inhibited by the action of 
antifolate drugs such as cycloguanil and pyrimethamine and so reduces pyrimidine 
production needed for DNA replication (Hyde, 2005). Point mutations in the Pfdhfr protein 
associated with pyrimethamine resistance are present at positions S108D. Further mutations 
at positions N51I, C59N, and I164L increase the resistance to pyrimethamine other than gene 
amplification (Thaithong et al., 2001).  
 
1.16.5 Plasmodium falciparum dihydropteroate synthetase 
 
The pfdhps gene is made up of 706 amino acid and has a molecular weight of 83.37kDa. It 
has three exons which encode for pfdhps and is located on chromosome 8. Pfdhps enzyme 
catalyzes the p-aminobenzoic acid (PABA) reaction with a pterin derivative in synthesizing 
dihydrofolate, which is a precursor of folate, needed for the synthesis of pyrimidine in the 
parasite (Foote and Cowman, 1994).  
Mutations in pfdhps have been linked to sulfadoxine resistance in P. falciparum. There 
mutations include S436A/F, A437G, L540E, A581G, and A613T/S (Wernsdorfer and Noedl, 
2003). At positions 436, 581 and 613, a higher level of resistance is associated with these 
codons while mutation at position 437 and 540 contribute to a low level of resistance but also 
having a modulation effect in association with other Pfdhps mutation (Hyde, 2007). 
Sulfadoxine is given in combination with pyrimethamine (SP) and resistance to SP have been 
associated with point mutation in both Pfdhfr and Pfdhps gene (Reed et al, 2000) 
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1.17 Artemisinin resistance in Africa 
 
With reports of artemisinin resistance in Southeast Asia (Dondorp et al., 2014; Witkowski et 
al., 2013), numerous studies have been carried out to investigate the spread of drug resistance 
in Africa for continuous monitoring of the therapeutic response of ACTs. This could aid in 
early detection and containment of drug resistance in endemic areas. To date, no study has 
found any delayed clearance of microscopically detectable parasites in Africa. Although there 
is limited information on the artemisinin in-vitro susceptibility of ring stage of P.falciparum 
development, there is also limited prevalence of mutations in Pfk13 (Taylor et al., 2015). 
A few studies have found the presence of the A578S mutation of the propeller region in 
Africa (Ashley et al., 2014; Conrad et al., 2014; Taylor et al., 2015; Hawkes et al., 2015), but 
none of these studies suggest that A578S is an artemisinin resistant mutation. Another study 
was carried out to ascertain the prevalence of mutations in Pfk13 in 14 sub-Saharan African 
countries and found no mutation associated with artemisinin resistance in Southeast Asia 
except one mutation at codon 543 (Kamau et al., 2015). It has been suggested that the 
majority of rare K13 alleles are neutral with respect to artemisinin resistance in Africa and 
lack evidence of artemisinin-driven selection on the K13 locus (Menard et al., 2016). 
It was shown that residual sub-microscopic parasites were present in Kenyan children on day 
3 after treatment with ACT and were associated with subsequent recrudescence and 
transmission (Beshir et al., 2013). Another study showed that parasites that harboured certain 
mutations in Pfmdr1, Pfcrt, Pfubp1, and Pfap2mu genes showed a higher survival rate at a 
sub-microscopic level after treatment with ACT (Henriques et al., 2014). To date, ACTs 
remains efficacious against malaria infections in Africa (Sawa et al., 2013; Ashley et al., 
2014). More in-vitro phenotyping studies and allele editing studies (Straimer et al., 2015) 
needs to be done to provide more information about the potential presence of drug resistance 
in Africa. 
This thesis sets out to do just that by testing the hypothesis that differences in drug sensitivity 
(EC50) exist between African isolates and these differences are genetically determined. These 
differences, if found can be used to assign drug sensitivity phenotypes for African isolates in- 
vitro. To test this hypothesis, I will examine field isolates of African origin and test them for 
their response to artemisinin in vitro. I will also compare these directly against the DHA 
sensitivity profiles of artemisinin resistant isolates from Cambodia. To achieve this, I will 
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modify the current standard in vitro assay by exposing the parasite to short pulses of 
artemisinin and making comparisons to the standard 48 hours exposure. I will also employ a 
ring stage assay (RSA) to assess the DHA response of African parasite lines and to validate 
already existing methods.  In this thesis, I will carry out next generation genome sequencing 
using the illumina platform on all African lines and elucidate genotypes at all candidate loci, 
in each line for which in-vitro DHA phenotype has been ascertained. 
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CHAPTER 2:  Aims and Objectives 
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2.1 Aim 
 
The aim of this study is to identify a scalable assay able to discriminate between parasite lines 
with small differences in artemisinin sensitivity. The study also aims to identify phenotypes 
relevant to the genetic exploration of artemisinin resistance in African settings. 
 
2.2 Hypothesis 
 
This study hypothesizes that differences in EC50 values exist within and between the African 
isolates and these differences are also detectable genetically. These genetic differences can be 
used to predict drug sensitivity phenotypes for African isolates in vitro. 
 
2.3 Objectives 
 
The specific objectives are as follows: 
 
Chapter 4: To understand dihydro-artemisinin (DHA) sensitivity by using parasite lines that 
are lab adapted. To identify an assay able to discriminate between parasite lines with small 
differences in artemisinin sensitivity by using a 6-hour pulse assay. Currently, the standard 48 
hr in vitro protocol is unable to discriminate between the response to artemisinin in parasite 
lines tested as they all appear sensitive to DHA (van Schalkwyk et al., 2013). Short-term 
exposure (pulse assay) protocol will be used to compare sensitivity of different parasite lines 
to the active metabolite (DHA), based on recent publications. The pulse assay is used to 
simulate in vivo DHA exposure time. DHA drug sensitivity profiles of parasite lines from 
Kenya, Nigeria and Ghana will be assessed. 
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Chapter 5: To assess the DHA sensitivity profile of artemisinin resistant lines from 
Cambodia using the novel 6-hour pulse assay and an alternative assay protocol (RSA 
0-3h
) by 
Witkowsi et al., To compare both assays to the standard 48 hr assay to see which assay best 
discriminates between the parasite lines. To use the ring stage assay to assess DHA response 
of African parasite lines and to validate already existing methods. This chapter aims to 
develop a methodology that works in both African and Cambodian setting. 
Chapter 6: To produce full genomic sequences for each polyclonal line. To examine 
genomic data for evidence of polymorphisms at established candidate loci and to inform 
future functional studies deploying gene editing.  
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CHAPTER 3:  Materials & Methods 
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3.1 Reagents, Buffers and Solutions 
 
3.1.1 Culture medium 
 
1. Albumax II, gentamicin sulphate (Invitrogen, Carlsbad, CA, USA) 
2. HEPES, RPMI 1640, human AB serum, hypoxanthine, L-glutamine and D-glucose 
(Sigma-Aldrich, St Louis, MO, USA) 
3. Antimalarial compounds supplied by Medicines for Malaria Venture (MMV, Geneva, 
Switzerland) 
4. Dimethyl sulphoxide (DMSO) 
5. Deionized water (Millipore, Watford, UK) 
 
3.1.2 PCR 
 
1. 10uM of each dNTP (Bioline, UK)  
     10ul of stock dNTP (100pM ) + 90ul water) 
2. 10um of each primer (Eurofin, Germany) 
    10ul of stock primer (100pM) + 90ul water 
3. 10um of each probe (Eurofin, Germany) 
    10ul stock probe (100pM) + 90ul water 
4. 10x NH4 buffer (Bioline, UK) 
    160mM (NH4) 2SO4, 670mM Tris-HCl (pH 8.8 at 25ºC) and stabilizers 
5. MgCl buffer (Bioline, UK) 
    160mM (NH4) SO4, 670mM Tris-HCl (pH 8.8 at 25ºC), 15mM MgCl2 and stabilizers 
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6. KCl buffer (Bioline, UK)   500mM KCl, 100mM Tris-HCl (pH 8.8 at 25ºC), 15mM 
MgCl2, and stabilizers 
 
3.1.3 Thawing solutions 
 
Thawing solution 1: 12% (w/v) NaCl (1.2g of Nacl, 10ml H20) 
Thawing solution 2: 1.6% (w/v) NaCl (0.8g of Nacl, 50ml H20) 
Thawing solution 3: 0.9% (w/v) NaCl + 0.2% glucose (0.45g of NaCl, 0.1g of D-glucose, 
50ml H20) (Sigma-Aldrich) 
 
3.1.4 DNA separation 
 
1.2% (w/v) agarose gel 
1.2g agarose (Sigma-Aldrich, UK) in 100ml 5X TBE 
2. 5x TBE (Tris-Borate-EDTA) buffer 
Tris (hydroxymethyl) aminomethane + Boric acid 
1 sachet TBE (Sigma-Aldrich, UK) in 1L of water 
 
3.1.5 PCR product purification 
 
1. FastAP (Thermosensitive Alkaline Phosphotase) (Fermentas, USA) supplied in 20mM 
HEPES-NaOH (pH 7.4), 1mM Mgcl2, 0.1 mM Zncl2, 0.1% Triton X-100 and 50% (v/v) 
glycerol. 
2. Exo I (Exonuclease I) (Fermentas, USA) supplied in 20mM Tris-HCl (pH 7.5), 0.1 mM      
EDTA, 1mM DTT and 50% (v/v) glycerol. 
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3. 10X FastAP Buffer (Fermentas, USA) 100mM Tris-HCl (pH 8.0 at 37C), 50mM MgCl2, 
1M KCl, 0.2% (v/v) Triton X-100 and 1mg/ml BSA. 
 
3.1.6 DNA sequencing 
 
1. Big dye terminator (Applied biosystems, UK) 
2. Big dye buffer (Applied biosystems, UK) 
 
3.1.7 Sequencing reaction purification 
 
1. Ethanol/Sodium acetate  
    3M NaOAc + absolute ethanol + water 
2. 3M NaOAc (Sodium acetate) (Sigma-Aldrich) 
    40.8g NaOAc + water made up to 100ml at 5.2 pH 
3. 70% Ethanol 
    70ml absolute ethanol AnalaR (Fisher chemicals, UK) + 30ml water  
4. HiDi (Applied Biosystems, UK). 
 
3.1.8 DNA extraction 
 
QIAmp DNA blood midi kit (20) (Qiagen, Manchester UK) 
1. QIAmp mini spin columns  
2. Collection tubes (2 ml) 
3. Buffers: Buffer AL, Buffer ATL, Buffer AWI, Buffer AW2, Buffer AE 
4. Qiagen Protease 
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5. Proteinase K 
6. 4.4ml distilled water added into the vial of lyophilized Qiagen protease provided. 
7. Buffer AW1: 25 ml of 100% ethanol added to make a final volume of 44 ml 
8. Buffer AW2: 150 ml of 100% ethanol added to make a final volume of 57 ml.  
 
3.1.9 Limiting dilution 
 
Malstat:  400 µL Triton ×100 (Thermofisher) + ~150 mL MilliQ H2O +  4 g Calcium L-
Lactate, 1.32 g Tris Base (Sigma-Aldrich)+ 22 mg of APAD. 
NBT/PES: 160 mg of Nitroblue Tetrazolium(Sigma-Aldrich) + 8 mg Phenazine Ethosulphate 
+ 100 mL of MilliQ H2O.  
 
3.1.10 Whole genome sequencing 
 
1. NEBNExt Sanger Sequencing sample Prep Kit I 
2. MiSeq Reagent Kit  
3. Qiagen Kit to clean up (mini elute and PCR clean up kits) 
4. Agencourt Ampure XP beads (Beckman Coulter) 
5. Kapa HiFi (KAPA Biosystems, South Africa) 
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3.2 Patient Sample 
 
3.2.1 African Samples 
 
Five African isolates were used in this study (HL1204, HL1210, HL1212, HL1402 and a 
Liberian isolate). Isolates HL1204, HL1210, HL1212 have been characterised elsewhere 
(Schalkwyk et al., 2013) (Table 4.1). Four of the isolates were obtained from patients who 
presented with malaria at the Hospital for Tropical Diseases, London (HTD), or the Accident 
and Emergency Department of University College London Hospitals (UCLH). A 4mL 
Vacutainer tube containing EDTA (BD) was used to obtain venous blood sample, some of 
which was used for laboratory adaptation of the malaria parasites in the malaria culture 
laboratory at the London School of Hygiene and Tropical Medicine. Ethical approval was 
obtained from the Research Ethics Committee of the University College London Hospitals 
(Application number: 07/Q0505/60). The Liberian isolate was obtained from the Sanger 
Institute, Cambridge.  
 
3.2.2. Cambodian Samples 
 
The Cambodian isolates (Cam 3.11wt, Cam 3.11C580Y and Cam 3.11R539T) were obtained 
from the Liverpool school of Tropical Medicine UK (Straimer et al., 2015) (Table 5.6) while 
the KH2 line was obtained from the Sanger Institute via Cambodia (Miotto et al., 2014). They 
were quickly adapted to complete medium supplemented with 10% (v/v) human AB serum, 
25mg/L gentamicin, 147µM hypozanthine, 23nM HEPES, and 25 mM Na2HCO3. After 
adaptation, isolates were cryopreserved in liquid nitrogen 
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3.3 Antimalarial drugs 
 
Two antimalarial drugs, namely chloroquine and DHA were used in this study. The drugs 
were supplied by the Medicines for Malaria Venture (MMV, Geneva, Switzerland). The first 
DHA stock solution was made by dissolving in dimethyl sulphoxide (DMSO) and subsequent 
dilutions were made using complete RPMI growth media (RPMI 1640 growth medium 
supplemented with 10% (v/v) human AB serum, 25 mg/L gentamicin, 147 μM hypoxanthine, 
25 mM HEPES, and 25 mM Na2HCO3). The primary stock for chloroquine was made by 
dissolving in deionized water (Millipore, Watford, UK). 
 
3.4 Laboratory adaptation 
 
3.4.1 Parasite thawing 
 
1ml cryovials of liquid nitrogen frozen clinical isolate stock of 4 isolates (3D7, HL1204, 
HL1210, Hl1212 and HL1402) were thawed using 3 thawing solutions (section 3.1.3).  The 
vials were placed in a 37ºC waterbath for 2 minutes and transferred to a 50ml tube. 1/5 of the 
volume of parasites of thawing solution 1 (200ul), was added dropwise while mixing gently. 
The mixture was allowed to stand for 2 minutes without agitation. 10x the original volume of 
parasites of thawing solution 2 (10ml), was added dropwise while mixing gently. The 
suspension was centrifuged at 500g for 5 minutes at room temperature. The supernantant was 
removed and discarded and 10ml of thawing solution 3 was added dropwise while mixing 
gently. The suspension was centrifuged at 500g for 5 minutes at room temperature. The 
supernatant was removed and discarded and the pellet was resuspended into complete RPMI 
media and added to culture. 
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3.4.2 Parasite culture and laboratory adaptation 
 
Complete media for culture adaptation of clinical isolates were prepared using reagents in 
section 3.1.1 and were put in a 37ºC waterbath before adding to culture. Whole blood sample 
(A+) obtained from the blood bank (National Health Blood & Transplant, UK) was washed 
twice using RPMI-1640 (centrifuged at 2,000 x g for 10 minutes). The supernatant and buffy 
coat was removed and the red cell pellet was suspended in 25mL of RPMI. This process was 
repeated twice and the washed blood was then diluted to 50% harmatocrit. Parasites were 
maintained in continuous culture in a sealed flask and incubated at 37ºC under a gas mixture 
of 93% (v/v) N2, 4% (v/v) CO2 and 3% (v/v) 02. The parasites were diluted in human A+ 
blood as the parasiteamia increased to maintain a parasitaemia of <4% and a haematocrit of 5 
%. 
For all KH2 isolate adaptation and routine parasite cultivation the amount of human serum 
added was reduced to 2% (v/v) from 10% (v/v) and the culture media further supplemented 
with 5 g/L Albumax II, 10 mM D-glucose and 2 mM L-glutamine. The parasites were 
maintained in continuous culture with shaking initially, and then later maintained in static 
conditons. The parasites were stored in a sealed flask incubated at 37°C under a gas mixture 
of 93% N2, 4% CO2 and 3% O2. As the parasitaemia increased the parasites were diluted in 
human A
+
 blood (National Health Blood & Transplant, UK) to maintain a parasitaemia <4% 
and a haematocrit of 5%. 
 
3.4.3 Parasite freezing 
 
Stocks of all 4 clinical isolates were frozen down at ring stage after culturing using 
glyceraldehyde solution and stored in -20°C, -80°C and liquid Nitrogen respectively for 
future experiments. 
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3.5 Anti-plasmodial activity assays 
 
3.5.1 Synchronisation 
 
Parasites were synchronised at ring stage before any drug assay experiment were carried out. 
This was done with 5% Sorbitol (Sigma-Aldrich). 6ml of sorbitol was added to the 
parasitized RBC and was left to sit for 2 minutes. The solution was centrifuged at 600g for 2 
minutes and the supernatant was removed. 25ml of RPMI was added and centrifuged as 
before and this wash was repeated twice. 
 
3.5.2 Drug dilution and 48hr assay (EC50
48h
) 
 
After synchronization at ring stage, parasites were diluted to a final parasitaemia of 0.5% and 
a haematocrit of 4% and left in the water bath at 37ºC. A 2-fold drug dilution was carried out 
on drug compounds DHA and chloroquine, with starting concentrations at 1uM and 200nM 
respectively.  A negative control of 20uM Chloroquine was used and a positive control 
(culture media and parasite solution) with no drug was also used. After the dilution, parasites 
were added to drugs in a 200ul volume within 96-well microtitre plates and incubated for 48 
hrs at 37ºC. Parasite viability is described in section 3.5. 
 
3.5.3 6 hour Pulse Assay (EC50
6h
) 
 
For a pulse assay, parasite and drug dilution was done in a 1ml eppendorf tube. The 
suspension was washed with RPMI on the 6
th
 hour before transferring into a 96 well plate for 
48 hour incubation. The starting concentrations were the same as previously described but the 
volume was 1ml in each tubes and a 1 in 2 drug dilution was done. 
6 hours into incubation, 200ul of solution for both CQ and DHA were transferred into a 96 
well plate in duplicate (400ul total). The remaining 600ul parasite solution was washed twice 
using 1ml RPMI and spun down for 1 minute. After the wash, 200ul of parasite solution for 
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both drugs were pipetted into the same 96 well plate, also in duplicate. The plate was 
incubated within a gassed container at 37ºC for 48 hours.  
 
3.5.4 EC50
6h
 
T0-T4
 assays 
 
The EC50
6h
 
T0-T4
 assay had was carried out in the same format as the 6 hour pulse assay with a 
few adaptations. Parasites were tightly synchronised at 0.5% parasitaemia (two rounds of 
synchronisation to get the early ring stage (0-3hrs)). Parasites were exposed to DHA at two 
time points, Time 0hr and Time 4hr. The Time 0hr DHA exposure was carried out 
immediately after tight synchronisation and then plated out in a 96 well plate. In a different 
plate, parasites were plated out without drug for an added 4 hour growth time in readiness for 
the 4hr DHA exposure. 6 hours later, the time 0hr DHA exposure plate was washed off and 
incubated within a gassed container at 37°C for another 42 hours (48 hours in total). The 
Time 4hr exposure was exposed to DHA 4hr into the growth of its life cycle and incubated. 
The DHA drug was washed off 10 hours later and then incubated in the same gassed 
contained as the first plate. A schematic diagram of this assay can be seen in appendix II, 
figure 1. 
 
3.5.4 Ring stage survival assay (RSA
0-3hr
) 
 
The ring stage assay was performed following the protocol provided by Witkowski and 
colleagues (Witkowski et al., 2013). Tight synchronisation of parasites was carried out across 
two consecutive ring stage cycles using sorbitol treatment (Section 3.5.1). Enrichment of the 
late schizont stage was done using heparinised RPMI and 75% (v/v) percoll solution at room 
temperature and cultured for 3 hours at 37°C with fresh erythrocytes. The parasites were 
treated with sorbitol again to ensure no late stages were present. Parasites were in the early 
ring stage (0-3hr), at 0.5% parasitaemia and 2% haematocrit in a final 2ml volume. These 
were exposed to 700nM of dihydroartemisinin for 6 hours in 0.1% DMSO after which the 
cultures were washed and resuspended in drug-free culture medium. This was cultured at 
37°C for another 66 hours.  The susceptibility to DHA was assessed using microscopy read 
out on thin films. This was done by estimating the percentage of viable parasites that had 
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developed into a new cycle after DHA exposure by comparison with parasites exposed to 
0.1% DMSO only (control). 
 
3.5.5 Synchronisation and drug pressure 
 
Parasites were synchronized at ring stage and drug pressure was initiated with a final 
parasitaemia of 0.5% and a haematocrit of 2% in a 200uL volume within a 96-well microtitre 
plate. Two drugs were used in this study to carry out drug pressure and these are DHA and 
chloroquine. For DHA, parasites were exposed to 700nM for 72 hours after which the drug 
was washed off and parasites were allowed to recover in complete medium. 
For chloroquine, a two-fold drug dilution was carried out with starting concentration of 
100uM. After the dilution, 100ul of parasitized red cells were added to the 96 well plate and 
incubated for 72 hours. After the drug pressure, parasitized red cells were transferred to a 
50ml tube and washed with 25ml RPMI at 2,000 x g for 10 minutes. Parasites were 
resuspended into a 10ml culture medium and incubated at 37°C under a gas mixture of 
93% N2, 4% CO2 and 3% O2 and allowed to recover from the chloroquine drug pressure. 
 
3.5 Viability of parasites 
 
Lysis buffer was made up using 29nM Tris, 5mM EDTA, 0.008% (w/v) saponin and 0.08% 
Triton X-100 (pH 7.5). Pico Green (Invitrogen, P7581) was diluted 1:200 (25ul Pico Green in 
5ml lysis buffer).Afterwards, 50ul of the lysis buffer was pipetted into each well of a 96 well 
plate and then 100ul of parasite solution that had been resuspended was transferred from the 
original plate which was used for growth assay into the plate containing Pico green. The 
solution was mixed well and was read in a Spectramax M3 microplate reader (Molecular 
Devices). The excitation wavelength used was 485nm and the emission wavelength used was 
538nm. 
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3.6 Limiting dilution 
 
The starting haematocrit for the limiting dilution experiment was 1.8%. The parasite stock 
was diluted in order to get 0.5 parasites per well or 5 parasites per 100ul, after counting using 
a haemocytometer. The parasites were plated out in a 96 well plate and 0.4% haematocrit of 
blood was added each week with fresh media change. The first row (row 1) was used as the 
positive control (100 uL of 1.8% haematocrit and 100 µL of complete medium). The plates 
were developed using Malstat and NBT/PES (Section 3.1.9). For development, each well was 
resuspended and 100ul of Malstat (room temperature)  was added to a duplicate microtitre 
plate. 15 uL of the cell suspension was added and 25ul of NBT/PES  was added after. 
Bubbles were removed using hair a hair dryer and the microtitre plate was stored in a dark 
cupboard to develop (NBT is light sensitive). After development (purper colour observed), 
the plate was read at an absorbance of 620nm (Molecular Devices). 
 
3.7 Purification of DNA from parasite whole blood 
 
200ul Qiagen protease was pipetted into the bottom of a 15ml centrifuge tube containing 
1.25ml of parasitized red blood cells (from culture-adapted parasites). 2.4ml buffer AL 
(Qiagen) was added and mixed thoroughly by inverting the tube 15 times, followed by 
additional vigorous shaking for 1 minute. When multiple tubes were used for multiple DNA 
extraction, they were inverted simultaneously by clamping them into a rack and inverting 
them together. The suspension was mixed thoroughly with buffer AL to yield a homogenous 
solution. The solution was incubated at 70ºC for 10 minutes. 
2ml of absolute ethanol (100%) was added to the sample and mixed by inverting the tube 10 
times. This was then shaken vigorously in order to ensure efficient binding and to achieve a 
homogenous solution.Parasite genomic DNA was extracted from 200 μL of packed red cells 
using the QIAamp DNA Blood Mini Kit (Qiagen) as per the manufacturer’s instructions. The 
DNA was stored at −80°C. 
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3.8 Assay data analysis 
 
Raw data from the Spectramax reader was transferred to a Microsoft Excel sheet and 
analysed to get percentage viability for each drug used and for all 4 clinical isolates. An 
average background figure for the negative control (20uM CQ) was calculated and subtracted 
from all 96 values. After this, the average control values (i.e. average of the values subtracted 
from the background) was used to calculate the percentage viability by dividing all values 
gotten after subtraction from the background value by the average control values.   
Drug concentration for both CQ and DHA were logged and the average for quadruplet 
readings was calculated together with a standard deviation. Prism v4.02 (Graphpad software) 
was used to create a dose response curve showing percentage viability vs. drug concentration 
for each clinical isolate. 
 
 
3.9 Whole genome sequencing 
 
1.25mls of parasiticed red blood cells for all three isolates at, HL1204, HL1210 and HL1212 
at schizont stage were stored in at 4ºC for whole genome sequencing. The method for DNA 
extraction of parasites was adapted specifically for the parasite lines used in this thesis to 
obtain high quality of DNA and a high DNA library quality (see section 6.2.1). To obtain a 
fragment size of approximately 300 bp, all the isolates were sheared using a S2 series 
ultrasonicator (Covaris Inc.). The settings used to achieve a 300 bp size have been described 
in chapter 6.2.2 (Table 6.2). Paired end sequencing libraries were constructed using the 
NEBNEXT DNA sample preparation kit (Illumina). This was done following the standard 
illumine sample preparation protocol with slight modifications. End-repair reactions (100 μl) 
contained 75 µl of sheared DNA sample, 10ul of phosphorylation reaction buffer, 5ul T4 
DNA polymerase, T4 polynucleotide kinase,4ul dNTPs, 1ul  Klenow DNA polymerase, and 
were incubated at 20°C for 30 mins. Resulting blunt phosphorylated DNA fragments (end-
repaired) were cleaned using the Agencourt Ampure XP beads (Beckman Coutier) following 
the manufacturer's instructions. A single A base was added (A-tailing) to the 3' end of the 
end-repaired DNA fragments in a 50 μl reaction containing  32ul end repaired DNA, 5ul 
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NEB buffer, 10ul dATP, 3ul of Klenow fragment (3’-5’) and incubated for 45 min at 37°C. 
A-tailed DNA fragments were cleaned using Ampure XP beads following the manufacturer's 
instructions and DNA eluted in 10 µl EB buffer. 
Pre-annealed paired-end (PE) adapter oligonucleotides (Illumina) were ligated to the A-tailed 
fragments in a 50 µl reaction containing 10 µl of dA tailed DNA sample, 25ul Quick T4 
DNA-ligase reaction buffer, 10 µl of NEBNEXT adapter, 5 µl of Quick T4 DNA ligase 
(NEB) and incubated at 20°C for 15 min. The ligation reaction was cleaned twice with 1× 
Agencourt Ampure XP beads (Beckman Coulter). 
All PCR amplifications were performed with an MJ Research Thermo Cycler PTC-225. 
Illumina PE 1.0 and 2.0 primers were used to amplify adapter-ligated library fragments 
(10ng) by PCR. See section 6.3.2 for the PCR modifications. Before libraries were loaded on 
the Illumina whole genome sequencing platform, they were quantified using Qubit 
(Thermofisher Scientific). 
 
3.10 Whole genome sequence analysis. 
 
The raw sequence data retrieved from the illumina platform was aligned against the 3D7 
reference genome. SAM files were converted to BAM files and sorted. Reads were mapped 
using the aligner bwa mem (Li H & Durbin R, 2009) running on default parameters. The 
reference used was the Plasmodium falciparum 3D7 version 3 downloaded from PlasmoDB 
(http://plasmodb.org/plasmo/). The results were screened using the genome browser 
tooltablet (Milne et al., 2013) and Geneious software version R9 (Biomatters Ltd).  
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3.11 Molecular analysis of drug-resistance associated genes 
 
3.11.1 Estimating Multiplicity of Infection 
 
Multiplicity of infection (MOI) for P.falciaprum isolates were assessed by nested PCR 
analysis of msp1 block 2 (K1, MAD20, RO33) and msp2 block 3 (FC27, 3D7/IC).These 
alleles comprise of conserved regions flanked by repeat sequences of different lengths.The 
length variation within the alleles can be used to discriminate different parasite clones by 
PCR fragment length polymorphism. The set of primers used were previously designed 
(Snounou et al, 1999), but with modified cycling conditions as follows: Nest 1 amplifications 
were performed in 25 μL reaction mixture containing 5 μL DNA, NH4 buffer, 4 mM MgCl2, 
1 mM deoxynucleotides (dNTPs), 0.2 μM forward primer, 0.2 μM reverse primer and 1 unit 
of BIOTAQ™ (Bioline, UK). The cycling conditions were: denaturation at 94°C for 3 min, 
30 cycles of 94°C for 30 sec, 58°C for 1 min and 68°C for 1 min, followed by a final 
extension of 5 min at 68°C. Amplifications for the Nest 2 reaction was performed in a 25 μL 
reaction mixture containing 1 μL of Nest 1 product diluted 1/10, NH4 buffer, 4 mM MgCl2, 
1 mM dNTPs, 0.2 μM forward primer, 0.2 μM reverse primer and 1 unit of BIOTAQ. The 
cycling conditions were: denaturation at 94°C for 3 min, 30 cycles of 94°C for 30 sec, 61°C 
for 1 min and 72°C for 1 min, followed by a final extension of 5 min at 72°C. 
The amplification products were separated and visualised using gel electrophoresis. Loading 
buffer was mixed with 15 μL of amplification products and was loaded onto 2% (w/v) 
agarose gels in 0.5% (v/v) TBE buffer, stained with 0.5 μg/mL ethidium bromide (EtBr). The 
minimum MOI was estimated to be the highest observed number of size variants for 
either Pfmsp1 or Pfmsp2. 
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3.11.2 Genotyping of pfcrt drug resistant marker 
 
The multiplex real-time qPCR performed in a Rotorgene RG3000 thermocycler (Corbett 
Research, Australia) was used to assess the genotype of pfcrt. The segment around codons 
72-76 was amplified using three dual-labelled probes complementary to CVMNK (FAM 
fluorophore), CVIET (JOE fluorophore) and SVMNT (ROX fluorophore) as described 
(Gadalla et al, 2010; Sutherland et al, 2007). A threshold for each probe was set manually 
using the positive and negative controls for data analysis. 
 
3.11.3 PfK13 Genotyping 
 
The K-13 propeller was amplified by using primers used in previous studies (Menard et al, 
2013). PCR reactions were carried out with the following conditions: Nest 1 amplifications 
were performed in 25 μL reaction mixture containing 5 μL DNA, 10 μM forward primer, 
10 μM reverse primer and 5x HOT FirePol master mix. The cycling conditions were: 
denaturation at 95°C for 15 min, 30 cycles of 95°C for 30 sec, 58°C for 2 min and 72°C for 
2 min, followed by a final extension of 10 min at 72°C. 
Nest 2 amplifications were performed in a 22.5 μL reaction mixture containing 2.5 μL of nest 
1 product, diluted 1/2 10 μM forward primer, 10 μM reverse primer and 5x HOT FirePol 
master mix. The cycling conditions were: denaturation at 95°C for 15 min, 40 cycles of 95°C 
for 30 sec, 60°C for 30 secs and 72°C for 1 min, followed by a final extension of 10 min at 
72°C. 10ul of the PCR product was visualised using gel electrophoresis and was loaded onto 
2% agarose gel in 0.5% TBE buffer, stained with ethidium bromide (EtBr) to confirm 
amplification.  
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3.11.4 Sequencing of PCR products 
 
Exonuclease I (ExoI) and Thermosensitive Alkaline Phosphatase (AP) enzymes (Fermentas, 
UK) were used to purify PCR-amplified products. This ensured non-incorporated dNTPs and 
primers were eliminated. The enzymatic purification step was carried out in a final volume of 
10 μL containing 5 μL of the PCR product, 3 U ExoI, 1 U AP and 1X AP reaction buffer. The 
mixture was incubated for 60 min at 37°C followed by 15 min at 72°C for enzyme 
denaturation. 
The sequencing cycle reactions were carried out using 1 μL ExoI/AP purified PCR 
amplicons, 0.5 μL BigDye® Terminator v3.1 Cycle Sequencing Kit reaction mix (Applied 
Biosystems, UK), 0.2 μM of each PCR primer, 1.75 μL Big Dye Sequencing Buffer (Applied 
Biosystems) in a total volume of 10 μL. Single-base extension was performed using the 
following conditions: one denaturation hold at 96°C for 1 min followed by 25 cycles of 96°C 
for 30 sec, 50°C for 15 sec, and 60°C for 4 min. 
The ethanol/sodium acetate precipitation method was used to purify the sequence reaction 
fragments, where 3 μL 3NaOAc (pH 4.6), 62.5 μL 100% ethanol and 24.5 μL of nuclease 
free water were added to each sample. The samples were mixed by inversion and incubated at 
−20°C for 25 min. Samples were centrifuged at 4°C at 3000 g for 30 min after incubation.The 
supernatant was discarded by inversion, 150 μL ice cold 70% ethanol was added and the 
samples centrifuged at 4°C at 3000 g for 10 min.After centrifugation, supernatant was 
discarded by inversion and each sample was allowed to dry at room temperature for 30 min 
after which pellets were resuspended in 10 μL Hi-Di formamide. Samples were loaded on an 
ABI prism 3730 Genetic Analyzer (Applied Biosystems). The sequence chromatograms data 
from the sense and antisense primers were edited, aligned and assembled into contigs using 
Geneious Pro software (version 5.5.3; Biomatters, New Zealand). Ambiguities were resolved 
by eye and single nucleotide polymorphisms were identified by comparing the sequence to 
that of the 3D7 reference genome. 
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CHAPTER 4: DHA sensitivity of recently adapted polyclonal 
African isolates of P. falciparum 
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4.1 Introduction 
 
Artemisinin based combination therapy (ACT) was recommended by the WHO for the 
treatment of Plasmodium falciparum malaria and its use has contributed to reductions in 
malaria disease burden, contributing to an estimated 30% reduction in global mortality rates 
in the past decade (WHO, 2013). There have been reports from Southeast Asia of parasite 
resistance to artemisinin and its derivatives, similar to earlier antimalarials like chloroquine 
and sulphadoxine-pyrimethamine. Reports of resistance have emerged from Western 
Cambodia, Western Thailand, Southern Burma, and Southern Vietnam and there are fears 
that resistance will spread to Africa as it occured in previous years (Wootton et al., 2002; 
Roper et al., 2003). Artemisinin resistance threatens malaria control, treatment and 
elimination efforts worldwide and the effect will be felt mostly in Africa which currently has 
the highest burden of the diseases and kills pregnant women and children (WHO, 2015). To 
prevent the spread of artemisinin resistant parasite to Africa, rapid detection of new 
artemisinin foci is important.  
Artemisinin resistance is recognised as relatively slow parasite clearance rate in patients 
receiving an ACT or artemisinin (Dondorp et al., 2009) and this is a major concern in the 
fight against malaria as highlighted by the WHO global plan for artemisinin resistance 
Containment (WHO, 2011). The parasite clearance half-life is estimated from frequent 
parasite density count from blood taken from patients who agree to several days of 
hospitalization. Such studies are both financially and logistically demanding and very 
inconvenient for patients and their families. So therefore, an alternative in-vitro method is 
used to ascertain parasite half-life by culture adapting parasite lines in the laboratory and 
determining the IC50 value – the ‘effective concentration’of drug that inhibits parasite growth 
by 50%. (EC50 – will be used in this thesis) 
Unfortunately, impressive gains are now being threatened by this emergence of resistance of 
P. falciparum to ARTs in South-East Asia and no alternative, fully effective first-line therapy 
is currently available to replace ACTs, should artemisinin fail globally.  
 
Recently, a Vietnamese patient who was infected with malaria in Angola failed to respond to 
artesunate/clindamycin which was administered intravenously, followed by an oral ACT after 
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returning to Vietnam (Hong et al., 2014). This type of incident makes it clear that emergence 
of resistance in sub-Saharan Africa is not unlikely and as a result, drug sensitivity profiles 
should be monitored.  In-vitro sensitivity assays may play an important role in the control of 
drug resistance and an advantage to this method is that it prevents the interaction of host-
related factors, thus, providing an objective insight into the intrinsic drug sensitivity of 
malaria parasites. 
For a parasite to be considered resistant, slow parasite clearance time in vivo has to have in 
vitro correlates. For years, consistent and significant correlations between half-lives and 
readouts from any invitro artemisinin susceptibility assay had not been demonstrated (Noedl 
et al., 2008; Dondorp et al., 2009; Amaratunga et al., 2012). 
 A potential explanation for this observation was that parasites were exposed to very low 
concentrations of dihydroartemisinin (DHA, the active metabolite of all artemisinins in-vivo) 
for 48-72hr, while in-vivo parasites were exposed to much higher concentrations of DHA for 
only 1-2hr. It has been reported that artemisinin resistance in drug selected P. falciparum 
lines is associated with decreased susceptibility of ring-stage parasites (Witkowski et al., 
2010; Klonis et al., 2013). As a result, a more recent study done in 2013 by a group of 
researchers demonstrated significant correlations between half-lives and readouts from an in 
vitro artemisinin susceptibility assay through a novel phenotypic assay known as the RSA
0-3h
 
(Witkowski et al., 2013). 
In this assay, long parasite clearance half-life (the time it takes for the peripheral blood 
parasite density to decrease by 50%) following treatment with ART monotherapy or an ACT, 
correlated with in-vitro studies. The invitro studies showed that the percentage of early ring 
stage parasites during 0-3hr post invasion of human erythrocytes survive when exposed to a 
pharmacologically relevant exposure to dihydro-artemisinin (Witkowski et al., 2013). 
Although the assay successfully discriminates between a DHA resistant and DHA sensitive 
parasites, it is laborious, expensive and time consuming. The standard EC50 assays that have 
been used for decades (48hr assay) are not sensitive enough to discriminate between 
differences in EC50 values that may exist between different isolates (Van Schalkwyk et al., 
2013, Witkowski et al., 2013). Moreso, the most well studied parasites strains used in in-vitro 
assays have been in use for more than two decades and so were isolated years before the 
widespread artemisinin-based combination therapy era and the majority of these used strains 
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have originated from the Americas and Asia but Africa is where the greatest transmission 
intensity occurs and where the majority of deaths from malaria are reported (WHO, 2011). 
As a result, there is an urgent need to develop an alternative assay that is less laborious, 
cheaper and developed specifically for African parasites which face the current ACT drug 
pressure. The standard 48-hour assay was designed for a longer acting drug, chloroquine 
which has a different pharmacological profile from ACTs. Artemisinins have a shorter half-
life and recent evidence of reduced sensitivity to artemisinin in-vivo suggests that parasites 
have developed a mechanism that allows dormancy in the ring stage of their life cycle in 
order to evade the toxic effects of the short half-life artemisinin derivative (Teuscher et al., 
2010; Witkowski et al., 2013). This has given rise to an altered phenotype which needs to be 
studied (Witkowski et al., 2013). 
This chapter aims to validate in vitro assays on parasite lines isolated since the use of ACT 
was widespread in Africa. The work in this chapter is to improve in vitro methodology using 
isolates from Ghana, Nigeria and Kenya.  
 
The specific aim of this chapter is  
1. To determine in vitro responses of African field isolates that have the current ACT 
exposure and are culture adapted. 
2. To identify a scalable assay able to discriminate between parasites lines with small 
differences in artemisinin sensitivity.  
3. To identify phenotypes relevant to the genetic exploration of artemisinin resistance in 
African settings. 
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4.2 Sample information of parasite lines used in this study 
 
The isolates used in this study were obtained from patients who presented with malaria at the 
Hospital for Tropical Diseases, London (HTD), or the accident and emergency department of 
the University College London Hospitals (UCLH).  A 4mL vacutainer tube containing EDTA 
(BD) was used to obtain venous blood sample, some of which was used for laboratory 
adaptation of the malaria parasites in the malaria culture laboratory at the London School of 
Hygiene and Tropical Medicine. Ethical approval was obtained from the Research Ethics 
Committee of the University College London Hospitals (Application number: 07/Q0505/60). 
 
4.2.1 Sample information for parasite lines 
 
 
HL1204  
 
This isolate was collected from a Kenyan male who is resident in the UK and had spent three 
weeks in coastal Kenya and Nairobi. Intravenous artesunate was given to the patient with a 
full course of oral artemether-lumefantrine after being discharged and at ~72 hours on 
(Schalkwyk et al, 2013). 
 
 
HL1402 
This isolate was collected from an adult male patient who resided in Kenya. He presented 
with malaria at the Hospital for Tropical Diseases, while on a work-related trip to the UK. 
 
 
 
HL1210  
 
This isolate was collected from an Indian-born young adult male who studied in the UK but 
was resident in Singapore. The subject travelled to Ghana for two weeks and had a course of 
chloroquine-proguanil as anti-malarial chemoprophylaxis from a high street pharmacy in the 
UK before departure. A prescription (Chloroquine-proguanil), which is not available in the 
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UK to purchase, is no longer considered appropriate chemoprophylaxis for sub-Saharan 
Africa. After diagnosis at HTD, the patient was admitted to UCLH and prescribed oral 
artemether-lumefantrine (Schalkwyk et al., 2013).  
 
 
HL1212  
 
This isolate was collected from an adult UK resident female who recently travelled to 
Nigeria. A written permission was given by the parent’s immediate family for any viable 
malaria parasites to be placed in culture for research (Schalkwyk et al, 2013). 
 
 
 
Table 4.1 List of Plasmodium falciparum parasite lines, origin, characteristics and year 
reported: DHA sensitivity data using a standard 48 hour assay on parasite lines HL1204, 
HL1210 and HL1212 were reported in a study done by Schalkwyk et al; drug sensitivity 
information on HL1402 is being published for the first time in this study. 
 
Parasite Line Origin Region Characteristics Year 
Isolated  
Reference 
3D7 Netherlands Europe Lab adapted 
line 
1985 Walliker et 
al , 1987 
HL1204 Kenya Africa Field isolate, 
culture adapted 
2012 Schalkwyk 
et al, 2013 
HL1210 Ghana Africa Field isolate, 
culture adapted 
2012 Schalkwyk 
et al, 2013 
HL1212 Nigeria Africa Field isolate, 
culture adapted 
2012 Schalkwyk 
et al, 2013 
HL1402 Kenya Africa Field isolate, 
culture 
2014 unpublished 
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4.3 Quality assurance of a solution of dihydroartemisinin in dimethyl sulfoxide 
 
To verify that freeze-thaw of DHA aliquots did not change drug concentration, a 100ul 
aliquot of frozen stock drug in DMSO was tested to confirm it contained 2.84 mg/ml of the 
active pharmaceutical ingredient DHA. This was done to ensure that the DHA drug 
concentration remained the same when freeze-thawed each time for new sets of experiment. 
 
HPLC separation of a solution of DHA (2.84 mg/ml) in DMSO 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: HPLC separation curve showing the concentration of the analysed sample. 
The solution had an initial DHA concentration of 2.84mg/ml in DMSO. This sample was 
tested in the pharmacology lab of the London School of Hygiene and Tropical Medicine 
and by Dr Harpakash Kaur.  
 
 
The test solution was subjected to high performance liquid chromatography (HPLC) analysis 
and confirmed to contain 2.75 mg/ml DHA. The solution contained the DHA in the 
acceptable range. Prior to analysis, the solution was sitting on the bench for a day because the 
machine had technical issues. As a result, the measured amount was not exactly 2.85 mg/ml 
but is within the acceptable 10% range by HPLC.  
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This result is very useful as DHA aliquots were thawed each time an experiment had to be 
carried out. Also, DHA aliquots in eppendorf tubes sometimes are placed in the level 3 safety 
cabinet for at least an hour before being used for an experiment. This result shows that in the 
event that this has happened, the DHA drug concentration did not deviate from the acceptable 
HPLC range. 
 
 
 
Calibration curve of solutions of DHA [0.0 -5.0 mg/ml] used to determine the 
concentration of the submitted solution. 
 
 
 
 
 
 
 
 
 
Figure 4.2:  HPLC calibration curve showing the concentration of the analysed sample. 
This sample was tested in the pharmacology lab of the London School of Hygiene and 
Tropical Medicine and by Dr Harpakash Kaur.  
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4.4 Standard 48-hour (EC50
48
) sensitivity to chloroquine in-vitro 
 
To determine the in-vitro responses of all P. falciparum lines used in this study, the 
chloroquine sensitivity of all lines had to be established using the standard 48-hour assay as 
described in section 3.4. The dose response curve shows chloroquine drug sensitivity assay 
for isolates HL1204, HL1212, HL1402, HL1210 and 3D7. Isolates with starting parasitaemia 
of 0.5% exposed to 1000nM of chloroquine showed a mean EC50
48
 value of 12.9nM, 10.0nM, 
15.7nM, 238nM and 14.5nM respectively. All the isolates except HL1210 were sensitive to 
chloroquine and showed no significant difference in EC50 values for chloroquine drug 
sensitivity. The HL1210 isolate was chloroquine resistant. 
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Figure 4.3 A standard 48-hour drug response curve for African isolates: Chloroquine drug 
sensitivity assays for parasite lines 3D7, HL1204 and HL1212. The standard 48 hour assay 
does not successfully discriminate between parasite lines as indicated by the EC50 values 
(EC50
48
) for both drugs. 
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4.5 Standard 48-hour (EC50
48
) sensitivity to dihydro-artemisinin in-vitro 
 
In order to establish the DHA sensitivity of all P.falciparum lines used in this study, the in 
vitro response of all lines to DHA were determined using the standard 48-hour assay as 
described in section 3.4. Sensitivity to DHA in vitro for African isolates HL1204, HL1212, 
HL1402, HL1210 were analysed with 3D7 as control. Isolates with starting parasitaemia of 
0.5% exposed to 100nM of DHA showed a mean EC50
48
 value of 4.7nM, 6.7nM, 6.8nM, 
2.8nM and 4.0nM respectively. All the isolates were sensitive to DHA and showed no 
significant difference in EC50 values for drug sensitivity. 
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Figure 4.4 Comparison of standard 48-hour drug response curve for African isolates: 
DHA drug sensitivity assays for parasite lines HL1204 and HL1402, HL1210 and HL1212 
with 3D7 as a control lab adapted line. The standard 48 hour assay does not successfully 
discriminate between parasite lines as indicated by the EC50 values (EC50
48
) for DHA. 
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4.6 Sensitivity to dihydro-artemisinin drugs in-vitro for African isolates 
 
The standard 48-hour assay could not successfully discriminate between the DHA EC50 
values of the 4 African isolates (Fig 4.4). In order to improve ability to discriminate, a novel 
6-hour pulse assay, where synchronised isolates (at 0.5% parasitaemia) were exposed to a 6hr 
DHA pulse at varying drug concentrations was designed (see Chapter 3.5). DHA drug 
exposure at the ring stage of the parasites life cycle was carried out and a dose response curve 
of DHA drug concentration and percentage parasite viability was plotted for all isolates.  
 
4.6.1 Sensitivity to dihydro-artemisinin drugs in vitro for HL1204 isolate from Kenya 
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Figure 4.5 6hr pulse and 48hr exposure of HL1204 isolate to dihydro- artemisinin in- 
vitro: Mean DHA (EC50
6hr
) drug sensitivity assay for parasite line HL1204 shows a higher 
value when compared to the standard (EC50
48hr
) assay for DHA. Experiments were carried 
out in quadruplets and repeated 4 times.  
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The mean EC50value for the parasite line HL1204 using the standard 48-hour assay was 
4.5nM while the mean EC50 using the 6-hour pulse assay was 9.1nM. This is shown by a shift 
to the right in EC50 values of the dose response curve. The DHA (EC50
6hr
) assay was able to 
successfully show differences in EC50values that exist for DHA (ΔEC50 =4.4nM) using the 
same isolate HL1204, with a P value = 0.004. 
 
4.6.2 Sensitivity to dihydro-artemisinin drugs in vitro for HL1210 isolate from Ghana 
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Figure 4.6 Sensitivity of HL1210 isolateto DHAin vitro with a 6 hr pulse and a 48 hr 
assay: DHA (EC50
6hr
) drug sensitivity assay for parasite line HL1204 shows a higher 
value when compared to the standard (EC50
48hr
) assay for DHA with an EC50 of 12nM for 
the pulse assay and 2.8nM for the standard assay. The DHA (EC50
6hr
) assay was able to 
successfully show differences in EC50 values for DHA with a P value = 0.04 (Two tailed t-
test). 
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The parasite isolate from Ghana, HL1210, had a mean EC50 value of 2.8nM for the standard 
48-hour assay and a mean EC50 value of 12nM for the 6-hour pulse assay. Again, the same 
trend of a shift to the right in the dose response curve was observed. The pulse assay was able 
to successfully show differences in EC50values that exist for DHA (ΔEC50 =9.2nM) using the 
same isolate HL1210, with a P value of 0.04 (two tailed t-test) which was statistically 
significant. 
 
4.6.3 Sensitivity to dihydro-artemisinin drugs in vitro for HL1212 isolate from Nigeria 
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Figure 4.7 6 hr pulse and 48 hr exposure of HL1212 isolateto dihydro- artemisinin in 
vitro: DHA (EC50
6hr
) drug sensitivity assay for parasite line HL1212 shows a shift to the 
right when compared to the standard (EC50
48hr
) assay for DHA with an EC50 of 26nM for 
the pulse assay and 6.7nM for the standard assay. The DHA (EC50
6hr
) assay was able to 
successfully show differences in EC50 values for DHA with a P value = 0.0001 (two tailed 
t-test). 
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For isolate HL1212 from Nigeria, the mean EC50value for the parasite line using the standard 
48-hour assay was 6.7nM while the mean EC50value using the 6-hour pulse assay was 26nM. 
This is shown by a shift to the right in EC50 values of the dose response curve, similar to 
other isolates. The DHA (EC50
6hr
) assay was able to successfully show differences in 
EC50values that exist for DHA using the same isolate HL1212. The difference in mean EC50 
values between both assay (ΔEC50 =19.3nM) was statistically significant with a P value of 
<0.0001. 
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4.6.4 Sensitivity to dihydro-artemisinin drugs in vitro for HL1402 isolate from Kenya 
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Figure 4.8 Sensitivity of HL1402 isolateto DHAin vitro with a 6 hour pulse and a 48 
hour assay: DHA (EC50
6hr
) drug sensitivity assay shows a shift to the right when 
compared to the standard (EC50
48hr
) assay for DHA with an EC50 of 45nM for the pulse 
assay and 7.1nM for the standard assay. The DHA (EC50
6hr
) assay was able to successfully 
show differences in EC50values for DHA with a P value = 0.0006 (Two tailed T-test). 
 
The HL1402 isolate had a mean EC50 value of 7.1nM using the standard 48-hour assayswhile 
the mean EC50 value using the 6-hour pulse assay was 4.9nM. This is shown by a shift to the 
right in EC50 values of the dose response curve, similar to other isolates. The DHA (EC50
6hr
) 
assay was able to successfully show differences in EC50 values that exist for DHA using the 
same isolate. The difference in mean EC50 values between both assay (ΔEC50 =37.9nM) was 
statistically significant with a P value of <0.0006. It is worth noting that the difference 
between HL1402 and HL1204 (both from Kenya) is that they both have different genotypes. 
HL1402 comprises of novel mutations (see Chapter 6). The former was collected in 2014 
while the latter was collected in 2012.  
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4.7 Multiplicity of Infection in clinical Isolates 
 
The numbers of parasite types present in the isolates, which are uncloned, were estimated by 
nested PCR amplification of the P. falciparum merozoite surface protein 1 (Pfmsp1) and 2 
(Pfmsp2). Clonal multiplicity for isolates HL1204, HL1210 and HL1212 which were 
successfully adapted to culture were estimated in a previous study (Schalkwyk et al, 2013). 
Before experiments were carried out for this project, Pfmsp1 and Pfmsp2 genotyping was 
repeated to confirm the population of clones present in each isolate. This experiment was 
repeated after a few weeks of the parasites being in culture in order to examine if the 
population of clones in each isolate had changed with time. For isolate HL1402, PCR 
amplification of the P. falciparum msp1 and msp2 were estimated for the first time (Table 
4.2). 
 
TABLE 4.2: Pfmsp1 and Pfmsp2 genotype of isolate HL1204. HL1210 and HL1212 
(Schalkwyk et al, 2013) 
 
 
Isolate  Sample    pfmsp1     pfmsp2 
Minimum number of 
clones* 
    K1 MAD20 R033 FC27 IC Per sample  Per isolate 
HL1204 Kenya 
Day 0 pre-
treatment 0 1 2 0 1 3 4 
  
Day 1 post-
treatment 0 2 2 0 1 4   
  culture-adapted 0 1 1 0 1 2   
HL1210 Ghana 
Day 0 pre-
treatment 2 2 0 0 1 4 4 
  
Day 1 post-
treatment 2 2 0 0 1 4   
  culture-adapted 2 2 0 0 1 4   
HL1212 
Nigeria 
Day 0 pre-
treatment 3 2 1 2 1 6 6 
  culture-adapted 2 1 0 3 1 4   
*The minimum number of clones in each sample was estimated by adding the highest number of bands for each 
pfmsp allele. No day 1 post-treatment sample was obtained for HL1212. (Van Schalkwyk et al, 2013). 
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In the previous study by Schalkwyk et al, HL1204, HL1210 and HL1212 were estimated to 
have 4, 4 and 6 clones respectively. When this experiment was repeated, HL1204 comprised 
of 2 clones present while HL1212 comprised of 3 clones. Further pfmsp1 and pfmsp2 
genotyping was carried out after parasites had been in continuous culture for about 3 weeks 
and the results show that HL1204 clonal population reduced to one clone while HL1212 
comprised of two clones. HL1402 isolate comprised of one clone after culture adaptation.  
 
It is worth noting that drug sensitivity assays were carried out on each isolate a few days after 
being freeze thawed. This was done each time for every experiment because the results show 
that the relative abundance changes in continuous culture and it was important to keep the 
experiment conditions as consistent as possible, and to represent the complexity of natural 
infections. 
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Table 4.3 Pfmsp1 and Pfmsp2 genotype of isolate HL1204, HL1210 and HL1212: The clone population present are shown after parasites 
had been freeze thawed and were adapted to culture. A no treatment control and 3D7 were used as controls.  
Isolate 
Pfmsp1 
K1 Mad20 R033 IC (3D7) 
Pfmsp2 
FC Interpretation  
3D7 1:50 
dilution 1 - - - - positive control  
HL1402_K 1 - - - 1 1  clone  
HL1204_K - - 1 1 - 2 clones  
HL1212 _N 1 - - 1 2 3 clones 
 
 
Table 4.4: TABLE 4.3 Pfmsp1and Pfmsp2 genotype of isolate HL1204. HL1210 and HL1212: The clone population present are shown after 
parasites had been freeze thawed and were adapted to culture. The parasites had been in culture for about 3 weeks. A no treatment control and 
3D7 were used as controls. The table shows the drop in clone population with increased culture time.(K =Kenya, N= Nigeria). 
Isolate 
 Pfmsp1  
K1 Mad20 R033 
 
IC (3D7) 
Pfmsp2 
FC Interpretation  
3D7 1:50 
dilution 1 - - - - positive control  
HL1402_K 1 - - - 1 1  clone  
HL1204_K - - - 1 - 1 clones  
HL1212 _N 1 - - - 1 2 clones 
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Table 4.5 Chloroquine and DHA sensitivity assay: A standard 48 hour assay was carried out using chloroquine and DHA drugs. Assays were 
carried out using parasite lines 3D7, HL1204, HL1210, HL1212 and HL1402. Data shows the number of experiments carried out and the number 
of replicates per experiment with corresponding EC50 values.  
PARASITE CQ Assay :      EC50
48h
 DHA Assay 1:      EC50
48h
 
 
# 
Experiments 
# replicates per 
experiment mean EC50 (SD) # Experiments 
# replicates per 
experiment mean EC50 (SD) 
3D7 6 8 14.5 ± 3.2 4 4 4.0 ± 0.6 
HL1204_K 3 8 12.9 ± 1.1 4 4 4.7 ± 0.2 
HL1212_N 4 8 10 ± 4.5 6 4 6.7 ± 3.9 
HL1210_G 3 8 238 ± 26.3 4 4 2.8 ± 1.4 
HL1402_K 3 8 15.7 ± 0.3 3 4 6.1 ± 1.0 
 
The abbreviations for isolates are K, G, N for Kenya, Ghana and Nigeria respectively. The EC50 values are averaged for at least three 
independent experiments with some repeated with up to six occasions. All data are represented as mean ± S.D 
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Table 4.6 DHA standard 48hr and 6hr pulse assay: The standard 48 hour assay was carried out using DHA. Data shows mean EC50 values 
for the 6 hour pulse assay and the standard 48 hour assay with corresponding fold difference and results for statistical significance 
PARASITE DHA_Assay 2:     EC50
6h
 DHA_Assay 1:     EC50
48h
 
  
 
# 
Experiments 
# Replicates mean EC50 (SD) 
mean EC50 (SD) 
# 
Experiments 
# 
Replicates 
fold 
difference 
P value 
(Ttest) 
3D7 3 
4 16.9 ± 4.0 
4.0 ± 0.6 4 4 4.2 0.13 
HL1204_K 3 
4 9.1 ± 0.8 
4.7 ± 0.2 4 4 1.9 0.004 
HL1212_N 3 
4 26 ± 13.0 
6.7 ± 3.9 6 4 3.8 <0.0001 
HL1402_K 3 
4 44.5 ± 5.0 
6.1 ± 1.0 4 4 7.2 0.0006 
HL1210_G 4 
4 12 ± 0.8 
2.8 ± 1.4 3 4 4.2 0.04 
 
The abbreviations for isolates are K, G, N for Kenya, Ghana and Nigeria respectively. The EC50 values are averaged for at least three 
independent experiments with some repeated with up to six occasions. All data are represented as mean ± S.E.M. A two-tailed test was used to 
test significance at P >0.05 
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4.8 DHA (EC50
6hr
) sensitivity profiles for HL1204, HL1210 and HL1212 isolates 
 
When all the data for the 6 hr pulse assays were superimposed, it showed that HL1212 isolate 
had the highest DHA EC50 value of 26nM. This was followed by HL1210 from Ghana 
(12nM) and lastly, HL1204 from Kenya (9.1nM) showed a higher sensitivity to dihydro-
artemisinin. 
 
 
-1 .0 0 -0 .7 5 -0 .5 0 -0 .2 5 0 .0 0 0 .2 5 0 .5 0 0 .7 5 1 .0 0 1 .2 5 1 .5 0 1 .7 5 2 .0 0 2 .2 5 2 .5 0
0
1 0
2 0
3 0
4 0
5 0
6 0
7 0
8 0
9 0
1 0 0
1 1 0
1 2 0
L o g  [D H A ](n M )
%
 V
ia
b
il
it
y
H L 1 2 0 4
H L 1 2 1 0
H L 1 2 1 2
H L 1 4 0 2
 
Figure 4.9 Comparison of DHA (EC50
6hr
) drug sensitivity profiles of African isolates: 
The graph shows the mean DHA (EC50
6hr
) for isolates HL1204, HL1210 and HL1212 all 
superimposed. Isolate HL1204 has the lowest EC50 value while HL1212 has the highest 
EC50
6hr
 value. These differences are statistically significant.  
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Table 4.7 Mean Difference in DHA EC50 (nM) between African isolates, by the standard 
48hr assay and 6hr pulse assay: Mean difference in DHA sensitivity of the 6 hour pulse 
assay and standard 48 hour assay. Comparisons were made between each African isolate and 
the P value of this difference is shown. (P < 0.05) 
 
 
 
 
 
 
 
 
When all the isolates were compared with each other, it was clear that the DHA EC50
48hr
 
assay was not successful in discriminating the differences in DHA sensitivity between 
parasites from the three regions of Africa. The mean differences were very little and had no 
statistical significance. However, when the isolates were compared using the DHA EC50
6hr 
assay, the mean difference between each comparison was significantly different at P >0.05 
(Table 4.7). 
 
DHA EC50 figures were compared between isolates to ascertain if the assay could tease out 
small differences in DHA sensitivity that may exist. Isolate HL1212 and HL1402 showed a 
mean difference of 16.9nM, with a statistically significant difference and P value of 0.005 
(appendix).  
 
When HL1204 was compared to HL1402, the difference in DHA EC50
6hr
 was statistically 
significant (mean difference 35.4, P=0.04). It can be seen that the two isolates from Kenya 
are different. 
 
Region 6hr Pulse assay: Mean 
difference nM (P value) 
48hr Standard assay: Mean 
difference nM (P value) 
3D7 vs. HL1204 7.8 (0.14) 0.8 (0.12) 
3D7 vs. HL1210 4.9 (0.01) 1.1 (0.20) 
 HL1212 vs. 3D7 9.1 (0.09) 2.8 (0.43) 
HL1402 vs. 3D7 27.6 (0.07) 2.9 (0.43) 
HL1212 vs. HL1204 16.9 (0.02) 2.0 (0.11) 
HL1402 vs. HL1212 18.5 (0.02) 2.1 (0.78) 
 
 
106 
 
 
4.9 PfK13 Genotyping of HL1204 (Kenya) and HL1212 (Nigeria) 
 
The isolates which showed the biggest differences in DHA EC50
6hr 
were genotyped in the P. 
falciparum propeller region (Pfk13) to investigate if this region had any described mutations 
associated with artemisinin resistance. The sequence was compared to a lab adapted control 
isolate, 3D7. 
 
 
 
Figure 4.10 Pfk13 Genotyping of artemisinin resistant locus: HL1204 and HL1212 
isolates are wild-type at position C580. 
 
Results show that both parasites do not have the C580Y mutation associated with artemisinin 
resistance. Other positions were also investigated in this study but both isolates were wild 
type at all positions associated with artemisinin resistance. 
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4.10: Susceptibility of H1204 and HL1212 to Artemisinin partner drugs 
 
To investigate the susceptibility of Plasmodium falciparum isolates, HL1204 and HL1212 to 
partner drugs in vitro, isolates were exposed to piperaquine and lumefantrine for 48 hours. 
Failure to partner drugs like lumefantrine has been reported in Southeast Asia (Amaratunga et 
al., 2016; Duru et al., 2015; Leang et al., 2015 Spring et al., 2015), where artemisinin 
resistance has occurred. As a result, it is important to ascertain the susceptibility of these 
drugs in the African isolates. 
 
TABLE 4.8 Susceptibility of African isolates to partner drugs: Standard 48-hour assay of 
partner drugs to HL1204 (Kenya) and HL1212 (Nigeria). The data shows EC50 and EC90 
values with corresponding standard deviation figures. CQ- Chloroquine, DHA- 
Dihydroartemisinin, PIP- piperaquine, LUM- lumefantrine. 
  CQ (nM) DHA(nM) PIP (nM) LUM )nM) 
  EC50 EC90 EC50 EC90 EC50 EC90 EC50 EC90 
3D7 15 ± 2 23 ± 3 5.5 ± 1.1 13 ± 2 15 ± 1 21 ± 2 86 ± 27 224 ± 70 
HL1204 14 ± 2 21 ± 2 2.7 ± 0.4 6.3 ± 1.1 26 ± 4 38 ± 6 115 ± 17 232 ± 38 
HL1212 9.3 ± 0.6 15 ± 1 3.8 ± 0.9 9.7 ± 1.9 21 ± 4 34 ± 7 88 ± 22 213 ± 58 
 
 
The data shows that for HL1204, piperaquine EC50 value is 26nM while that of HL1212 is 
21nm. For lumefantrine, the EC50 values are 115nM and 88nM respectively. Both HL1204 
and HL1212 are sensitive to the partner drugs tested based on this data.  
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4.10 Discussion 
 
This chapter aims to explore appropriate methodology to discriminate between parasite 
genotypes with small differences in artemisinin susceptibility. It aims to investigate which 
method best discriminates between DHA sensitive and tolerant isolates by using two assays, 
the standard 48-hour drug assay and a 6 hour pulse assay. The 6 hour pulse assay ensures 
antimalarial drugs are washed off the parasite after 6 hrs, to simulate short half-life in vivo 
conditions and to observe any differences that may exist in DHA EC50 values. 
The chloroquine standard assay on all isolates tested showed that all were sensitive to 
chloroquine apart from isolate HL1210 (Ghana). When comparisons were carried out to see if 
the sensitivity profiles of these isolates from three different African countries differed, no 
significant difference in mean EC50 values were observed. Chloroquine mean EC50
48hr
 values 
were 12.9nM, 10.0nM, 15.7nM and 14.5nM for HL1204, HL1212, HL1402 and 3D7 
respectively (Fig.4.3). These findings are consistent with another study which tested 
chloroquine sensitivity profiles of different African isolates. The study found the chloroquine 
EC50
48hr
 values of the same strains, HL1204 from Kenya and HL1212 from Nigeria for 
example, to be within the range of 13nM ± 2 and 12nM ± 3 and 3D7 being 15nM ± 2 
(Schalkwyk et al, 2013).  
The DHA standard 48-hour assay on all isolates tested showed that all were sensitive to 
DHA. The mean DHA EC50
48hr
 values for HL1204, HL1212, HL1402, HL1210 and 3D7 
were 4.7nM, 6.1nM, 6.8nM, 2.8nM and 4.0nM respectively (Table 4.5). Again, these values 
are consistent with other published studies ((Schalkwyk et al, 2013). When comparisons were 
made between isolates to see if the sensitivity profiles differed, there was no significant 
difference in mean EC50
48hr
 values were observed (Table 4.3). This means that the standard 
DHA EC50
48hr
 assay could not successfully discriminates between the different African 
isolates, including the lab adapted strain 3D7. A study carried out by Witkowski et al, where 
culture-adapted parasites from 13 fast- and 13 slow-clearing infections collected in Pursat, 
Cambodia, in 2010 were exposed to DHA in a standard 48-hour assay showed similar 
findings. The isotope-based sensitivity assay (ISA) that monitored replication of parasites 
exposed to drug for 48 h, showed that the fast- and slow-clearing parasites did not differ 
significantly in EC50 values for DHA (Witkowski e al, 2013). 
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A potential reason why the standard EC50
48hr
 assay has failed to tease out the differences in 
DHA EC50 between different isolates is that parasites are exposed for 48 hr while parasites in 
vivo are exposed to concentrations of DHA for only 1-2 hr. Artemisinin resistance in P. 
falciparum has been associated with decreased susceptibility of ring-stage parasites 
(Saralamba et al., 2011; Klonis et al., 2013). As a result, the standard assay does not focus on 
this stage, rather it extends to the whole life cycle and so might miss out on the important 
stage of the parasite life cycle. Moreso, another study showed that a consistent decrease in 
sensitivity using standard in-vitro assays was not exhibited in parasites that were isolated 
from patients that showed delayed clearance in-vivo (Dondorp et al., 2009). This means the 
standard assay is not sensitive enough to discriminate between different artemisinin 
sensitivity profiles. As a result, the 6 hr pulse assay was used to find a more sensitive method 
of assaying artemisinin and to validate in vitro assays on African parasite lines. 
The effect of the 6 hr pulse format is a marked shift to the right in the dose response curve 
graph which was observed for all the isolates tested with both CQ and DHA. This simply 
reflects the fact that overall, the mean DHA EC50 values for the 6 hour pulse assays were 
higher than the mean EC50 values for the standard 48 hr assay. This result shows that there is 
a difference in EC50 values when both assay methods are compared. The results also show 
that this difference is larger in isolates HL1210 and HL1212 compared to HL1204. A two 
tailed T-test carried out showed that the differences in DHA EC50 for both assays are 
statistically significant (Table 4.6). For the laboratory clone 3D7, the EC50 value for DHA for 
the 6 hr assay was approximately 3-fold higher than that of the 48 hr assay.  
The same trend of a shift to the right was observed in all isolates for the chloroquine drug 
sensitivity assay when the 6-hour pulse was compared to the standard 48-hour assay 
(appendix 1). The 48hr assay using chloroquine was also included as a control due to the fact 
that there is extensive wealth of knowledge regarding chloroquine EC50 value and drug 
action. 
HL1210 from Ghana was chloroquine resistant hence the high mean EC50
48hr
value for 
chloroquine (238 nM ±26) while HL1204, HL1212 and HL1402 were all sensitive to 
chloroquine. These findings are consistent with published studies which reported chloroquine 
resistance (150nM ± 7) in the same HL1210 strain and chloroquine sensitivity in the HL1204 
and HL1212 strain. (Schalkwyk et al., 2013). Isolates that are resistant to chloroquine have 
been found to be sensitive to artemisinin (Henriques et al., 2013). A very early study done by 
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Brasco and Bras (1993) demonstrated this and showed that chloroquine-resistant isolates 
were significantly more susceptible to artemisinin with EC50 values of (7.67 nM), arteether 
(EC50 3.88 nM), artemether (EC50 3.71 nM), and artelinate (EC50 3.46 nM). In this study, the 
HL1210 chloroquine resistant isolate was found to be the most sensitive isolate to DHA 
(EC50
48hr
 2.8nM±1.4). 
The mean DHA EC50 and in vivo values for the standard 48 hr assays which ranged from 
2.8nm -6.7nm for all isolates are not far from other known EC50 values in published studies 
which gives confidence in the data from this study. In a study that tested the in vitro 
susceptibility of ACTs in travellers returning with Plasmodium, mean EC50 for DHA was 
3.62nM (Pillai et al., 2012). Our laboratory reported a range of 1.7nM to 5.5nM among 7 
isolates from travellers returning into the UK (Schalkwyk et al., 2013). 
When the African parasite lines were compared to each other (Table 4.3) using the standard 
48-hour assay, there was no significant difference in DHA EC50
48h
 values for all isolates. For 
example, comparison of HL1212 (Nigeria) and HL1402 (Kenya) were not significantly 
different (mean difference = 2.0nM, P =0.15) which means the standard assay was not 
successful at teasing DHA drug sensitivity differences apart. However, when the isolates 
were compared using the 6-hour pulse assay, the mean difference in EC50 value was 
statistically significant (mean difference = 16.9nM, P = 0.005). 
 In-vitro studies have shown that artemisinin effects vary across the different intra-
erythrocytic parasite stages, as mature trophozoites and schizonts are susceptible to 
artemisinin irrespective of in-vivo phenotype, in contrast to ring-stage, trophozoites (Kuile et 
al., 1993; Witkowski et al., 2010).  Studies have shown however, that ring-stage parasites 
aged 0–3 hr possess differential ability to survive pulses of artemisinin in vitro among 
parasites that are genetically distinct (Witkowski et al, 2013; Dogovski et al, 2015). Klonis et 
al (2013) showed that tightly synchronized parasites exposed to short drug pulses show large 
stage-dependent differences in their response to artemisinin and this correlates with 
haemoglobin digestion throughout most of the asexual cycle. As a result, ring-stage parasites 
can exhibit >100-fold lower sensitivity to short drug pulses than trophozoite stage. 
The pulse assay designed in this study also focused on the tightly synchronized ring stage and 
the application of a 6 hour pulse was introduced to mimic in vivo conditions and as a result, 
higher estimates of EC50 to drug pulses were observed when compared to the standard assay 
which had the asexual stages that digest haemoglobin. Crucially, DHA EC50
6h
 estimates 
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showed greater variability between isolates. The findings in this chapter are consistent with 
published work that show that laboratory strains show little differences in drug sensitivity in 
standard in vitro assays but when exposed to short drug pulses,  exhibit substantial (>95-fold) 
difference in sensitivity (Klonis et al, 2013). 
It is worth mentioning that pulse assays were carried out in the same 96 well plate as standard 
assays so parasites in both assays were from the same vial and were under the same 
conditions. Also, when 48 hr assays were done independently with all isolates, the Mean 
EC50 values shown were in close range to EC50 values of a standard 48 hr assay done in the 
same 96 well plate as the pulse assay. 
Variations in EC50 values were seen between each experiment in a single isolate. This may 
have been due to the polyclonal nature of isolates used in this study. The HL1212 isolate 
however had the most variation within experiments (6hr pulse and 48hr assay) compared to 
the other isolates and had a higher population of clones (6 clones). Another possible reason 
could be linked to a study carried out in Nigeria about a possible artemisinin-based 
combination therapy resistance (Ajayi et al, 2013). 
Variations in DHA EC50 values between each isolate could be explained by the different drug 
policies that exist in these countries. For example, Ghana and Nigeria which have a higher 
mean DHA EC50 value in the pulse assay are neighbouring West African countries which 
have a different drug use history compared to Kenya which is in East Africa.  
What all African countries however have in common, is that the use of Artemether-
Lumefantrine (AL), has been the front-line anti-malarial treatment recommended by the 
WHO compared to the greater Mekong region, this treatment (ACT) still has high cure rates 
in Africa (Sawa et al., 2013). There are efficacy studies from a few African countries such as 
Uganda (Yeka et al., 2016), Nigeria (Ajayi et al., 2013) and Angola (Kiako et al., 2015; 
Plucinski et al., 2015) that show a decrease in cure rates of patients given AL compared to 
baseline studies performed a decade ago when ACTs were first introduced. Moreso, treatment 
failure was documented in some case reports in non-immune travellers who got infected with 
malaria and were treated with AL in European hospitals (Farnet et al., 2012; Repetto et al., 
2011). Another study carried out in Mbita, Kenya in 2009 found that 20.7% of AL-treated 
children showed recurrent parasitaemia within 42 days after commencement using a 
combination of PCR and microscopy end-points (Henriques et al., 2014). In the study by 
Schalkwyk et al., (2013), isolates HL1212 and HL1204 had lumefantrine EC50 estimate of 
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67nM and 119nM while HL1210 was sensitive to lumefantrine with an estimate of 24nM. 
Sensitivity to lumefantrine was assessed for HL1402 in this study and the EC50
48 
was found to 
be 50nM. To date, there is no validated EC50 cut off below which lumefantrine susceptibility 
is considered adequate. One possible explanation could be that there has been no correlation 
of in-vitro estimation of lumefantrine to in-vivo studies or treatment response. 
Studies from Southeast Asia show that reduction in susceptibility to artemisinins is associated 
with single point mutations in the propeller region of the P. falciparum pfk13 locus (Ashley et 
al., 2014; Ariey et al., 2014; Witkowski et al., 2013). However, no point mutation was found 
in the propeller region of the K13 gene in African isolates in this study. Although another 
study has shown that reduction in AL is associated with carriage of alleles of a few 
resistance-associated genes (Henriques et al., 2014), Pfk13 was not included in the resistant 
genes (Muwanguzi et al., 2016).  
The 6 hr pulse assay can serve as a useful tool in assaying artemisinin resistance on the 
African continent and can be used to test the DHA susceptibility of artemisinin resistant 
parasite lines from Cambodia for validation. 
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4.11 Conclusion 
 
In this chapter, a difference in DHA EC50 values in all three field isolates tested for the 6 hr 
pulse assay compared to the standard 48 hr assay was found and the differences were 
statistically significant. The assay was able to distinguish differences in drug sensitivities that 
exist between parasites from different regions. HL1212 isolate from Nigeria had the highest 
EC50
6h
 value compared while the HL1204 isolate from Kenya had the lowest EC50
6h 
value. 
Further investigation into the Pfk13 region of the propeller domain found no point mutation 
associated with artemisinin resistance.  
Although a recent study found a correlation between in-vitro and ex-vivo assay (Witkowski et 
al., 2013) and another study found a molecular marker for artemisinin resistance (Ariey et al., 
2013) both studies used isolates from Cambodia and so are not representative of the isolates 
found in the field in Africa where majority of deaths from malaria does occur. If a significant 
difference in DHA EC50 values exists between the 6 hr pulse and the 48 hr assay within and 
between isolates, then we may be able to identify a new phenotype which could form the 
basis to which artemisinin resistance could be further explored. 
The next chapter would involve including Cambodian isolates with known artemisinin 
resistance and see how they compare with the African isolates used in this chapter. This 
would involve using 700nM DHA exposure to mimic the high drug exposure that occur in 
vivo for more pharmacological relevance and to validate already published data on DHA 
sensitivity. This is done to compare assays in the African isolates and the Cambodian isolates 
in the hope to find a more sensitive approach of drug sensitivity testing. 
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6.1 Strengths of study 
 Parasite lines used in this study are representative of the current drug pressure 
experienced in the field in Africa 
 There is no known study that has carried out a 6 hour pulse assay using field isolates 
from Africa and compared with the standard assay used in drug susceptibility tests. 
6.2 Study limitation 
 There was no use of a known slow clearing parasite as control (e.g. from Cambodia) 
in this study so this caused limitations in direct comparison of DHA EC50 values 
between isolates in this study and other studies.  
 Parasites in this experiment were exposed to low concentration of DHA for both 6 hrs 
and 48hrs even though parasites in-vivo are exposed to much higher drug 
concentrations of DHA for only 1-2 hours. 
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CHAPTER 5 In-vitro studies of Cambodian P.falciparum isolates 
with known Pfk13 C580Y/R359T polymorphisms: new 
approaches to the in-vitro phenotype 
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5.1 Background 
 
In the previous chapter, the novel 6-hour pulse assay was successful at discriminating 
differences in DHA sensitivity that exists among 4 P. falciparum isolates from Africa. A 
limitation of the chapter was not including an isolate with known slow clearance as this 
would have been an artemisinin resistant control and perhaps, validated the study. Slow 
clearing isolates from Cambodia, were obtained from Rick Fairhurst and David Fidock and 
the DHA sensitivity of this isolate panel according to the novel 6hour pulse assay was 
ascertained.  
 
Clinical efficacy studies designed to study artemisinin resistance showed that parasite 
clearance rates were twice as slow in Battambang, a western Cambodia province (Noedl et 
al., 2010), Pursat (Amaratunga et al., 2012) and Pailin (Dondorp et al., 2009) compared to 
the Thai-Myanmar border, despite adequate drug levels. Although other studies indicated 
slow parasite clearance (Phyo et al., 2012). It has since been reported that slow clearing 
infections are common across mainland Southeast Asia (Kway et al., 2013; Ashley et al., 
2014). 
Despite the deterioration of artemisinin clinical response in vivo, slow parasite clearance 
could not be demonstrated in-vitro using the standard 48-hour assay (50% growth inhibition 
in a standard 48 hr exposure).  After the studies carried out by Dondorp et al., (2013) showed 
that artemisinin resistance affected predominantly ring-stage parasites, Witkowski et al., 
(2013) described a ring-stage survival assay which confirmed that ring stages of P. 
falciparum isolates from western Cambodia were highly resistant to DHA, independently of 
host variables (Witkowski et al., 2013). This assay deploys a 700nM DHA exposure for 72 
hours and an endpoint microscopic readout and has some flaws; therefore our 6 hr pulse 
assay may be a better method for phenotyping Cambodian parasites.  
To ascertain a phenotype for DHA drug resistance, it is important to develop a sensitive in-
vitro assay as the current one being used (standard 48hr) has not been successful in 
discriminating between differences in DHA IC50 values in parasite lines (Chapter 4.5). The 
RSA has proved a very useful research tool but has three serious flaws that limit its 
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usefulness as already mentioned in chapter 4.  The novel 6-hour pulse assay which was 
successful in discriminating small differences in DHA EC50 that exists between parasite lines 
from Africa will be used to test the DHA susceptibility of KH2 and Cam 3.11 artemisinin 
resistant lines from Cambodia. 
This chapter aims to validate a bespoke 6h pulse assay method deployed on artemisinin 
resistant Cambodian lines, with full dose-response capacity in 96-well format, using the 
fluorescent DNA reporter Pico-green to measure growth inhibition by DHA. 
Towards this effort, we obtained a KH2 strain from Cambodia (Miotto et al, 2014) and added 
this to be tested along with our African lines from HTD which are samples that have origin in 
regions where artemisinin combination therapies (ACTs) are routinely used for treatment of 
malaria. We also obtained another artemisinin resistant line Cam 3.11 (Straimer et al, 2014), 
which was retrieved as a result of the unsuccessful separation of the contaminated KH2 
artemisinin resistant strain. Further assay work was carried out using this isolate.  
During lab experiments, the KH2 strain contaminated with another strain and so efforts were 
focused on trying to separate mixed Plasmodium falciparum cultures through phenotypic and 
genetic characterisation. This chapter also focuses on the work carried out to isolate the KH2 
clone from a mixed culture.  
 
5.2 Aims 
 
The specific aims of this chapter are: 
 
1. To genetically characterise all Cambodian lines. 
2. To determine DHA in vitro responses of all Cambodian lines using the standard 48-hour 
assay and the novel 6hr pulse assay. 
3. To compare DHA susceptibility data of the Cambodian lines to the HL1204, HL1210, 
HL1212 and HL1402 parasite lines to see if the 6-hour pulse assay can tease out any 
differences in DHA EC50 values. 
4. To identify a scalable assay to discriminate between the artemisinin resistant lines Cam 
3.11 
C580Y
, and Cam 3.11 
R539T
, and sensitive line Cam 3.11 
WT
 (Straimer et al, 2014). 
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5. To test if the assay can discriminate between the isolates from Cambodia and the 
African lines in Chapter 4. 
6. To identify phenotypes that could be relevant to the genetic exploration of artemisinin 
resistance in Cambodia and in Africa. 
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5.3 Results 
 
5.3.1 DHA and chloroquine sensitivity of KH2 in-vitro 
 
To determine the in-vitro response of KH2 to DHA and chloroquine, parasites were exposed 
to drugs using the standard 48 hour assay and a 6 hour pulse assay as described in Chapter 
3.5 and 3.6 with starting parasitaemia of 0.5%. The dose response curve shows the percentage 
viability and the subsequent EC50 values for each drug exposure.  
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Fig 5.1 Chloroquine EC50
6hr
 pulse assay and 48hr assay: Graph showing EC50 
values of KH2 isolate after treatment with chloroquine in the 6 hour pulse assay and 
48 hour assay.  
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Fig 5.2 DHA EC50
6hr
 pulse assay and 48hr assay: Graph showing EC50 values of 
KH2 isolate with treatment with DHA in the 6 hour pulse assay and 48 hour assay.  
 
 
 
When KH2 was exposed to chloroquine and DHA, there was an elevated EC50 value in the 
dose response curve. This is the same trend that was observed in chapter 4 using the 6 hour 
pulse assay on all the African isolates. From the 48 hour assay result, it was noticed that the 
mean EC50 value for chloroquine was 21.9nM. KH2 comes from a chloroquine resistant 
background (Imwong et al, 2010) and as a result, the EC50 value was expected to be a lot 
higher. As a result, it was important to characterise the KH2 isolate genetically and to also 
characterise the phenotype before further experiments on drug sensitivity using the pulse 
assay was carried out. 
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5.4 PfK13 Genotyping of isolate KH2 
 
Since KH2 is supposed to be an artemisinin resistant isolate harbouring mutation in PfK13, 
genotyping of the kelch propeller region was carried out using methods described in chapter 
3.7. DNA was extracted from parasites maintained in continuous culture, immediately after 
drug assay experiments were carried out. The positive control used was 3D7.  
 
Table 5.1: Genetic information of Pfk13 region of KH2 
Isolate Origin Condition Pfk13 
3D7  Netherlands Culture adapted Wild-type 
KH2* (Passage # 2) Cambodia Culture adapted Wild-type 
 
*Since receipt at The London School of Hygiene and Tropical Medicine 
 
The results showed that after KH2 was placed in continuous culture and drug assay 
experiments were carried out, the Pfk13 mutation could not be detected. Further experiments 
were carried out to ascertain the genetic characteristics of the KH2 before further drug assays 
were carried out. 
 
 
5.5 Msp 2 Genotyping of KH2 clone after 700nm of DHA drug exposure 
 
The KH2 isolate was adapted to culture after a freeze thaw. Genotyping experiments were 
carried out and it was confirmed that the KH2 culture also contained an additional parasite 
with a genotype similar to 3D7. Since the KH2 isolate is artemisinin resistant and contains a 
Kelch mutation, we decided to select for the KH2 isolate by exposing it to 700nm DHA for 
72 hours. This was done in the hope that the high concentration of DHA will kill off any 3D7 
in culture (artemisinin sensitive). After this, the surviving parasites were placed in culture and 
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then cloned through limiting dilution method (Chapter 3). DNA was extracted from 
successfully cloned parasites and msp genotyping was carried out. 
 
 
Table 5.2: Msp Genotyping of KH2 clones derived after limiting dilution method 
samples loaded for msp2 
reaction 
Band seen in 
msp2 IC 
family (3D7) 
Band seen in 
msp2 FC 
family Interpretation  
3D7  1 0 positive control confirmed 
KH2 clone D4 1 0 3D7 
kH2 clone H6 1 0 3D7 
KH2 clone F12 1 0 3D7 
KH2 clone A6 0 0 3D7 
KH2 clone C2 1 0 3D7 
KH2 clone C5 1 0 3D7 
KH2 clone C8 1 0 3D7 
KH2 clone A11 1 0 3D7 
Culture DNA (cryo vial) 1 1 Culture contains two clones 
After the clonal dilution of KH2, 8 clones were derived. The letter and the number of each 
clone signify the well row and position on a 96 well plate.  
 
 
The table shows that all the clones are 3D7 and not KH2.  The culture DNA sample which 
was put into culture from a cryopreserved vial that was stored right after the initial KH2 clone 
was adapted to culture showed that two clones are present. One of the clones present was 
3D7 and the other might have been KH2 but further experiments were done to confirm this.  
There was no signal for sample KH2 A6 and so an msp1 genotyping experiment was carried 
out to confirm this result. The msp1 result showed the sample was indistinguishable from 
3D7. 
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5.6 Msp 2 Genotyping of cryopreserved KH2 
 
Following the result of the sample which was put into culture from a cryopreserved vial 
(Table 5.2), DNA was directly extracted from a cryopreserved vial (was not put in culture) to 
confirm if the KH2 clone was present in the original sample stock and if it was already 
contaminated with an additional 3D7 like parasite. Extracted DNA sample was used to carry 
out further Msp 2 genotyping experiment as this gene alone can discriminate KH2 from our 
putative contaminant. The result is shown in table 5.3.  
Table 5.3: Msp 2 Genotyping of cryopreserved KH2 
samples loaded for msp2 
reaction 
Band seen in msp2 IC 
family (3D7) 
Band seen in 
msp2 FC family Interpretation  
3D7  Yes No 
Expected 3D7 band seen 
 
KH2 from cryo vial Yes Yes 
Expected KH2 band seen + band 
indistinguishable from 3D7 
 
The results confirm the presence of at least two clones, one of which is indistinguishable 
from 3D7 (IC family). It was likely that the other clone was the derived KH2 (FC 
family).Thus an alternative way to isolate a pure KH2 culture from this mixture was sought. 
 
 
5.7 Chloroquine drug pressure of KH2 
 
The DHA drug pressure was unsuccessful in selecting for the KH2 DHA resistant strain. 
Since the KH2 strain has a chloroquine resistant background, a chloroquine drug pressure 
was carried out in order to kill any chloroquine sensitive 3D7 present and at the same time, 
select for the chloroquine resistant KH2 strain. 
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TABLE 5.4 Pfmsp1and Pfmsp2 genotype of isolate KH2 before and after CQ drug pressure: The clone population present are shown after 
parasites had been freeze thawed and were adapted to culture. A no treatment control and 3D7 were used as controls.  
Isolate K1 
Pfmsp1 
Mad20 R033 
Pfmsp2 
IC (3D7) FC Interpretation 
3D7 1 - - - - positive control 
KH2  from cryo vial 1 1 - 1 1 2 clones 
KH2 clone A6 (no drug) 1 - - 1 - 2  clones 
KH2 clone I5 CQ 100nm 1 1 - 1 1 2 clones 
KH2 clone D3 CQ 50nm 1 1 - 1 1 2 clones 
 
KH2 clone A6 was culture adapted and cloned through limiting dilution method. KH2 from cryo vial came straight from the cryopreservation 
tank and DNA extraction followed (no continuous culture). KH2 clone I5 was exposed to 100nm of chloroquine drug pressure once while KH2 
D3 was exposed to 50nm of chloroquine drug pressure twice. All drug pressure was carried out for 72 hours at 37°C.
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Before Chloroquine drug pressure of KH2 (100nM), two clones, 3D7 and KH2 were present 
in the culture. After 100nm of chloroquine drug pressure, two clones still appeared on the 
agarose gel except this time; the KH2 presumed band had a stronger signal while the 
presumed contaminant band had a weaker/faint signal. There was no difference in the number 
of bands before chloroquine pressure and after chloroquine drug pressure. The chloroquine 
drug pressure was unsuccessful in killing off the contaminant retaining the KH2 isolate in 
culture.  
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5.7.1 Standard 48-hour Chloroquine drug assay on KH2 
 
To further investigate the presence of the KH2 isolates and its composition in culture, a 
standard 48 hour drug assay was carried out on one of the chloroquine drug pressured KH2 
clone. This was done to ascertain the EC50 value of the isolates in culture and compare with 
known EC50 values already established in previous experiments and other studies. If the 
isolate can be identified by its drug susceptibility and therefore its EC50 value, its identity 
could possibly be deduced.  
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Fig 5.3 DHA IC50
48hr
assay: Graph showing EC50 value of KH2 isolate (Clone I5) 
after a 48 hour exposure to chloroquine.  
 
The dose-response curve shows that the EC50 value for the chloroquine drug pressured KH2 
was 9nm. This value is within the EC50 range for the standard 48hr value for 3D7 (9nM-
15nM) and not in the range of the EC50 of a chloroquine resistant isolate, which KH2 is 
expected to be. This dose response result confirms the presence of a fast-growing CQ 
sensitive parasite in the continuous culture mix with KH2. 
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5.8 Pfcrt Genotyping of KH2 
 
Previous results have shown the presence of both KH2 and a contaminant in culture. Since 
the chloroquine resistant phenotype was not picked up in the drug assay experiment, a Pfcrt 
genotyping experiment was carried out in order to confirm if the KH2 isolate has a 
chloroquine resistant mutation. The table below shows the results. 
 
Table 5.5: Pfcrt haplotype of KH2 isolate and derived clones 
Parasite Line Condition Haplotype Pfcrt 72-76 
3D7 Lab adapted line CVMNK 
DD2 Lab adapted line CVIET 
7G8 Lab adapted line SVMNT 
KH2 cryo From cryopreserved sample CVMNK 
KH2 Culture adapted line CVMNK 
KH2 I5 100nm drug pressure CVIET 
KH2 D3  Two rounds of  500nM drug 
pressure  
CVMNK 
 
 
The KH2/contaminant culture has both isolate mixes which has been very difficult to separate 
(Table 5.2). The 100nM drug pressure killed off majority of the parasites which are 
chloroquine sensitive. Since KH2 is chloroquine resistant (fig 5.3), it was able to grow in 
culture and recover from the drug pressure. Immediate DNA extraction after drug pressure 
and further analysis by Pfcrt genotyping showed that after drug pressure, mostly KH2 isolate 
remains as shown in Table 5.4 (KH2-I5) where the CVIET genotype can be observed. The 
KH2 isolate before drug pressure shows a strain with genotype CVMNK (Table 5.4: KH2, 
KH2-cryo). This data shows that the contaminant is the dominant clone in in-vitro culture, 
and enjoys a fitness advantage over KH2 in-vitro in the absence of drug pressure. 
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After chloroquine drug pressure where the majority of the non-KH2 parasites were killed off, 
the Pfcrt genotype expressed was CVIET, which is a chloroquine resistant mutation known to 
be fixed among artemisinin resistant Cambodian parasites.  
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5.9 Pfk13 Genotyping of Chloroquine drug pressured KH2 
 
Seeing the chloroquine pressured KH2 isolates had the CVIET genotype (Table 5.5), it was 
important to confirm the Pfk13 genotype on these cloned isolates as they were expected to 
also harbour the artemisinin resistant genotype. 
 
 
Fig 5.4a Pfk13forward alignment: The arrows show the C580Y mutation in the 
chloroquine pressured KH2 clones  
 
 
Fig 5.4b Pfk13Reverse alignment: The arrows show the C580Y mutation in the 
chloroquine pressured KH2 clones  
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3D7 
KH2 cryo 
KH2 D3 
KH2 
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The drug pressured cloned KH2 isolates comprised of artemisinin resistant mutation 
at position C580Y. This result was expected. A limiting dilution experiment was 
carried out on the isolates to separate the resistant isolates from the mixed culture. 
Msp genotyping was again carried out to confirm the clonal mix. The experiments 
were unsuccessful in separating KH2 from the contaminating genotype or genotypes. 
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5.10 Acquisition of artemisinin resistant Cam3.11 lines. 
 
The previous experiments described in the first part of this chapter highlight the difficulty 
involved in separating a mixed Plasmodium falciparum culture. The experiments to separate 
KH2 from 3D7 isolate were discontinued. This was because artemisinin resistant isolates 
were provided by Jill Davies at the Liverpool School of Tropical Medicine and originally 
developed by David Fidock & Judith Straimer (Straimer et al., 2014). Once expanded in our 
laboratory, the 6 hr pulse assay and the standard 48 hr assay were carried out with the new 
artemisinin resistant lines. Three isolates were retrieved and their information can be seen in 
table 5.6 below.  
 
Table 5.6 List of Plasmodium falciparum lines, origins, characteristics and year 
isolated: The isolates are comprised of artemisinin sensitive and resistant lines.  
 
Parasite Line Origin Region Characteristics Year 
reported 
Reference 
Cam 3.11 WT Cambodia SE Asia Genetically 
modified 
2014 Straimer et 
al, 2015 
Cam 3.11 
C580Y 
Cambodia SE Asia  Genetically 
modified  
2014 Straimer et 
al, 2015 
Cam 3.11 
R539T 
Cambodia SE Asia  Parental  2014 Straimer et 
al, 2015 
Cam 3.11
WT
 isolate is an artemisinin sensitive (wild type) strain. Cam 3.11 
C580Y
 and 
R539T
 
are artemisinin resistant strains with mutations in the C580 and R539 positions of the 
Pfkelch 13 gene respectively.  
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5.11 Pfk13 Genotyping of Cam 3.11 lines 
 
Before any assays were carried out on the new artemisinin resistant Cam 3.11 lines, it 
was important to ascertain the genotypic information of all the isolates first. Pfk13 
genotyping was done on both resistant lines Cam 3.11 lines (C580Y, R539T) as 
described in Chapter 3.11.3. 
 
 
 
 
Fig 5.5 Direct sequencing of pfk13 gene in Cam 3.11 lines: Both parasites were 
confirmed to have the kelch mutation at the positions expected, C580Y (figure above) 
and R539T (figure below). The numbers correspond to the amino acid number on the 
Pfk13 gene.  
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 Fwd 
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C539T
 Rev 
3D7 PfK13 Ref 
genome 
3D7 Pfk13 Ref 
575 591 
533 550 
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5.12Sensitivity to dihydroartemisinin in-vitro for Cam 3.11 lines 
 
All 3 isolates (Table 5.6) from Cambodia were exposed to DHA in a 6 hour pulse and a 
standard 48-hour pulse in order to ascertain if the 6-hour pulse can discriminate differences in 
DHA EC50
6hr
. Parasites were synchronised at ring stage (0.5% parasitaemia) and exposed to a 
6hr drug pulse at varying drug concentrations (Chapter 3.5). A dose response curve of DHA 
drug concentration and percentage parasite viability was plotted for all Cambodian isolates.  
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Fig 5.6Mean DHA IC50
6hr
 pulse assay of P.falciparum isolates Cam 3.11: 6 hour 
pulse assay on Cam 3.11
WT 
(artemisinin sensitive), Cam 3.11 
C580Y
 and Cam 3.1 
R539T
 
lines (artemisinin resistant). See table 5.7 for mean EC50 values. 
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When all the isolates from Cambodia were exposed to DHA for 48 hours, there was no 
difference in the EC50 values observed. This trend was also observed when all African 
isolates were exposed to DHA for 48 hours (Chapter 4, Table 4.5).  
When the Cambodian isolates were exposed to a 6-hour pulse of DHA, differences were 
observed when compared to the 48-hour assay. Cam 3.11WT had a 4.8-fold difference in 
DHA EC50 between the pulse assay and the standard assay with a P value of 0.005. Cam 3.11 
C580Y had a 4-fold difference in DHA EC50 between the pulse assay and the standard assay 
(P = 0.01), while Cam 3.11 R539T had a 3.5-fold difference in DHA EC50 between the pulse 
assay and the standard assay with a P value of 0.01. 
 However, when all the isolates were compared to each other using the 6 hour pulse assay, 
this novel assay could not discriminate between DHA EC50 values i.e the assay could not 
tease out differences that exist between the Cam 3.11WT (artemisinin sensitive line) and Cam 
3.11 C580Y, R539T which are the artemisinin resistant lines (Table 5.8). 
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TABLE 5.7 DHA standard 48hr and 6hr pulse assay: The standard 48-hour assay was carried out using DHA. Data shows mean EC50 values 
for the 6-hour pulse assay and the standard 48hour assay with corresponding fold difference and results for statistical significance between 2 
assays. 
PARASITE DHA_Assay :     EC50
6h
 DHA_Assay :     EC50
48h
     
 
# 
Experiments 
# Replicates mean EC50 (SD) 
mean EC50 (SD) 
# 
Experiments 
# 
Replicates 
fold 
difference 
P value 
(Ttest) 
Cam 3.11
WT
 3 
4 
24.0 ± 3.2 6.0  ±0.6 3 4 4.8 0.005 
Cam 
3.11
C580Y
 3 
4 20.0 ± 1.05 
6.0 ±0.2 3 4 4.0 0.01 
Cam 3.11 
R539T
 3 
4 23.0 ± 4.5 
6.0 ±3.9 3 4 3.5 0.01 
 
The abbreviations for isolates are Cam (Cambodia), WT (wild type), and C580Y and R539T are the mutation positions. The EC50 values are 
averaged for at least three independent experiments. All data are represented as mean ± S.E.M. A two-tailed test was used to test significance at 
P >0.05 
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TABLE 5.8 Mean difference in DHA EC50 (nM) between the Cambodian isolates, by 
the standard 48hr assay and 6hr pulse assay: Mean difference in DHA sensitivity of the 
6 hour pulse assay and standard 48 hour assay. Comparisons were made between each 
African isolate and the P value of this difference is shown. (P < 0.05) 
 
Isolates 6hr Pulse assay: Mean 
difference nM (P value) 
48hr Standard assay: Mean 
difference nM (P value) 
Cam R539T vs. Cam C580Y 0.1 (0.98) 0.3 (0.85) 
Cam 967WT vs. Cam C580Y 3.4 (0.21) 0.3 (0.71) 
Cam 967WT vs. Cam R539T 3.3 (0.17) 0.6 (0.71) 
 
 
Further comparison of all Cambodian P. falciparum isolates showed the same trend. The 
mean difference in EC50 values between Cam 3.11
R539T
 and Cam 3.11
580Y
was 0.1 (P value = 
0.98). This means that the pulse assay was unsuccessfull in discriminating between the 
differences in drug sensitivity that may exist between the two isolates. Comparisons between 
the wild type Cambodian isolate and each artemisinin resistant line also gave a similar result. 
The mean difference in EC50 between Cam 3.11WT and Cam 3.11 C580Y was 3.4nM. This 
differences was not statistically significant (P= 0.21). More so, comparisons in EC50 values 
between Cam 3.11WT and Cam3.11 R539T (3.3nM) also was not statistically significant (P 
= 0.17) (Table 5.8). Comparisons of the mean difference in EC50 values between the 
artemisinin sensitive and the artemisinin resistant lines using the standard 48 hour assay also 
showed no significant differences in DHA sensitivity between these isolates (Table 5.8) 
This means that like the standard 48 hr assay, the 6 hr pulse assay was not successful in 
teasing apart differences in DHA sensitivity profiles that may exist between the artemisinin 
sensitive line and the artemisinin resistant lines derived from the same Cambodian parent 
isolate. 
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TABLE 5.9 Mean difference in DHA EC50 (nM) between isolates from Cambodia and 
African isolates, by the standard 48hr assay and 6hr pulse assay: Mean difference in 
DHA sensitivity of the 6-hour pulse assay and standard 48-hour assay. Comparisons were 
made between each isolate and the P value of this difference is shown. (P < 0.05) 
 
Region 6hr Pulse assay: Mean 
difference nM (P value) 
48hr Standard assay: Mean 
difference nM (P value) 
Cam C580Y vs. HL1204 11.6 (0.01) 1.0 (0.17) 
Cam R539T vs. HL1204 11.7 (0.02) 1.3 (0.51) 
HL1402 vs Cam C580Y 23.8 (0.04) 1.1 (0.34) 
HL1402 vs. Cam R539T 23.7 (0.07) 0.8 (0.67) 
Cam C580Y vs. HL1210 8.7 (0.02) 2.9 (0.38) 
Cam R539T vs. HL1210 8.8 (0.04) 3.2 (0.19) 
HL1212 vs. Cam C580Y 5.3 (0.91) 1.0 (0.86) 
HL1212 vs. Cam R539T 5.3 (0.91) 0.7 (0.97) 
 
 
To see if the pulse assay could discriminate between the DHA sensitivity profiles of the 
isolates from Cambodia and those from Africa, a comparison was made using the mean 
differences. The pulse assay this time was very successful in teasing apart the differences that 
exist between the isolates from Cambodia (C580Y, 539T) versus those from Africa (HL1204, 
HL1210). However, the assay could not differentiate between the DHA sensitivity profile of 
both C580Y and R539T when compared with the HL1212 isolate (Nigeria: Mean difference: 
5.3nM, P = 0.91; 5.3nM, P= 0.91) 
 
The pulse assay could discriminate different DHA-susceptibility phenotypes between the 
Cam 3.11 C580Y, Cam 3.11 R539T when compared with HL1204 and HL1210 but not 
HL1212. The mean EC50 value for HL1212 is 26nM while the mean EC50 value for both 
Cam 3.11 C580Y and R539T are 23nM. The standard 48 hour assay could not discriminate 
the differences in EC50 in any pairwise comparison (Table 5.9) and this is the same 
observation made in the previous chapter and in other published studies. In the 6 hour assay, 
the 2 Cambodian lines with K13 mutation were less susceptible to DHA compared to the 
African lines HL1204, HL1210. However, the least susceptible to DHA HL1212, was 
indistinguishable from the Cambodian lines in this assay. 
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5.12 DHA EC50
6h
 
T0-T4
 assay on Cambodia and Africa lines 
 
Since it was important that the pulse assay should produce consistent results (it did not 
achieve discrimination in the Cambodian lines like it did the Africans). A variation of the 6-
hour pulse assay was designed, which incorporates a tightly synchronised ring stage of the 
parasite with comparison to a later stage, to observe any differences that may exist between 
stages experiencing a short pulse. 
According to the literature, the ring stage is the parasite stage that has been directly linked to 
artemisinin resistance so it was important to make sure this stage was captured and compared 
with a later parasite stage to see if a more consistent phenotype could be achieved. As a 
result, a novel assay format was used where a 6 hr DHA pulse at time 0hr was compared to 6 
hr DHA pulse at time 4hr. This means that the synchronised parasites were exposed to DHA 
at time 0hr and time 4hr and then the drug was washed off six hours later, at times 6hr and 
10hr respectively, and plated in a 96 well plate for another 43 hours (a total of 48 hours 
incubation time). The difference between the two time point exposures (at time 0 hr and time 
4 hr) gives a measurement designated as the EC50
6h
 
T0-T4
. Isolates were stratified according to 
the EC50 from the differences in both time points. Isolates with a low ∆T0 -T4 EC50
6hr
 value 
are on the left of Figure 5.7 while isolates with a high EC50
6h
 
T0-T4
 are on the right. 
Across the board it can be seen that isolates that are artemisinin sensitive (Cam3.11WT, 
HL1204, HL1210) all show little differences in DHA EC50 values at exposure time points 0 
hour and 4 hours, thereby displaying a low EC50
6h
 
T0-T4
 value. Whereas isolates that have 
been shown to be resistant to artemisinin and have the K13 mutation show much higher 
differences in DHA EC50 values at exposure time points 0 hour and 4 hours, thereby showing 
higher differences in their EC50
6h
 
T0-T4
 value. The Hl1212 isolate however, show a different 
trend with higher differences in DHA EC50 values (compared to HL1204 and HL1210) at 
exposure time points 0 hr and 4 hrs with an absence of mutations in the propeller domain of 
the Pfk13 gene (chapter 4, figure 4.9). 
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Fig 5.7 DHA EC50 ∆ T0 -T4 assay of P. falciparum isolates from SE Asia and 
Africa: 6 hour pulse assay on Cam 3.11
WT 
(artemisinin sensitive), Cam 3.11 
C580Y
 and 
Cam 3.1 
R539T
 lines (artemisinin resistant) and HL1204, HL1210 and HL1212. Isolates 
with a low EC50
6h
 
T0-T4
 value are on the left (A, B, C) while isolates with a high EC50
6h
 
T0-T4
 are on the right (D, E, F). The dose-response curve show an elevated EC50
6h
 
T0-T4
 
value in the less susceptible lines and are superimposed in the wild-type lines. 
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5.12.1 DHA EC50
6h
 
T0-T4
 assay for Cam 3.11 lines 
 
After DHA drug exposure at time T0-T4, wild type P. falciparum isolates Cam 3.11
WT
 had a 
∆EC50
6h
 
T0-T4
 value of 1.4 with a P value of 0.07. This result shows that the changes in EC50 
between the two time point exposures are not significant (Mean EC50 T0 -23.3nM, T4-
24.8nM). In comparison, both artemisinin resistant lines Cam 3.11 C580Y (Mean EC50 at T0-
30.6nM, T4 -14.7nM) and R539T (Mean EC50 at T0 -36.5nM, T4 -15.3nM) had a ∆T0 -
T4value of 15.9and 11.2 with a P value of 0.04 and 0.0007 respectively, which shows a 
statistically significant difference in both exposure time points (Table 5.10). 
 
5.12.2 DHA EC50
6h
 
T0-T4
 assay for the African lines 
 
The DHA pulse assay carried out on isolates HL1204, HL1210 and HL1212 showed very 
interesting results. The HL1204 isolate (artemisinin sensitive) had a ∆EC50
6h
 
T0-T4
 value of 1.2 
with a P value of 0.68 while the HL1210 isolate, also artemisinin sensitive, had a EC50
6h
 
T0-T4
 
value of 1.6 with a P value of 0.16. The EC50 differences in both exposure time points were 
not statistically significant. However, the HL1212 isolate which does not have a K13 
mutation, had a ∆EC50
6h
 
T0-T4
 value of 19.2 with a P value of 0.008. The EC50 differences in 
both exposure time points for HL1212 were statistically significant. All the data for DHA 
EC50
6h
 
T0-T4
 assay (assay 3) are summarised in Table 5.10 below. 
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TABLE 5.10 Mean difference in DHA EC50 (nM) between isolates from Cambodia and African isolates, by the standard 48hr assay 
and 6hr pulse assay: Mean difference in DHA sensitivity of the 6-hour pulse assay and standard 48-hour assay. Comparisons were made 
between each isolate and the P value of this difference is shown. (P < 0.05) 
PARASITE DHA_Assay 3:      IC50
6h T0-T4
  
  
# 
Expts # replicates per xperiment mean IC50
T0
 (SD) mean IC50
T4
 (SD) mean IC50
T0-T4
 P value (Ttest) 
3D7 2 4 14.0 ± 3.1 5.6 ± 0.8 8.4 0.11 
Cam_3.11
WT
 2 4 23.4 ± 0.5 24.8 ± 0.2 1.4 0.07 
Cam_3.11
R539T
 2 4 26.5 ± 0.3 15.3 ± 0.4 11.2 0.0007 
Cam_3.11
C580Y
 2 4 30.6 ± 0.1 14.7 ±1.5 15.9 0.04 
HL1204_K 2 4 10.8 ± 0.8 12.0 ±3.1 1.2 0.68 
HL1210_Gh 2 4 12.0 ± 0.7 13.6 ±0.7 1.6 0.16 
HL1212_N 2 4 38.2 ±1.7 18.3 ±3.7 19.2 0.008 
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Fig 5.8 Comparison of all 3 assays tested on P.falciparum isolates from SE Asia and Africa: The graph shows data from the standard 
48 hour assay, the 6 hour pulse assay and EC50
6h
 
T0-T4
 assay carried out on isolates Cam 3.11
WT 
(artemisinin sensitive), Cam 3.11 
C580Y
 
and Cam 3.1 
R539T
 (artemisinin resistant) and HL1204, HL1210 and HL1212 (artemisinin sensitive). The graph shows the assay which 
best discriminates between the differences in DHA sensitivity.  
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5.13 Comparison of the 3 assays tested on P. falciparum isolates from Southeast 
Asia and Africa 
 
The general aim of this Chapter is to ascertain the best assay that can discriminate 
between differences in DHA susceptibility that may exist between isolates from 
different regions. From the data analysis (Figure 5.9), the standard 48 hour assay 
(EC50
48hr
), which is the assay that has been used in the literature for years (developed 
initially for chloroquine), was unsuccessful in discriminating between DHA EC50 
differences that exists between the parasite lines. 
 
The novel hour pulse assay (EC50
6hr
) was successful in discriminating the differences 
that exist between the DHA sensitivity profiles of HL1204, HL1210 and HL1212. 
This assay however was unsuccessful in discriminating between DHA EC50 
differences that exists between the Cam 3.11 parasite lines from Cambodia (Figure 
5.9). 
 
The novel 6 hour pulse assay at Time 0 hours and 4 hours (EC50
6h
 
T0-T4
) was 
successful at discriminating the differences in DHA EC50 that exists between the 
artemisinin resistant Cambodian line and the artemisinin sensitive Cambodian and 
African line (Figure 5.9). This assay was also able to show a different phenotype for 
HL1212 (∆T0 -T4= 19.2; P value 0.008) even though genetically, it does not have the 
K13 mutation. 
 
 
 
 
 
 
 
144 
 
5.14 Ring stage survival assay (RSA
0-3hr
) on P. falciparum isolates from SE Asia 
and Africa 
 
According to the literature, the ring stage survival assay has been shown to produce a 
phenotype for artemisinin resistance in-vitro, based on evidence that artemisinin 
resistance affects predominantly the ring-stage of the parasite lifecycle (Witkowski et 
al, 2013). We therefore set out to compare relative DHA susceptibility by ring stage 
survival assay compared to our other assays on the P.falciparum lines from Cambodia 
and Africa.  This was done to validate the RSA
0-3hr 
assay and to also investigate if the 
assay could produce a phenotype in-vitro for the African lines. Parasites were exposed 
to 700nM DHA concentration at the tightly synchronised early ring stage of the 
parasite. The drug was washed off after a 6 hour exposure and the cells incubated at 
37°C for 72 hours. The RSA method has been described extensively in Chapter 3. 
 
TABLE 5.10 Mean difference in DHA EC50 (nM) between isolates from 
Cambodia and African isolates, by the standard 48hr assay and 6hr pulse assay: 
Mean difference in DHA sensitivity of the 6-hour pulse assay and standard 48-hour 
assay. Comparisons were made between each isolate and the P value of this difference 
is shown. (P < 0.05) 
 
PARASITE DHA_Assay 4:     RSA  
  # Expts # replicates per xperiment Survival (%) 
Cam_3.11
WT
 1 1 0 
Cam_3.11
R539T
 1 1 26.5 
Cam_3.11
C580Y
 1 1 14 
HL1204_K 2 1 0 
HL1210_Gh 2 1 0 
HL1212_N 2 1 0 
 
The results from the RSA experiments showed that Cam3.11 WT had a 0% survival. 
This was the same trend in the African lines HL1204, HL1210 and HL1212 which all 
do not have a PK13 mutation. However, Cam3.11
R539T
 had a 26.5% survival while 
Cam_3.11
C580Y
 had a 14% survival. Both isolates are artemisinin resistant with 
mutation in PfK13 region of the propeller domain. 
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5.15   Discussion 
 
This Chapter aimed to determine in vitro responses of Cam 3.11 artemisinin resistant 
and artemisinin sensitive isolates in comparison to the African lines and to find new 
approaches to the in-vitro phenotype. Three assays were used to determine DHA 
sensitivity profiles between African and Asian lines. Some assay formats were able to 
successfully discriminate the differences that exist between artemisinin 
resistant/tolerant and artemisinin sensitive lines while others were unsuccessful. One 
format which derived DHA sensitivity differences is the EC50
6h
 
T0-T4
 assay and this 
approach could now be developed further with lines of interest.  
 
Parasite lines from Cambodia (Cam 3.11
WT
, Cam 3.11
C580Y
 and Cam 3.11
R539T
) 
showed no significant difference in EC50 values when exposed to DHA for 48 hrs. 
The comparisons of the mean difference in DHA showed that the 48 hr assay was 
unsuccessful in discriminating between artemisinin resistant and the artemisinin 
sensitive isolates. The corresponding P values for the comparisons show that the 
results were not statistically significant (Table 5.8). This result is consistent with 
published data which show that the standard 48 hr assay was unsuccessful in teasing 
out differences in DHA sensitivity between fast clearing and slow clearing parasites 
(Dondorp et al., 2009; Witkowski et al., 2013). 
When the novel 6 hour pulse assay was compared to the standard 48 hour assay for 
the Cambodian lines, the mean difference in EC50 for all 3 isolates were statistically 
significant and showed a higher mean DHA EC50 value. The pulse assay showed a 
shift to the right in the dose response curve which a similar trend observed with DHA 
pulse exposure in the African lines (Chapter 4), and this shift in EC50 was statistically 
significant in all Cam 3.11 lines (Table 5.7). However, when the mean differences 
between the artemisinin sensitive and the resistant parasites were compared using the 
6 hour pulse assay, the result showed that the assay could not tease out differences in 
EC50 that exists between the 3 Cambodian parasite lines (Table 5.8). This suggests 
that the 6 hour pulse assay, while very successful in discriminating the differences in 
DHA sensitivity that exists between African parasites, could not tease apart 
differences in DHA sensitivity of the Cambodian parasites in the current test format. 
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A further comparison of the 6 hr pulse assay between the Cambodian lines and the 
African lines showed that the assay could in fact discriminate the differences in DHA 
sensitivity between these isolates with one exception, the HL1212 isolate which 
showed that the mean difference was not statistically significant (Table 5.9, P = 0.91) 
Since the 6 hr pulse assay was not discriminating among fast and slow clearing 
Cambodian lines, an altered assay EC50
6h
 
T0-T4
)  was designed to take into account the  
early ring stage of the parasite  lifecycle, which had been shown to be directly 
associated with artemisinin resistance (Witkowski et al., 2013; Dogovski et al., 2015). 
This assay involved exposing parasites to DHA between the 0-6 hr stages of its 
lifecycle, the stage associate with artemisinin resistant, and comparing the exposure 
with an exposure, 4-10 hrs into the parasite lifecycle. By altering the assay, a 
phenotype was derived using the ∆ T0 -T4measurement. The artemisinin sensitive 
Cam 3.11
WT
 line showed a different phenotype to the artemisinin resistant Cam 
3.11
C580Y
 and Cam 3.11
R539Tlines. The ∆ T0 -T4 for the sensitive line was 1.4 while the 
resistant lines were 15.9nM and 11.2 nM respectively, a difference that was 
statistically significant. This suggests that the ∆ T0 -T4 assay was capturing the 
important stage of the parasite life cycle where artemisinin resistance occurs. 
Although the 6 hour pulse assay is also based on a tightly synchronised ring stage, the 
6 hour pulse assay may have missed out on the very important early ring stage (0-
3hr). The 6 hour pulse assay, not based on the early ring stage, contains a mixture of 
ring stages (early, mid, late ring) and as a result, this may have affected the ability for 
the assay to teas out the differences in DHA sensitivity of the Cambodian lines like it 
successfully did with the African lines.  
The EC50
6h
 
T0-T4
 assay was also successful in discriminating between African lines 
with different DHA susceptible. While HL1204 (artemisinin sensitive) and HL1210 
(artemisinin sensitive, chloroquine resistant) had a ∆T0 -T4 of 1.2 and 1.6nM 
respectively, HL1212 had a ∆T0 -T4value of 19.2nM, an observation similar to the 
artemisinin resistant isolates from Cambodia, except that HL1212 does not have any 
K13 propeller domain mutation (Chapter 4). The ∆T0 -T4 assay, taking the early ring 
stage of the HL1212 parasite lifecycle into account shows that this parasite has lower 
susceptibility to artemisinin when compared to the other African lines and as such, 
this must be due to a Pfk13-independent event which is not clearly understood. The 
ring stage assay was successful as it validates studies carried out by Witkowski et al., 
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(2014) where parasites with the R539T mutation had a higher percent survival 
compared to parasites with the C580Y mutation. The RSA also showed that the 
African lines are artemisinin sensitive according to this assay. The HL1212 line had 
0% parasite survival using the RSA. This suggests that while the RSA is successful at 
identifying a phenotype associated with artemisinin resistance in the Cambodian lines, 
it may not be very useful in elucidating small differences in DHA susceptibility 
among African lines. The RSA is an absolute measure which works perfectly when 
artemisinin resistance has already occurred in Cambodia, however, resistance takes 
some time to arise and as a result, a useful assay for this purpose would be able to 
measure subtle DHA sensitivity changes over time.  As a result, the 6 hr pulse assay 
and/or the ∆T0 -T4 assay can be a useful assay for tracking down artemisinin 
resistance on the African continent. 
Comparison of all assays tested show that the EC50
6h
 
T0-T4
 assay could potentially 
provide new approaches to the in-vitro phenotype as it was successful in 
discriminating the differences in DHA sensitivity that may exists between parasites 
from different regions of the world.  
The assay format was a drawback in this study. Experiments were carried out in 1.5ml 
microcentrifuge tubes which meant that the parasites at the bottom of the tube may 
not have been exposed to DHA like the parasites at the top of the microcentrifuge 
tubes. A solution around this would be to carry out the experiments in a 96 well plate 
where the surface area is big enough for all the parasites to get exposed to DHA. 
Another drawback of the study was that the HL1212 isolate had a high standard 
deviation. This may be due to the polyclonal nature of this isolate.  
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ASSAY ADVANTAGE DISADVANTAGE 
EC50
48h
 
- less laborious 
- cheap 
Does not discriminate between parasite 
lines 
EC50
6hr
 
- Discriminates between 
African lines 
- scalable 
- cheap 
- Does not discriminate  between 
Cambodian lines 
- prone to contamination 
EC50
6hrT0-T4
 
-Discriminates between both 
African & Cambodian lines 
- scalable 
- cheap 
Quite laborious, prone to contamination 
Takes time 
RSA 
Discriminates between 
Cambodian isolates 
 
- absolutely laborious, 
- long prep time before assay, 
- expensive compared to the other assays 
- gives absolute measure for African lines, 
- not very scalable, not useful for African 
lines with Pfk13 independent mutation 
 
TABLE 5.11: Advantages and disadvantages of the EC50
48h 
EC50
6hr 
EC50
6hrT0-T4 
and 
the Ring stage survival assay. 
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5.16   Conclusion 
 
With rising artemisinin resistance, it is crucial to develop an in vitro assay that can 
successfully track down resistance before it spreads.  While the ring stage assay 
successfully discriminates between DHA resistant and DHA sensitive Cambodian 
parasites, it is laborious, expensive and time consuming. The 6 hour pulse assay, 
while not successful in discriminating EC50 differences between isolates from 
Cambodia, it successfully does so with the African lines and can be used as a 
surveillance tool on the African continent to prevent the spread or artemisinin failure. 
The EC50
6h
 
T0-T4
 assay which has been successful in teasing out the differences in 
DHA sensitivity that exists between all isolates used in this project, can be also be 
used as a new approach to the in vitro phenotype. It can also be used as a surveillance 
tool to contain artemisinin resistance. 
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CHAPTER 6: Genetic and genomic analysis of multi-parasite 
lines; genotype-phenotype associations 
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6.1 Background 
 
Emergence of drug resistance has continuously occurred after new drugs for the 
treatment of malaria have been introduced. Drug resistance emerged for chloroquine, 
sulfadoxine/pyrimethamine and mefloquine. Resistance also emerged for atovaquone, 
which occurred the same year the drug was introduced (Looareesuwan et al., 1996). 
Malaria became very difficult to treat after P. falciparum became resistant to these 
derivatives are usually combined with a partner drug, typically from a chemical 
family such as the 4- aminoquinolones or the aryl alcohols, to make up artemisinin-
based combination therapies (ACTs). Artemisinins are usually given in combination 
because they will delay the appearance of drug resistance occurring since with ACTs, 
parasites would need to acquire resistance to two drugs instead of one (artemisinins 
have a short half-life, so combination with a drug with a longer half-life is a strategy 
to prevent resistance). ACTs are currently the most effective treatments for P. 
falciparum malaria, however, clinical trials from Southeast Asia have shown that 
parasites have acquired artemisinin resistance when given as monotherapy and some 
ACTs appear to be losing effectiveness (Saunders et al., 2014). If there continues to 
be a decline in ACT efficacy, this could result in malaria becoming a very difficult 
disease to treat. 
There are ongoing clinical trials on novel classes of antimalarials compounds, but 
none will be available for licensing within the next two years. As a result, scientists 
have been trying to identify genetic markers that would predict artemisinin drug 
resistance in the parasite. These markers will be used to track the spread of resistance 
and hopefully, be used for containment which would in turn prevent early stage 
treatment failures and possible deaths from occurring. A genetic marker or set of 
markers could also be used as surveillance to identify the widespread presence of 
alleles associated with resistance in any geographic region. In early studies that 
looked at genes involved in artemisinin resistance, it was hypothesised that 
transporter-encoding genes contribute to resistance. These include pfmdr1 (Wilson et 
al., 1989) which encodes the P. falciparum multidrug resistant protein 1 (pfmdr1), and 
pfcrt (Sidhu et al, 2002), encoding the P. falciparum chloroquine resistance 
transporter (pfcrt). Studies have shown that artemisinin sensitivity increases when the 
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copy number of genes encoding Pfmdr1 decreases (Sidhu et al, 2006). Mutations in 
pfmdr1 have also been shown to modulate IC50 values for artemisinin in vitro (Sidhu 
et al, 2005). Furthermore, after treatment with parasite causing recurrent infections 
using artemether-lumefantrine, field studies in Africa show an overrepresentation of 
the pfmdr1 I1876V mutation (Dahlstrom et al., 2009).   
Prevalent mutant forms of pfcrt that confer chloroquine resistance have been shown to 
increase parasite susceptibility to artemisinin, and epidemiological studies have 
shown selection for wild-type pfcrt occurs in endemic settings where ACTs are used 
(Sisowath et al., 2009; Henqirues et al., 2014). There have been reports of 
associations between candidate genes, pfatp6, pfap2mu and pfubp1 to resistance in 
artemisinins (Eckstein-Ludwig et al., 2003; Krishna et al., 2004; Henriques et al., 
2013). Despite this, in Cambodia where artemisinin resistance occurs and where 
monotherapy has been used, it was found that these candidate genes are not strongly 
correlated with resistance (Imwong et al., 2010). Although there is a lack of disease 
association with these genes in Asia, it does not mean they do give a different 
resistance phenotype or contribute to drug resistance. 
In order to investigate in-vivo artemisinin susceptibility, researchers genetically 
exposed Plasmodium chabaudi rodent parasites with sub-lethal concentrations of 
artemisinin and artesunate to create resistant parasites. The artemisinin resistant line 
was then crossed with an artemisinin sensitive line of parasites that were different 
from the original at many genetic positions (Hunt et al., 2005). Selection in bulk, was 
applied to the recombinant progeny lines and the relative proportion of alleles for 
each of the two parent lines was determined by pyrosequencing, using a method 
known as linkage group selection (Martinelli et al., 2005). The region enriched in 
resistant parasites was sequenced and two different mutations were identified in a 
gene encoding a deubiquitinating enzyme, pcubp-1, which suggested this gene could 
have alleles that confer resistance (Hunt et al., 2007). Another study showed that 
variant alleles of the pfubp-1 gene in P.falciparum (E1528D) were significantly more 
prevalent (P<0.001) in Kenyan children post-treatment, with reduced responsiveness 
to ACTs than in those who had a better ACT response (Henriques et al., 2014). 
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In terms of sensitivity and cost, whole genome sequencing and analysis methods are 
becoming more tractable. These methods have allowed researchers genes that are 
involved in drug resistance through analyzing whole genome sequence of multiple 
resistant clones from in vitro experiments. Tucker and colleagues created several 
artemisinin and artelinic resistant lines (Tucker et al, 2012) and found changes in 
candidate genes, including pfmdr1 copy number variations. Whole genome sequence 
analysis showed that there were nonsynonymous mutations, including in one protein 
which was uncharacterised and present on chromosome 13, pf13_0238. In the 
reference genome, this locus is designated PF3D7_1343700 and is now known as 
“kelch13” (Ariey et al, 2014). In order to identify mutations associated with drug 
resistance, another study by Cui and colleagues used gene expression microarrays to  
parental parasites that were 25 times more resistant to DHA and had amplifications of 
a locus containing pfmdr1 (Cui et al, 2012). 
 
Genome sequencing has also been an important tool to identify artemisinin drug 
resistance markers within a population-based study setting. The design of parasite 
population genetic studies that could be used to map genes involved in resistance was 
spurred after it was shown that parasites with heritable resistance exists (Anderson et 
al, 2010). Researchers sought to identify genomic regions under selection using large 
collections of parasites that already existed, when there was absence of patient 
phenotype data. For many years, it had been known that linkage disequilibrium exists 
around genes which are involved with either pyrimethamine resistance (Roper et al, 
2004) or chloroquine resistance (Wooton et al, 2002). It was hypothesized that 
genomic regions in disequilibrium which correlates with artemisinin sensitivity might 
exist. 
In a study, 61 parasite lines were screened against 2,816 compounds, which were 
provided by the NIH Chemical and Genomic Centre Pharmaceutical collection. 
Genotyping of the lines facilitated an examination of the association of differential 
drug sensitivity to endoperoxides (Yuan et al, 2011).  
 
 
 
 
155 
 
The genes that were found to be associated with response to artemisinin included 
pfa0655w (SURFIN), mal13p1.268 (a Plasmodium conserved protein), pfe0565w (a 
conserved Plasmodium protein), pf08_0130 (a ribosomal-RNA-processing WD-repeat 
protein), pf11_0188 (a heat shock protein 90), and pfi0355c (an adenosine 
triphosphate-dependent heat shock protein) (Yuan et al, 2011). 
 
Subsequently, 189 culture-adapted parasites collected from diverse locations were 
genotyped including 146 from Asia (Mu et al, 2010). In the study, a genome wide 
scan for loci associated with dihydroartemisinin (DHA) response showed novel loci 
on chromosome 1,3 and 8, using only Asian parasites (Mu et al, 2010). Another study 
which used 45 culture adapted P. falciparum parasites from different geographical 
regions ( Park et al., 2012) revealed some chromosomal regions found to be 
associated with an increase in DHA and artemisinin sensitivity, notably on 
chromosome 4, but none of the associations were significant (Park et al., 2012). There 
was strong evidence of selection around known resistance genes such as pfdhfr, pfcrt 
and pfmdr1 in both of these studies (Park et al., 2012). 
Later studies utilized both clinical phenotype data and parasite samples to 
demonstrate resistance. These studies recruited patients and measured the amount of 
time needed for parasites to clear after artemisinin monotherapy was administered. 
Parasite material for genome analysis was obtained from areas like Cambodia where 
there was confirmed genetically determined resistance and also from control areas 
(Phyo et al., 2012). In 2012, the first study which analyzed 91 parasites samples from 
Thailand, Laos and Cambodia which was phenotyped for parasite clearance time was 
published (Cheeseman et al., 2012). The researchers demonstrated that a clinical slow 
parasite clearance rate was strongly associated with a selective sweep on chromosome 
13, although artemisinin resistance probably did not occur as a result of a single 
originating event either temporally or geographically i.e. not a “hard” sweep. A 35kb 
region on chromosome 13(bases 1,759,466 to 1,794,766, PlasmoDB 11.1) was 
proposed as a possible drug resistance marker (Cheeseman et al., 2012). 
Three hundred and thirty one parasites that had been phenotyped for parasite 
clearance time, after artesunate monotherapy were genotyped from patients with 
clinical infections from Cambodia, Pailin, Wang Pha, Bangladesh and Thailand 
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(Takala-Harrison  et al, 2013). Takala-Harrison and colleagues used an Affymetrix 
SNP array to analyze parasite genotypes at 8,079 positions. Two SNPs were 
calculated to be ‘located within a top-ranked signature of recent positive selection’ 
(Takala-Harrison et al, 2013). Both SNPs were found on chromosome 13 at locations 
MAL13-1718319 and MAL13-1719976, which were described to be within 2,000 bp 
of each other. One SNP was within pf3d7_1343400 (formerly mal13p1.216, located 
between bases 1,714,443 to 1,719,255, PlasmoDB 11.1). The specific alleles causing 
resistance were not identified in this study as it was not designed to do so, however, 
the authors further highlighted the importance of the 100-kb region on chromosome 
13 (Takala-Harrison  et al, 2013). 
 
Miotto and colleagues genotyped 825 P. falciparum infections from 10 locations in 
West Africa and Southeast Asia in order to identify possible causal SNPs in the locus 
under selection. The phenotype for identifying resistant infections was lengthened 
parasite clearance time after treatment with artesunate monotherapy in Southeast 
Asia, and genotyping was by short-read high throughput sequencing on an Illumina 
platform (Miotto et al., 2013). The Cambodian parasites exhibited distinct population 
structure with 5 sub-population identified. One resistant subpopulation of parasites 
from Southeast Asia (KH2) was shown to have a single haplotype which extended 
across half of chromosome 13, from 1.4 Mb to 3.4 Mb, indicating a recent selective 
sweep with strong evidence. This group highlighted the importance of this region and 
its association to artemisinin drug resistance, but failed to identify a discrete marker. 
In a report published in 2014, it was shown that a candidate artemisinin-resistance 
gene was identified with high confidence (Ariey et al., 2014). In this study, a 
combination of population genetics studies and next generation whole genome 
sequence of an artemisinin resistant line that was selected through continuous 
exposure for five years in-vitro were used. The group compared the genomic 
sequence from their laboratory evolved artemisinin-resistance isolate with that of an 
isogenic parent. After ruling out synonymous mutations, variants in multigene 
families and alleles with mixed reads, eight non-synonymous candidate mutations in 
seven genes, each of which had emerged during resistance selection, were identified 
(Ariey et al., 2014). The time of mutations arising was examined retrospectively, and 
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it was established that the M476I coding change in PF3D7_1343700, a Kelch 
propeller domain- containing protein (K13), emerged concurrently with the 
appearance of strong artemisinin resistance in their in vitro population. The study 
asserted that it was most likely causative (Ariey et al, 2014).  
The regions around the eight candidate SNPs were sequenced in 49 culture-adapted 
isolates from Southeast Asia which were associated with artemisinin sensitivity datain 
vivo. Ariey and colleagues showed that only mutations in PF3D7_1343700, which 
included a C580Y change, had strong associations with long parasite clearance half-
life in patients and survival in the ring-stage assay (RSA) in-vitro. It is worth noting 
that the in vitro derived M476I mutation was not found in their sample (Ariey et al, 
2014). The frequency of mutations in this gene was then analysed in parasite samples 
from regions with and without resistance and further associations between resistance 
and this gene were discovered. Follow-up work has now looked at the frequency of 
kelch13 mutations globally (Miotto et al., 2015; Kamau et al., 2015; Menard et al., 
2016). 
Another detailed study which characterised parasite clearance half-life after patients 
were given artesunate monotherapy at ten sites, found long parasite clearance times in 
Indochina with no significant resistance in any patient from India or Africa (Ashley et 
al., 2014). A strong association between mutations in pfkelch13 and the artemisinin-
resistance phenotype was found. 
Genetic engineering studies further showed that mutations in the propeller-domain 
region in pfkelch13 were only strongly associated with resistance and were not causal. 
A method known as the CRISP-Cas9 system, a genome editing method created for 
use in other eukaryotes (Jinek et al, 2012) and has been adapted in P. falciparum 
(Ghorbal et al., 2014), was used to show conclusively that one of the alleles caused 
resistance. The change in position C580Y was engineered into the Kelch propeller 
domain of pfkelch13 in the drug resistant NF54 background which is of unknown 
origin. In-vitro assays carried out on two clones which were modified showed 
evidence of an increase in ring-stage resistance (Ghorbal et al., 2014). This provided 
additional support that the certain mutations in pfkelch13 gene plays a role in drug 
resistance, and these were sufficient on their own to generate a measurable resistant 
phenotype in-vitro. 
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Rationale 
The majority of malaria infections occur in sub-Saharan Africa where ACTs still 
appear to clear parasites quickly and where mutations in pfkelch13 have not yet 
appeared at elevated rates (Ashley et al., 2014). Although Southeast Asian alleles 
seem to be absent in Africa (Torrentino-Madamet et al, 2014), it is worth noting that 
parasites in Africa have other mutations in pfkelch13 (Taylor et al., 2015). The 
common African mutation, A578S, was not associated with clinical or in vitro 
resistance to artemisinin in one other study (Menard et al., 2016). In another study 
where dihydroartemisinin-piperaquine was administered, one patient harboured a non-
synonymous mutation at position A578S on day 0; however, this allele was replaced 
by the wild-type form on day 3, showing no association with any phenotype 
(Muwanguzi et al., 2016). These studies highlight that events in Africa are very 
different from those in other regions of Southeast Asia and thus, might be independent 
of the pfkelch13. There may be other important genes which may also play a role or 
might be involved in artemisinin drug resistance. 
It was shown that residual sub-microscopic parasites were present in Kenyan children 
on day 3 after treatment with ACT and were associated with subsequent 
recrudescence and transmission (Beshir et al, 2013). Another study showed that 
parasites which harboured certain mutations in pfmdr1, pfcrt, pfubp1, 
and pfap2mu genes showed a higher survival rate at a sub-microscopic level after 
treatment with ACTs (Henriques et al, 2014). It is thus important to identify 
molecular markers which may be associated with artemisinin drug resistance and are 
pfk13 independent. To assist with this, whole genome sequencing of 4 African isolates 
was carried out and SNPs that exist in 11 putative genes associated with artemisinin 
drug resistance were described. This Chapter aims to link in-vitro phenotype work 
described in Chapters 4 and 5 to genotype information described here. The in-vitro 
IC50
6hr
 pulse studies will be linked to the genome sequence information for each 
African isolate although no strong phenotype-genotype correlation can be made. The 
description of non-synonymous mutations present in 13 genes of interests associated 
with artemisinin drug resistance could inform future functional studies deploying gene 
editing. The information provided in this Chapter can be used to monitor the presence 
of drug resistance markers especially as it relates to artemisinin drug sensitivity in 
Africa.  
 
 
159 
 
 
Specific objectives  
1. To produce full genomic sequences for each polyclonal line HL1204, HL1210 
and HL1212 lines, together with an extra added field isolate from a patient 
from Liberia (Sutherland et al, 2016)  
2. To examine genomic data for evidence of polymorphisms at established 
candidate loci. This could inform future functional studies deploying gene 
editing. 
3. To assess the relative abundance of different allele variants among the clones 
present within each isolate. 
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6.2 Results 
 
The majority of the work done in this Chapter used methods that have not been 
described elsewhere. Due to this, some of the modifications to methods are described 
as results. The first part of the result section describes the experiments performed to 
achieve whole genome sequencing of isolates HL1204, HL1210 and HL1212 while 
the second part shows the whole genome sequencing data results. This work was the 
first in-house P. falciparum whole genome sequencing experiments carried out using 
the Illumina sequencing platform at the London School of Hygiene and Tropical 
Medicine.  
 
6.2.1 DNA extraction and quantification 
 
In order to prepare DNA for library construction and whole genome sequencing, 
parasite DNA was extracted using the Qiagen kit and an adapted/amended protocol.  
In particular, the experiment was initially carried out using the methods in malaria 
protocol where 2% parasitaemia was suggested for parasite DNA extraction. 
However, this approach did not produce high quality DNA or high yield which is 
essential for the construction of the sequencing libraries before whole genome 
sequencing can commence.  
 
The adapted method used in this chapter, used 3% -4% parasitaemia in schizont stage 
with the presence of other stages (rings and trophozoites) in approximately 2% 
parasitaemia. The adapted method also added an extra step to the DNA extraction 
protocol where incubation at 70°c was carried out. This adapted method ensured high 
product yield was achieved. DNA quantity and yield was measured using a nanodrop 
spectrophotometer as described in the methods section (3.9). 
DNA quality and yield were calculated for isolates 3D7, HL1204, HL1210, HL1212 
and HL1402. Refer to Section 3.2.1for information on the characteristics and 
origination of the isolates. 
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Table 6.1: Showing an improvement in DNA quality and concentration after 
adaptation of the DNA extraction protocol (see chapter 3.6) 
 
Isolates  DNA quality A260/A280 DNA Concentration 
Before adaptation After adaptation Before adaptation After adaptation 
3D7 1.75/1.45 2.27/2.08 24.2ng/ul 150.9ng/ul 
HL1204 1.90/1.28 2.04/1.87 33.5ng/ul 135.8ng/ul 
HL1210 1.63/1.77 2.07/1.96 26.8ng/ul 179.3ng/ul 
HL1212 1.69/1.55 2.24/2.31 9.9ng/ul 198.3ng/ul 
 
 
6.2.2 DNA shearing 
In order to prepare a library for whole genome sequencing, DNA was sheared using 
an ultrasonicator (described in Chapter 3). This step was very important to obtain 
band sizes of approximately 200-500bp for library preparations. The protocol for 
shearing provided by this machine was used initially but after much trial and failure to 
achieve the required band size, the protocol was adapted to achieve exactly 300bp in 
this study by varying factors like the peak incident power, duty factor, cycles per 
burst, treatment time and sample volume. This adapted treatment produced sheared 
DNA with required size of 300bp as confirmed by gel electrophoresis. Table 6.2 
shows the treatment used for DNA shearing, which led to the required band size.  
 
Table 6.2 Ultrasonicator treatment for extracted DNA from isolates 3D7, HL1204, 
HL1210 and HL1212. 
Target BP (Peak) 200 
Peak incident power (W) 50 
Duty factor 20% 
Cycles per burst  200 
Treatment time (s) 240 
Temperature (ºC) 20 
Sample volume (ul) 75 
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In order to achieve the right sheared DNA size (bp), different treatment times were 
used with the above condition. These were 25s, 32s, 50s, 65s, 80s, 120s 175s 240s 
300s and 375s. The right size was achieved at 240 seconds after sheared DNA with 
approximately 300bp was seen on an agarose gel. 
 
Figure 6.1: The product of ultrasonification using HL1204 shows a band size of 
300bp. This DNA size was used for library preparation of all African isolates. 
 
 
6.3 Library preparation 
 
The preparation of the library was initially carried out following methods described 
by Oyola et al, 2012 (Methods section). However, after many unsuccessful attempts at 
creating a library, the methods were modified for the purpose of the work in this 
chapter.  
 
6.3.1 DNA end repair 
 
End repair of fragmented DNA was carried out with less than 100ng of DNA for all 
isolates initially as instructed by the Illumina NEBNEXT protocol. Unfortunately, the 
experiment was unsuccessful as no product was visualised using the bioanalyser. In 
order to understand the problem, the DNA product was saved at every stage of the 
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library preparation for troubleshooting after running them on the bioanalyzer. This 
assisted the understanding of the underlying reasons for unsuccessful steps, and an 
assessment of the effects of the implement changes in conditions to make the 
experiments work and improve yield and library integrity. 
The end preparation step was modified to use less than 50ng of DNA. The protocol 
for the end preparatory step, the adaptor ligation step, the clean-up step with Ampure 
XP beads before and after the PCR amplification steps were carried out following the 
modified illumina protocol as described in Chapter 3.9. 
 
6.3.2 PCR Libraries 
 
Modification of both the Illumina protocol and the approach suggested by Oyola et 
al., (2012) were carried out. PCR (50ul) with Kapa HIFI (KAPA Biosystems, South 
Africa) contained 1x Kapa HiFI buffer (with TMAC), 10mM of dNTP mix, 0.4uM of 
each primer pair and 1 unit of Kapa HiFI and was amplified with thermocycling 
conditions in table 6.2.  PCR products were purified with 1x Agencourt Ampure XP 
beads and eluted in EB buffer as described in Section 3.9. PCR amplification products 
were analysed using Agilent 2100 Bioanalyzer as described in Section 3.9. 
 
It is worth noting that on different experiments in the PCR enrichment step, three 
different DNA polymerase enzymes were used. These were Phusion, Kappa 2G and 
Kappa Hifi; all with varying PCR amplification conditions. The conditions that 
worked best are shown in Table 6.3 and the enzyme that proved most successful was 
Kapa Hifi, which was also deployed by Oyola et al., (2012). 
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Table 6.3: PCR amplification/enrichment condition:  This condition was successfully 
used throughout the library preparation experiments. The Kapa HiFi Enzyme was the 
used in this step with success, and was replicated for 3D7, HL1204, HL1212 and 
HL1402 isolates 
 
Cycle step Temp Time Cycles 
Initial denaturation  98ºC 30 seconds 1 
Denaturation 
Annealing 
Extension 
98ºC 
65ºC 
72ºC 
10 seconds 
30 seconds 
30 seconds 
12 
Final extension 72ºC 30 seconds 1 
Hold 4ºC ∞  
 
Only successful amplifications were processed for sequencing. Library dilutions at 
varying concentrations were carried out before whole genome sequencing was done 
because initial sequencing without library dilution also proved unsuccessful. Below is 
a summary table of the steps and trials carried out and detail of the condition which 
worked for sequencing P. falciparum isolates in this study.  
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Table 6.4a: The flow of experiments: The experiment numbers do not exactly reflect the number of repeats carried out at each library 
preparation step before success was achieved. It highlights the flow of experiments and the stages where troubleshooting had to occur before the 
experiments could carry on. At 7, Kappa 2G and Phusion was swapped for Kappa HiFi. At 8, the PCR amplification/enrichment conditions got 
changed. At 9, PCR products were diluted (x10 dilution). 
 
 
Experiment  Library Prep steps 
 DNA extraction 
yield 
DNA 
shearing 
Adaptor ligation  Purification with 
Ampure beads  
PCR 
amplification 
Bioanalyzer Sequencing 
1 x - - - - - - 
2 x x - - - -  
3 x x - - - - - 
4  x - - - - - 
5   x x x x - 
6   x x x x - 
7      Kappa HiFi x - 
8      PCR conditions - 
9        Dilution 
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Table 6.4b: Genes sequenced in all African P. falciparum isolates. The table shows function of each gene and chromosome location. 
Gene  Chromosome  Function  
Pfcrt (chloroquine resistant transporter) 7 Transmembrane transporter 
Pfkelch13 13 Protein binding 
Pfmrp2 (multidrug resistance-associated protein 2) 12 Transmembrane transporter 
Pfmdr1 (multidrug resistance protein 1) 5 Transmembrane transporter 
Pfubp1 (ubiquitin carboxyl-terminal hydrolase 1) 1 Ubiquitinyl hydrolase activity 
Pfap2mu (clathrin vesicle-associated adaptor 2) 12 Vesicle-mediated transport 
Pfnhe1 (sodium/hydrogen exchanger) 13 Sodium ion transport 
Pfatpase6 (calcium-transporting ATPase) 1 Calcium ion transport 
Pf26s-protsu (26S proteasome regulatory subunit ) 14 Endopeptidase activity 
Pfatpase4 (non-SERCA-type Ca2+ -transporting P-ATPase ) 12 Hydrogen ion transmembrane transporter activity  
Pfmrp1 (multidrug resistance-associated protein 2) 1 Transmembrane transporter 
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6.3.3 Summary statistic of sequence data 
 
The quality of reads achieved for all African isolates sequenced was analysed for read length, 
paired end reads and reads mapped against the 3D7 reference. The data summary is shown in 
Table 6.4b 
 
Table 6.4c: Summary of sequence data for isolates HL1204, HL1210 and HL1212. 
Isolate Read length PE reads Reads mapped against reference 
HL1204: 200 829,157 84.40% 
HL1210: 200 5,398,716 84.50% 
HL1212: 200 11,334,878 61.10% 
PE = paired end, reads were mapped against the 3D7 reference. 
 
 
6.3.4 Isolate from Liberia 
 
A new isolate from Liberia was added to the analysis carried out in this Chapter. The isolate 
was from a patient who presented with P. falciparum malaria at the Hospital for Tropical 
Diseases in London after an initial treatment in Liberia with artemether-lumenfantrine. The 
patient was successfully treated with atovaquone-proguanil.  
Whole genome sequencing of the isolate before and after treatment with atovaquone-
proguanil was carried out by the Sanger Institute while the data analysis for this isolate was 
carried out as part of this chapter of this thesis. Genome analysis was carried out looking at 
single nucleotide polymorphisms present in 11 candidate genes of interest, associated with 
artemisinin resistance. The mutations present before and after treatment were described and 
presented in the appendix section.
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6.3.5 Data Analysis 
 
Analysis of whole sequencing data was carried out using both tablet software, which facilitated the visualisation of SNP and Geneious software 
as described in the Methods section in Chapter 3.10. 
 
Figure 6.2: showing a pairwise alignment of the 3D7 pfcrt gene and the HL1210 (Ghana) pfcrt gene. The arrow shows mutations at position 72-
76 which corresponds to change in amino acid from CVMNK to CVIET.  
3D7 
PfCRT 
Ref 
HL1210 
PfCRT 
gene 
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PfCRT 74-76 140 220 239-244 269 297 368 
3D7 MNK S A KIDILR L S D 
Hl1210 IET S S EIFILM L S D 
HL1212 MNK S A KIDILR L L D 
HL1204 MNK S A KIDILR L S D 
Lib IET H A KIDILR E S I 
 
PfMDR1 86 184 
3D7 N Y 
Hl1210 Y F 
HL1212 N F 
HL1204 N F 
Lib N F 
 
PfMRP2 199 578 583 630 714 796 798 940 1395 1531 1643 1910 
3D7 L N N D K S R R L L A N 
Hl1210 L D S D K S A R I L A D 
HL1212 V N N D K A R R L I A N 
HL1204 L N N D K S R S I L A D 
Lib V N N N I S R R L L V N 
 
 
Table 6.5: Whole genome sequencing data from all P. falciparum isolates showing single nucleotide polymorphisms (SNPs) present in genes 
pfcrt, pfmdr1 and pfmrp2. The variant frequency shows the percentage of the SNPs present relative to the coverage at that position. 
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6.4 Polymorphisms in HL1210 isolate 
 
Whole genome sequencing data for HL1210 isolate is shown in Tables 6.5, 6.6 and 6.8. 
HL1210 has the pfcrt mutation CVIET at positions 74-76, which is known to confer 
resistance to chloroquine. Other observed mutations in the pfcrt gene include mutation in 
position A220S which have been described in studies done in Ghana, Senegal, Mali, Burkina 
Faso (West Africa), Kenya, Malawi (East Africa), Thailand, Cambodia, Vietnam (Southeast 
Asia) and Papua New Guinea (Preston et al., 2012). Other mutations found in the pfcrt gene 
of the HL1210 isolate include mutations at positions K239E, D241F, and R244M. These 
mutations are novel and not been described in any published studies. 
Mutations observed in pfmdr1 include an amino acid change of asparagine to tyrosine at 
positions 86, and tyrosine to phenylalanine at position 184. There were 5 non-synonymous 
mutations found in pfmrp2 gene of HL1210 which have not been described in any published 
work to date. The mutations are N578D, N583S, R798A, L1395I and N1910D (Table 6.5). 
Various non-synonymous mutations were found in the Pfubp1 gene and none have been 
described in any published work to date (Appendix III, Table 4 & 5). Similarly, mutations in 
Pfnhe1 for HL1210 were also found at positions L415R, N621F, and D1022P, and none have 
been described previously.  
Non synonymous mutations were found in the pfap2mu gene with a mutation at position 336 
from asparagine to serine. More so, one mutation was observed in the pfatpase 6 gene at 
position E424Y and another mutation in the pf26s-protsu gene at position K529A (Table 6.6, 
6.8). These mutations are novel. No mutations in pfk13, Pfmrp1, Pfmrp2 and Pfatpase4 were 
observed in the HL1210 isolate
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PfNHE1 415 494 621 950 1022 1362 1366 1380 
3D7 L L N V D N K K 
Hl1210 R L F V P N K K 
HL1212 L I N V D N K K 
HL1204 L L N V D N K K 
Lib L L N G D H N N 
 
AP2MU 336 
3D7 N 
Hl1210 S 
HL1212 N 
HL1204 N 
Lib N 
 
ATPASE6 424 431 
3D7 E E 
Hl1210 Y E 
HL1212 E E 
HL1204 E E 
Lib E K 
 
Table 6.6: Whole genome sequence data from all P. falciparum isolates showing SNPs present in genes pfnhe, pfap2mu and pfatpase6.  Genes 
in all African isolates were compared to a 3D7 reference. 
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6.5 Polymorphisms in HL1212 isolate 
 
Whole genome sequencing data for HL1212 isolate are shown in Tables 6.5, 6.6 and 6.8. 
While HL1212 is wild type at positions 72-76 (CVMNK) in the Pfcrt gene, it has a mutation 
at position 297 with amino acid change from valine to leucine. This non synonymous 
mutation has not been described in any published work till date.  
Mutations in the multi-drug resistant protein 2 of HL1212 show non-synonymous mutations 
that have been reported in various other studies. These mutations are L199V, S796A and 
L1531I and were present in the HL1212 isolate with 100% variant frequency. Mutations in 
the Pfmdr1 gene of HL1212 also showed a non-synonymous mutation at position 184, with 
an amino acid change from tyrosine to phenylalanine (Y184F). This mutation gives the 
NFSND mutation in Pfmdr1.  
Analysis of the Pf26-protsu gene showed a non-synonymous mutation present at position 533 
with an amino acid change from tryptophan to alanine (Table 6.8). This mutation has not 
been described in any published work. One non-synonymous mutation was observed in Pfnhe 
gene at position 494 with an amino acid change from leucine to isoleucine with a 100% 
variant frequency (Table 6.6). 
Analysis of the pfUbp1 showed the most variation compared to all other genes of interest 
analysed in this study. All of the identified mutations have not been described in any 
published work till date (Appendix III, Table 8 & 9). However, the HL1212 ubp1 gene shares 
some similar mutations as the HL1210 pfubp1 mutations shown in the Appendix section. 
No SNPs were observed in genes Pfk13, pfmrp1, Pfatpase4, Pfatpase6 and Pfap2mu of the 
HL1212 isolate. However, there were many nucleotide variations present.
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Mitochondria 
      Position Ref amino acid Mutation Change Gene SYN/NONSYN 
772 TTA L CTA LEUCINE (L) 
Cox 
gene SYN 
 
 
 
Apicoplast 
     
 
 
     412 GGT G-Glycine AGT Serine (S) 
 
NON SYN 
431 TGT C-Cysteine TAT Tyrosine (Y) 
 
NON SYN 
10603 CAA Q-Glutamine AAA Lysine (K) 
 
NON SYN 
20427 TTA L-leucine TTG Leucine (L) 
 
SYN 
 
Table 6.7: Mutations present in the mitochondrial and Apicoplast genome of HL1212 isolate 
shows the presence of 3 non-synonymous mutations present at positions 412, 431 and 10603. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
174 
 
6.6 Polymorphisms in HL1204 isolate 
 
The HL1204 isolate (Kenya) had wild-type alleles at positions 72-76 for the Pfcrt gene 
(CVMNK). Also this isolate possessed no mutation in the Kelch propeller region of P. 
falciparum. It was also wild-type for SNPs in Pfap2mu and pf26s-protsu genes. However, 
HL1204 did have 3 non-synonymous mutations in MRP2 gene (Table 6.5) which have not 
been described in any published work. For mutations in the Pfmdr1 gene, HL1204 contains 
the NFSND mutation with a SNP which changes from tyrosine to phenylalaline at position 
184. The Pfubp1 gene contained low numbers of insertions/deletions, and these have been 
listed in appendix section. 
 
PfK13 112 580 539 
3D7 G C R 
Hl1210 G C R 
HL1212 G C R 
HL1204 G C R 
Lib E C R 
   
 
 
 
 
 
PfATPASE4 1045 1081 
 3D7 N Q 
 Hl1210 N Q 
 HL1212 N Q 
 HL1204 N Q 
 Lib K K 
  
Pf26s-
PROTSU 529 533-534 711 
3D7 K WE K 
Hl1210 A WE K 
HL1212 K AE K 
HL1204 K WE K 
Lib K WA R 
 
Table 6.8: Observed non-synonymous mutations in the pfk13, pfatpase4 and pf26s-protsu 
gene in all P. falciparum African isolates. The pfubp1 genes for all isolates sequenced 
contains SNPs and insertions and deletions and can be found in the appendix section. 
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Isolate  
Mean  
DHAEC50(nm) ΔT0-T4 pfk13a pfcrtb pfmdr1c pfap2mud pfubp1 
pf26s-
protsu mrp2 
1 HL1204 2.4 1.2 wt CVMNK NFSND wt multiple wt 
 
multiple 
2 HL1210 12 1.6 wt CVIET YFSND N336S multiple K529A 
 
multiple 
3 HL1212 23 19.2 wt 
CVMNK 
  V297L NFSND wt multiple W533A multiple 
 
Table 6.9: Phenotypic and genetic information of isolates HL1204, HL1210 and HL1212  
a. Nomenclature used shows wild-type (reference) amino acid encoded at the codon of interest.  
b. Nomenclature used shows single letter amino acid code for codons 72-76 which is associated with chloroquine resistance 
c. Mutations in pfmdr1 locus correspond to changes at codon 86, 184, 1246 (NFD) 
d. Nomenclature used shows wild-type  amino acid encoded at the codon of interest, followed by amino acid encoded by the variant observed 
e. Multiple: refers to the presence of various mutations in the gene of interest. 
f. The shaded regions show the isolates which show the biggest difference in both phenotypic and genotypic information.
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Polymorphisms in the isolate from Liberia 
Before treatment with atovaquone-proguanil (after initial treatment with artemether-
lumefantrine), the isolate from Liberia had the CVIET mutation indicative of resistance to 
chloroquine. Other mutations present in Pfcrt were S140H, L269E and D368I. After 
treatment with atovaquone-proguanil, all these mutations described were not detected and the 
isolate harboured the chloroquine wild-type haplotype, CVMNK. 
The Liberian isolate harboured a G112E mutation in the Pfk13 locus which was also present 
after treatment atovaquone-proguanil. An insertion was observed in the ap2mu gene at 
position 233 (N233k), which was not present after treatment. One SNP in the Pfatpase6 gene 
was found before and after treatment (E431K) while 2 SNPs were found in the atpase4 gene 
(Q1081K and N1045K). Numerous SNPs were found in the ubp1 gene (appendix III, Table 
11), which were also present after treatment with atovaquone-proguanil. New mutations were 
also detected in the ubp1 gene after treatment and these are listed in the appendix. 
The pf26s-protsu gene had 2 non-synonymous mutations which were also detected after 
treatment with atovaquone-proguanil (E534A, K711R). 
Twelve SNPs were found in the mrp2 gene, four of which were present after treatment. These 
are the A1643V, K714I, D630N and L199V mutation. Nine mutations were found in the 
Pfnhe1 gene before treatment, four of which were detected after treatment (appendix III, 
Table 13). 
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6.7 Comparison of genetic information for HL1204 and HL1212 
 
HL1204 and HL1212 isolates showed the biggest difference in mean DHA EC50 in both 
Chapters 4 and 5. A comparison of mutations present in selected genes of interest was 
performed to assess if both isolates differed and to what extent. The graphs show binary data 
generated for the presence of a mutation (mutant) or the absence of a mutation (wild-type). 
 
 
 
Figure 6.2: Histogram showing the presence or absence of a mutation in selected genes of interests. 
Binary data was generated (wild-type =1, mutant=2) to identify the types of mutations present in both 
HL1204 and HL1212.  HL1212 contains CNMNK and a mutation in S297L. The Y-axis represents 
binary data that denotes wildtype =1, mutant =2. 
HL1204 
pfk13
pfcrt
pfmdr1
pfap2mu
pfubp1
pf26s-protsu
mrp2
 Mutant              Wildtype 
S297L 
HL1212 
pfk13
pfcrt
pfmdr1
pfap2mu
pfubp1
pf26s-protsu
mrp2
Mutant             Wildtype  
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Figure 6.3: Global sequence diversity in pfmrp2 gene across genome sequences from P. falciparum isolates mapped to 3D7 reference genome 
(Preston et al, 2014). Coloured bars at any chromosome position (horizontal axis) denote a nonreference substitution at that residue in the 
relevant isolate (vertical axis). Mutations at codon L199V, S796A and L1531I are highlighted using red arrows. These non-synonymous 
mutations are present in the HL1212 isolate from Nigeria.
L199V 
S796A 
L153
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6.8 Discussion 
 
This chapter described non-synonymous mutations present in 11 candidate genes associated 
with artemisinin resistance in the African isolates HL1204, HL1210, HL1212 and the added 
P.falciparum line from Liberia. The HL1204 isolate from Kenya had the least amount of 
mutations observed in candidate genes when compared to mutations in HL1210 and HL1212 
isolates. All isolates HL1204, HL1210 and HL1212 were wild-type at the propeller–encoding 
domain of the pfk13 locus, which shows that the phenotypic profiles observed in Chapters 4 
and 5, particularly for HL1212 (Mean EC50 23nM; ΔT0-T4 = 19.2) are independent of 
events in the kelch13 propeller region of the parasite. This result shows that the African 
isolates do not exhibit reduced artemisinin susceptibility as seen in the Greater Mekong 
Region (Ashley et al, 2014; Ariey et al, 2014; Menard et al, 2016) and is consistent with other 
studies which have shown that genetic events in Africa are independent of pfk13 (Menard et 
al, 2016).  
The isolate from Liberia does have a novel pfk13 non-propeller region mutation (Gly112Glu) 
which was present before and after treatment with atovaquone-proguanil. This mutation has 
not been described elsewhere and would require further study. 
Mutations observed in the Pfcrt gene coupled with drug sensitivity assay (Chapter 4) show 
that HL1204 and HL1212 are chloroquine sensitive compared to HL1210 which is resistant 
to chloroquine. However, HL1212 harboured another mutation S297L which has not been 
described in published studies. The CVMNK haplotype has been associated with artemether-
lumefantrine (AL) in Kenya (Humphreys et al, 2007). The presence of a novel mutation 
S297L in HL1212 isolate from Nigeria is a potential concern as certain P.falciaprum 
genotypes at pfcrt have been reported to survive ACT at submicroscopic level and could 
contribute to onward transmission (Henriques et al, 2013). 
Both HL1204 and HL1212 had the NFD mutation at codons 86, 184, and 1246 in the pfmdr1 
locus, which has been shown to be associated with arthemeter-lumefanttrine (AL) failure in 
Kenya and Tanzania (Humphreys et al., 2007; Henriques et al., 2013). None of the isolates 
contained any mutation at codons 1034, 1042 and 1246 of the Pfmdr1 genes. The data shown 
here is consistent with other published research especially for the HL1212 isolate from 
Nigeria (Oladipo et al, 2015). 
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Mutations in pfap2mu that have been described  elsewhere to be associated with artemisinin 
drug resistance were not found in this study, particularly the S160N mutation. However, 
another novel mutation at position 336 with amino acid change from asparagine to serine was 
found in the HL1210 isolate, and a mutation at position N233K (insertion) was found in the 
isolate from Liberia, before and after treatment with atovaquone-proguanil. 
For all African isolates, numerous novel mutations were found in the Pfubp1 gene. Mutations 
in the Pfubp1 gene have also been shown to survive more often after ACT treatment at sub-
microscopic level through directional selection (Henriques et al., 2014). A novel mutation 
was also found in the Pf26s-protsu gene of HL1212 which has not been described in any 
published work to date nor has it been described in the Plasmoview software (Preston et al., 
2014). The Pf26-protsu gene in the Liberian isolate has two novel mutation E534A and 
K711R which were present before and after treatment and these have not been published in 
any study. 
Analysis of the pfmrp2 gene for all isolates showed various non-synonymous mutations. 
While the HL1204 and HL1210 isolates had 5 non-synonymous mutations each in Pfmrp2 
genes which have not been described in any published work, HL1212 had 3 mutations which 
have been described in other studies. The first mutation found was L199V, which has been 
described in West Africa (Gambia, Senegal, Ghana, and Burkina Faso), East Africa (Kenya 
and Malawi), and Southeast Asia (Thailand, Cambodia and Vietnam) and also Papua New 
Guinea (PNG) (Preston et al., 2014). The second and third mutations, S796A and L1531I 
have also been described in countries across West Africa, EastAfrica, Southeast Asia and 
Papau New Guinea (Preston et al., 2014). The isolate from Liberia also has the L199V 
mutation found in HL1212 but the other mutations found before and after treatment with 
atovaquone-proguanil (A1643V, D630N) are novel.  
It was shown that pfmrp2 gene is mostly expressed in the ring stages of P.falciparum (Le 
Roch et al., 2003). Another study has also showed that that drug pressure could induce a 
subpopulation of ring stages into developmental arrest, which can explain artemisinin 
tolerance in P. falciparum (Witkowski et al., 2010). This may be an explanation as to why the 
HL1212 isolate showed a high EC50 value (23nM) and ΔT0-T4 value (19.2nM) that is 
comparable to drug sensitivity values for slow-clearing isolates from Cambodia (Chapter 5). 
While there were numerous SNPs found in the pfubp1 gene in HL1210, HL1212 and the 
Liberian isolate (insertions/deletions in HL1204), none of these have been described in other 
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studies. All isolates were wild-type at codon 1528, identified by Bormann et al., (2013) as 
being associated with in-vitro parasite responses to artemisinin in Kenya. Other mutations in 
pfubp1 found in other studies (Henriques et al., 2014) were also not observed in this study. 
Analysis of Pf26s-protsu in HL1212 from Nigeria showed the presence of a novel gene at 
codon 533, with a change in amino acid from tryptophan to alanine. 
All isolates were polyclonal in nature and exhibited variations at nucleotide positions in the 
candidate genes of interest analysed (Appendix showing the HL1212 pfcrt gene as an 
example). The role these variations at nucleotide positions play with regards to susceptibility 
to DHA needs further study. 
The HL1204 and HL1212 isolates were prioritised in chapter 5, primarily because they had 
thelargest phenotypic differences measured. Direct comparison of whole genome sequence of 
both isolates showed a clear difference in the presence of mutations associated with 
artemisinin drug resistance (Table 6.12 or Figure 6.2).  Whilst the HL1204 isolate was shown 
with the pulse assay to be sensitive to DHA, the H1212 isolate showed a clear reduction in 
sensitivity to DHA (Chapter 5, Table 6.12), again quite comparable to EC50 values shown for 
the slow clearing parasite lines from Cambodia (Cam 3.11
C580Y
, Cam 3.11 
R539T
). 
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6.9 Conclusion 
 
Work done in this thesis has shown that small differences in DHA susceptibility do exist and 
can be measured in-vitro. These differences, especially as shown in HL1212, may be 
mediated by complex multi-locus genotypes as shown in this Chapter, and are definitely not 
associated with variants of the pfkelch13 locus seen in the Greater Mekong region. It is 
therefore important to protect the efficacy of the current front-line ACT by validating 
potential genetic markers, as those shown in this chapter, for monitoring the African parasite 
population. The work done in this chapter could inform future functional studies deploring 
gene editing. 
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CHAPTER 7:  General conclusions and future work
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7.1 General Conclusion 
 
The central aim of this thesis is to identify a scalable assay able to discriminate between 
parasite lines with small differences in artemisinin susceptibility and to identify phenotypes 
relevant to the genetic exploration of artemisinin resistance in African settings.  As a result, 4 
assays (EC50
48h
, EC50
6h
, EC50
6hT0-T4 
and RSA 
0-3h
) were used to determine DHA susceptibility 
of African lines and comparisons were made with artemisinin resistant lines from Cambodia 
to determine which assay best discriminates small differences that exists in DHA sensitivity.  
The work done in Chapter 4 showed that the EC50
6h 
assay was successful in teasing out small 
differences that exists, in DHA sensitivity of African lines HL1204, HL1210, HL1212 and 
HL1402. It also showed that the standard assay EC50
48h
 was not sensitive in discriminating 
the differences in DHA EC50 that exist in these parasite lines.The pulse assay was done as a 
development of this project and so the work done in the next chapter tested this methodology 
and made comparisons using parasite lines from Cambodia (Cam 3.11
wt
, Cam 3.11
C580Y
, Cam 
3.11
R539T
). The key findings in this Chapter are that the EC50
6h
 assay can be used to test 
artemisinin drug sensitivity in Africa. The assay provides an alternative test that is less 
laborious, cheaper and developed specifically for African parasites which face the current 
ACT drug pressure.   
In chapter 5, the EC50
6h
 assay was successful at discriminating small differences in DHA 
susceptibility that exist between parasite lines from Africa but was unsuccessful in doing the 
same for slow clearing Cambodian lines with known artemisinin resistance mutation in pfk13.  
As a result, the assay was adapted taking into account evidence that the early ring stage of 
P.falciparum is associated with drug resistance (Teuscher et al., 2010; Witkowski et al., 
2010). The adapted assay, EC50
6hT0-T4
assay was used to test all parasite lines and this assay 
was successful at discriminating the differences that exists in DHA sensitivity of both lines 
from Africa and Cambodia. The HL1212 isolate showed the most interesting result with 
DHA sensitivity profile similar to the slow clearing Cambodian lines tested even though a 
pfk13 mutation was absent. The ring stage survival assay (RSA) was deployed to compare 
relative DHA susceptibility of African and Cambodian isolates and then see how it compares 
to our other assays. 
 The RSA was successful in estimating percentage parasite survival after DHA exposure in 
the Cambodian lines tested and showed no parasite survival estimates for the African lines.  
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Key findings in this chapter are that the RSA is successful at identifying artemisinin resistant 
parasites and also successful at identifying artemisinin sensitive parasites. Since it gives a 
binary measure, this assay cannot be used to investigate artemisinin resistance over a period 
of time. As a result, the EC50
6hT0-T4
assay is the most sensitive assay that best discriminates the 
DHA sensitivity that exists between all isolates used in this project. This assay can be used as 
a new approach to the in vitro phenotype and can be used as a surveillance tool to contain 
artemisinin resistance especially in the African setting. The ΔT0-T4 assay can also be used to 
check for change in drug sensitivity over a period of time.  
The work done in chapter 6 showed single nucleotide polymorphisms present in 11 chosen 
genes of interest associated with artemisinin resistance. Phenotype data from chapter 4 and 5 
were linked to genotype information analysed in chapter 6, although no strong correlation 
could be made. The presence of novel SNPs in these isolates could be used to inform 
functional studies deploying gene editing, particularly in HL1212 which showed an elevated 
mean EC50 estimate in both the EC50
6h
, and EC50
6hT0-T4
assay. The key findings in this chapter 
are that the small differences in DHA susceptibility may be mediated by complex multi-locus 
genotypes, which are not associated with variants of pfk13 locus seen in the Greater Mekong 
Region. 
 
7.2 Study limitations 
 
The parasite lines used were polyclonal and as a result, variations were observed within and 
between drug assay experiments for the pulse assay (EC50
6h
).  A solution would be to carry 
out limiting dilution cloning on all African lines to separate the clones and then test all clones 
using the assay methods and comparing estimates to the parental lines. 
The format used to carry out the assays employed 1.5ml microcentrifuge tubes. During 
experiments, it was observed that not all parasites may have been exposed to the DHA 
specifically the ones which settle at the bottom of the eppendorf tube. A solution to this 
would be to use a 24 well plate with bigger surface area to ensure all parasite cells get 
adequate DHA exposure. This method is currently being investigated in our lab. 
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7.3 Future work 
 
 Limiting dilution of all parental African lines  
 Testing the assays (EC50
48h
 EC50
6h
, ΔT0-T4 assay, RSA 
0-3h
 on each clone and 
investigating how they compare to the parental line. 
 Carrying out whole genome sequencing of each clone and compare SNPS to parental 
line 
 Using a 24 well plates to optimise the 6 hour pulse assay 
 Deploying functional studies testing some of the novel mutations (in pfmrp2, pfubp1, 
pfap2mu) discovered in chapter 6 and seeing if these allele changes affect the DHA 
susceptibility of the isolate HL1212.  This could be done using zinc-finger nuclease 
(ZFN) - mediated gene editing or the clustered, regularly interspaced, short 
palindromic repeat (CRISPR) technology. Transgenic lines can be generated 
harbouring some of the novel mutation using a laboratory adapted strain. Parasite 
clones which express the variant alleles can then be tested for their susceptibility to a 
panel of antimalarial drugs including artemisinin derivatives (DHA) and partner drug 
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APPENDIX I - 
 
Figure 1: Showing the EC50
6hr
 estimate for KH2 isolate changing with each DHA 6-hour 
pulse assay and 48-hour standard assay. The top graph shows an EC50
6hr
 estimate of 53.6nM, 
which changed to 31.2nM and finally to 23.2nM (bottom graph). These highlight changes 
seen in the KH2 isolate signifying a contamination with an unknown isolate (See Chapter 5). 
-0.50 -0.25 0.00 0.25 0.50 0.75 1.00 1.25 1.50 1.75 2.00 2.25 2.50 2.75 3.00
0
10
20
30
40
50
60
70
80
90
100
6 hour pulse [IC50- 53.6nM] CI (32nM to 90nM)
Graph showing IC50 values of KH2 after a 6 hr and 48hr treatment with DHA
48 hours [IC50 - 7.7nM] CI (7.0nM to 8.5nM)
Log[DHA] (nM)
Pa
ra
sit
e 
pr
ol
ife
ra
tio
n
 (%
 o
f c
on
tr
ol
)
-0.50 -0.25 0.00 0.25 0.50 0.75 1.00 1.25 1.50 1.75 2.00 2.25 2.50 2.75 3.00
0
10
20
30
40
50
60
70
80
90
100
110
120
130
140
150
6 hour pulse [IC50- 31.2nM] CI (22.8nM to 42.7nM)
Graph showing IC50 values of KH2 after a 6 hr and 48hr treatment with DHA
48 hours [IC50 - 6.4nM] CI (5.8nM to 7.0nM)
Log[DHA] (nM)
Pa
ra
sit
e 
pr
ol
ife
ra
tio
n
 (%
 o
f c
on
tr
ol
)
-0.50 -0.25 0.00 0.25 0.50 0.75 1.00 1.25 1.50 1.75 2.00 2.25 2.50 2.75 3.00
0
10
20
30
40
50
60
70
80
90
100
6 hour pulse [IC50- 23.2nM] CI (20.6nM to 26.0nM)
Graph showing IC50 values of KH2 after a 6 hr and 48hr treatment with DHA
48 hours [IC50 - 5.2nM] CI (4.6nM to 5.7nM)
Log[DHA] (nM)
Pa
ra
sit
e 
pr
ol
ife
ra
tio
n
 (%
 o
f c
on
tr
ol
)
 
 
207 
 
 
APPENDIX II - 
 
 
Figure 1: Showing a schematic diagram of the EC50
6hr
 
T0-T4
 assay. The steps are explained in 
Chapter 3 (Methods Chapter).
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APPENDIX III - 
Table 1: Genetic variation present in the HL1212 pfcrt gene.Variant frequency was set at 5% in order to capture variation present in the gene. 
HL1212 is a multiclonal isolate with the number of clones described in Chapter 4 of this thesis. Allele variation was also observed in the other 
African isolates used in this study. This table is used as an example and to highlight this phenomenon is the same for other African isolates. 
Change Min Max Change Coverage 
Polymorphism 
Type 
Reference 
Nucleotide(s) 
Variant 
Frequency Codon position 
A 1,216 1,216 G -> A 34 SNP (transition) G 8.80% 406 
A 1,215 1,215 T -> A 36 SNP (transversion) T 22.20% 405 
G 1,212 1,212 A -> G 46 SNP (transition) A 8.70% 404 
A 1,209 1,209 G -> A 61 SNP (transition) G 19.70% 403 
T 1,206 1,206 A -> T 63 SNP (transversion) A 6.30% 402 
T 1,200 1,200 A -> T 64 SNP (transversion) A 14.10% 400 
G 1,198 1,198 A -> G 62 SNP (transition) A 25.80% 399 
T 1,196 1,196 A -> T 62 SNP (transversion) A 9.70% 398 
T 1,191 1,191 C -> T 44 SNP (transition) C 18.20% 397 
A 1,188 1,188 T -> A 26 SNP (transversion) T 19.20% 396 
A 1,185 1,185 T -> A 23 SNP (transversion) T 34.80% 395 
T 1,184 1,184 A -> T 21 SNP (transversion) A 19.00% 394 
T 1,179 1,179 A -> T 17 SNP (transversion) A 35.30% 393 
A 1,178 1,178 T -> A 17 SNP (transversion) T 23.50% 392 
A 1,173 1,173 C -> A 15 SNP (transversion) C 26.70% 391 
T 1,172 1,172 A -> T 17 SNP (transversion) A 23.50% 390 
A 1,163 1,163 C -> A 13 SNP (transversion) C 30.80% 387 
A 1,161 1,161 T -> A 13 SNP (transversion) T 30.80% 387 
A 1,158 1,158 T -> A 13 SNP (transversion) T 30.80% 386 
T 1,152 1,152 C -> T 15 SNP (transition) C 20.00% 384 
AA 1,146 1,147 TG -> AA 15 Substitution TG 53.30% 382 
G 1,144 1,144 T -> G 15 SNP (transversion) T 53.30% 381 
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Table 2: Genetic variation present in the HL1212 pfcrt gene. Variant frequency was set at 5% in order to capture variation present in the gene. 
HL1212 is a multiclonal isolate with the number of clones described in Chapter 4 of this thesis. Allele variation was also observed in the other 
African isolates used in this study. This table is used as an example and to highlight this phenomenon is the same for other African isolates. 
Change Minimum Maximum Change Coverage Polymorphism Type 
Reference 
Nucleotide(s) 
Variant 
Frequency Codon position 
AA 1,141 1,142 TT -> AA 11 -> 13 Substitution TT 18.2% -> 30.8% 380 
A 1,140 1,140 T -> A 11 SNP (transversion) T 27.30% 380 
GTG 1,137 1,139 AAC -> GTG 13 -> 16 Substitution AAC 30.8% -> 43.8% 379 
ATA 1,133 1,135 TCG -> ATA 16 Substitution TCG 43.80% 377 
ATA 1,129 1,131 GAT -> ATA 16 Substitution GAT 43.80% 376 
A 1,112 1,112 G -> A 18 SNP (transition) G 50.00% 370 
TA 1,108 1,109 GT -> TA 18 Substitution GT 50.00% 369 
GAA 1,104 1,106 TGT -> GAA 19 Substitution TGT 47.40% 368 
G 1,103 1,103 A -> G 21 SNP (transition) A 19.00% 367 
T 1,100 1,100 G -> T 21 SNP (transversion) G 28.60% 366 
TAG 1,096 1,098 GCC -> TAG 21 Substitution GCC 28.60% 365 
ATAC 1,038 1,041 TATT -> ATAC 25 Substitution TATT 16.00% 346 
AA 1,025 1,026 CC -> AA 24 Substitution CC 16.70% 341 
GAATA 1,010 1,014 
TCGAC -> 
GAATA 24 Substitution TCGAC 25.00% 336 
G 1,006 1,006 A -> G 28 SNP (transition) A 21.40% 335 
A 1,002 1,002 C -> A 26 SNP (transversion) C 76.90% 334 
A 999 999 C -> A 24 SNP (transversion) C 16.70% 333 
C 991 991 T -> C 24 SNP (transition) T 33.30% 330 
T 989 989 A -> T 20 SNP (transversion) A 40.00% 329 
T 978 978 C -> T 16 SNP (transition) C 25.00% 326 
T 977 977 A -> T 18 SNP (transversion) A 33.30% 325 
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Table 3: Whole genome sequencing data from P. falciparum isolate HL1210 showing single nucleotide polymorphisms (SNPs) present in genes 
pfcrt, pfmdr1 and pfmrp2. The variant frequency shows the percentage of the SNPs present relative to the coverage at that position. 
  
 
 
Gene Gene ID Chromosome Gene position 
Base 
Change Coverage 
Polymorphism 
Type Variant Frequency Position Mutation 
1 PfCRT MAL7P1.27 7 403,222 to 406,317 GA -> TG 15 Substitution 100.00% 74 M74I 
     
T -> A 15 SNP (transversion) 100.00% 75 N75E 
     
A -> C 15 SNP (transversion) 100.00% 76 K76T 
     
G -> T 29 SNP (transversion) 100.00% 220 A220S 
     
A -> T 24 SNP (transversion) 100.00% 239 K239E 
     
C -> T 24 SNP (transition) 100.00% 241 D241F 
 
    
G -> T 26 SNP (transversion) 100.00% 244 R244M 
2 PfMDR1 PFE1150w 5 957,890 to 962,149 A -> T 45 SNP (transversion) 100.00% 86 N86Y 
  
    
A -> T 40 SNP (transversion) 100.00% 184 Y184F 
3 PfMRP2 PFL1410c 12 1,192,888 to 1,199,214 G-> T 66 SNP (transversion) 100.00% 578 N578D 
     
A->T 64 SNP (transversion) 100.00% 583 N583S 
     
A->G 65 SNP (transition) 100.00% 798 R798A 
     
T-> A 62 SNP (transversion) 100.00% 1395 L1395I 
 
    
G-> C 62 SNP (transversion) 100.00% 1910 N1910D 
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  Gene Gene ID Chromosome Gene position Change Coverage Polymorphism Type Variant Frequency Position Mutation 
4 PfUBP-1 PF3D7_0104300 1 299,759 to 308,804 C -> T 24 SNP (transition) 100.00% 252 H252Y 
     
CT -> TC 28 Substitution 100.00% 258 L258S 
     
G -> A 28 SNP (transition) 100.00% 259 A259T 
     
G -> A 26 SNP (transition) 100.00% 262 V262I 
     
G -> T 26 SNP (transversion) 100.00% 263 C263F 
     
A -> G 22 SNP (transition) 100.00% 2600 K2600E 
     
G -> A 24 SNP (transition) 100.00% 2608 E2608K 
     
A -> G 24 SNP (transition) 100.00% 2613 S2613G 
     
A -> T 24 SNP (transversion) 100.00% 2614 I2614F 
     
T -> G 32 SNP (transversion) 100.00% 2702 I2702R 
     
CA -> AG 34 Substitution 100.00% 2704 H2704S 
     
AC -> GT 42 Substitution 100.00% 2708 T2708V 
     
T -> A 42 SNP (transversion) 100.00% 2709 S2709T 
     
CAA -> 
GTG 42 Substitution 100.00% 2710 S2710C 
     
C -> T 44 SNP (transition) 100.00% 2712 T2712I 
     
C -> G 54 SNP (transversion) 100.00% 2721 H2721D 
     
T -> G 57 SNP (transversion) 100.00% 2723 I2723S 
     
A -> T 57 SNP (transversion) 100.00% 2724 I2724F 
     
G -> A 56 SNP (transition) 100.00% 2735 G2735R 
     
A -> T 63 SNP (transversion) 100.00% 2743 I2743F 
     
T -> A 58 SNP (transversion) 100.00% 2745 I2745F 
     
T -> A 59 SNP (transversion) 100.00% 2752 W2752R 
 
    
T -> A 54 SNP (transversion) 100.00% 2767 S2767T 
 
Table 4: Whole genome sequence data from P.falciparum isolate HL1210 showing single nucleotide polymorphisms (SNPs) present in the 
pfubp1 gene. The variant frequency shows the percentage of the SNPs present relative to the coverage at that position.
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Gene Gene ID Chromosome Gene position Change Coverage Polymorphism Type Variant Frequency Position Mutation 
4 PfUBP-1 PF3D7_0104300  1 299,759 to 308,804 
CGCT -> 
TATA 46 -> 49 Substitution 100.00% 2775 R2775Y 
     
GA -> TT 51 Substitution 100.00% 2781 R2781I 
     
A -> G 51 SNP (transition) 100.00% 2779 Q2779R 
     
G -> A 40 SNP (transition) 100.00% 2794 G2794R 
     
A -> G 32 SNP (transition) 100.00% 2806 E2806K 
     
G -> A 32 SNP (transition) 100.00% 2806 E2806K 
     
C -> T 32 SNP (transition) 100.00% 2805 L2805F 
     
C -> G 25 SNP (transversion) 100.00% 2827 H2827D 
     
TG -> GA 29 Substitution 100.00% 2873 C2873D 
     
CA -> TG 28 Substitution 100.00% 2871 Q2871W 
     
T -> A 25 SNP (transversion) 100.00% 2870 S2870T 
     
G -> A 30 SNP (transition) 100.00% 2886 E2886K 
     
T -> A 31 SNP (transversion) 100.00% 2884 W2884R 
     
CTCT -> 
AAAA 36 -> 37 Substitution 100.00% 2893 L2893K 
     
G -> A 38 SNP (transition) 100.00% 2901 G2901E 
     
T -> A 37 SNP (transversion) 100.00% 2906 Y2906N 
     
C -> A 38 SNP (transversion) 100.00% 2911 Q2911K 
     
T -> C 37 SNP (transition) 100.00% 2925 Y2925H 
     
T -> C 37 SNP (transition) 100.00% 2924 S2924P 
     
CCG -> TAA 40 Substitution 100.00% 2915 P- STOP? 
     
T -> A 24 SNP (transversion) 100.00% 2939 F2939I 
     
G -> A 26 SNP (transition) 100.00% 2938 R2938H 
     
T -> A 29 SNP (transversion) 100.00% 2937 S2937T 
 
    
T -> C 22 SNP (transition) 100.00% 2944 F2944L 
Table 5: Whole genome sequence data from P.falciparum isolate HL1210 showing single nucleotide polymorphisms (SNPs) present in the 
pfub1 gene. The variant frequency shows the percentage of the SNPs present relative to the coverage at that position 
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  Gene Gene ID Chromosome Gene position Change Coverage Polymorphism Type Variant Frequency Position Mutation 
5 pfnhe1 P13_0019 13 169,874 -175789 A->G 66 SNP (transition) 100.00% 415 L415R 
     
A->T 64 SNP (transversion) 100.00% 621 N621F 
     
A->C 68 SNP (transversion) 100.00% 1022 D1022P 
     
T->A 68 SNP (transversion) 100.00% 1773 STOP-R 
  
          6 AP2MU 
 
12 717955-719820 G->C 25 SNP (transversion) 100.00% 336 A336S 
           7 pfatpase6 PFA0310c 1 265,208 to 269,173 A->T 46 SNP (transversion) 100.00% 424 E424Y 
  
    
A->C 34 SNP (transversion) 100.00% 
 
STOP- 
920Y 
           
           
8 
Pf26s-
protsu PF3D7_1466300 14 2,709418-2,713,192 A->C 32 SNP (transversion) 100.00% 529 K529A 
 
Table 6: Whole genome sequencing data from P.falciparum isolate HL1210 showing SNPs present in genes pfnhe, pfap2mu and pfatpase6 and 
pf26s-protsu. 
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  Gene Gene ID Chromosome Gene Position Change Coverage Polymorphism Type 
Variant 
Frequency Mutation 
1 PfMRP2 PFL1410c 12 1,192,888 to 1,199,214 C -> A 25 SNP (transversion) 100.00% L1531I 
     
T -> G 63 SNP (transversion) 100.00% S796A 
     C -> G 80 SNP (transversion) 100.00% L199V 
2 
Pf26s-
Protsu PF3D7_1466300 14 2,709418-2,713,192 A -> C 69 SNP (transversion) 100.00% W533A 
3 PfCRT MAL7P1.27 7 403,222 to 406,317 C -> T 16 SNP (transition) 100.00% V297L 
4 PfMDR1 PFE1150w 5 957,890 to 962,149 A -> T 68 SNP (transversion) 100.00% Y184F 
5 PfNHE P13_0019 13 169,874 -175789 G -> A 76 SNP (transition) 100.00% L494I 
 
Table 7: Whole genome sequencing data from P.falciparum isolate HL1212 showing single nucleotide polymorphisms (SNPs) present in genes 
pfnhe, pfap2mu and pfatpase6 and pf26s-protsu. 
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  Gene Gene ID Chromosome Gene Position Change Coverage Polymorphism Type 
Variant 
Frequency Mutation 
6 PfUBP1 PF3D7_0104300 1 299,759 to 308,804 CCG -> TAA 40 Substitution 100.00% R2915K 
     
TCA -> ATG 40 Substitution 100.00% V2912A 
     
C -> T 38 SNP (transition) 100.00% D2902N 
     
A -> T 50 SNP (transversion) 100.00% Y2790F 
     
GA -> TT 51 Substitution 100.00% E2781L 
     
A -> G 51 SNP (transition) 100.00% K2779E 
     
G -> A 43 SNP (transition) 100.00% G2794R 
     
G -> A 49 SNP (transition) 100.00% E2806K 
     
C -> T 51 SNP (transition) 100.00% L2805F 
     
C -> G 31 SNP (transversion) 100.00% H2827D 
     
TG -> GA 29 Substitution 100.00% C2873D 
     
CA -> TG 39 Substitution 100.00% Q2871W 
     
T -> A 39 SNP (transversion) 100.00% S2870T 
     
G -> A 30 SNP (transition) 100.00% E2886K 
     
T -> A 43 SNP (transversion) 100.00% W2884R 
     
CTCT -> AAAA 36 -> 37 Substitution 100.00% L2893K 
     
G -> A 49 SNP (transition) 100.00% G2901E 
     
T -> A 49 SNP (transversion) 100.00% Y2906N 
     
C -> A 53 SNP (transversion) 100.00% Q2911K 
     
T -> A 24 SNP (transversion) 100.00% F2939I 
     
G -> A 26 SNP (transition) 100.00% R2938H 
     T -> A 29 SNP (transversion) 100.00% S2937T 
 
Table 8: The pfubp1 gene of isolate HL1212 shows multiple non-synonymous SNPs and 5 substitutions at various codon positions 
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6 Gene Gene ID Chromosome Gene Position Change Coverage Polymorphism Type 
Variant 
Frequency Mutation 
 
PfUBP1 PF3D7_0104300 1 299,759 to 308,804 T -> C 22 SNP (transition) 100.00% F2944L 
     
T -> A 53 SNP (transversion) 100.00% I2745F 
     
A -> T 63 SNP (transversion) 100.00% I2743F 
     
G -> A 57 SNP (transition) 100.00% G2735R 
     
A -> T 57 SNP (transversion) 100.00% I2724F 
     
T -> G 57 SNP (transversion) 100.00% I2723S 
     
C -> G 54 SNP (transversion) 100.00% H2721D 
     
C -> T 47 SNP (transition) 100.00% T2712I 
     
CAA -> GTG 42 Substitution 100.00% S2710C 
     
T -> A 42 SNP (transversion) 100.00% S2709T 
     
AC -> GT 42 Substitution 100.00% T2708V 
     
CA -> AG 34 Substitution 100.00% H2704S 
     
T -> G 38 SNP (transversion) 100.00% I2702R 
     
A -> T 34 SNP (transversion) 100.00% I2614F 
     
A -> G 34 SNP (transition) 100.00% S2613G 
     
G -> A 34 SNP (transition) 100.00% E2608K 
     
A -> G 34 SNP (transition) 100.00% K2600E 
     
G -> T 26 SNP (transversion) 100.00% C263F 
     
G -> A 26 SNP (transition) 100.00% V262I 
     
G -> A 28 SNP (transition) 100.00% A259T 
     
CT -> TC 28 Substitution 100.00% L258S 
     C -> T 24 SNP (transition) 100.00% H252Y 
 
Table 9: The pfubp1 gene of isolate HL1212 shows multiple non-synonymous SNPs and 9 substitutions at various codon positions. None of the 
observed mutations have been described in any published studies
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Gene Gene ID Chromosome Gene Position Change Coverage Polymorphism Type 
Variant 
Frequency Mutation 
1 PfMRP2 PFL1410c 12 1,192,888 to 1,199,214 G-> T 54 SNP (transversion) 100.00% Q578D 
     
A -> T 76 SNP (transversion) 100.00% R582S 
     
T -> A 69 SNP (transversion) 100.00% F1395Y 
     
T -> C 85 SNP (transition) 100.00% F1745L 
     
G-> C 65 SNP (transversion) 100.00% Q1910R 
2 PfMDR1 PFE1150w 5 957,890 to 962,149 A -> T 62 SNP (transversion) 100.00% T184F 
          
 
Gene Gene ID Chromosome Gene Position Change Coverage Polymorphism Type 
Variant 
Frequency Position 
3 PfUBP1 PF3D7_0104300 1 299,759 to 308,804 -TG 35 Deletion 100.00% 195 
     
+T 31 Insertion 100.00% 198 
     
-G 30 Deletion 100.00% 190 
     
-TGT 17 Deletion 100.00% 1293 
     
-T 17 Deletion 100.00% 2279 
     
(A)2 -> (A)3 16 
Insertion (tandem 
repeat) 100.00% 1072 
     
-GAGA 16 Deletion 100.00% 
2518-
2519 
     
-TGT 17 Deletion 100.00% 
1292-
1293 
     
-T 17 Deletion 100.00% 2279 
     
(A)2 -> (A)3 16 
Insertion (tandem 
repeat) 100.00% 1072 
          GAGA 16 Deletion 100.00% 
2519-
2520 
 
Table 10: Observed non-synonymous mutations in the pfmrp2 and pfmd1 gene in the HL1204 isolate from Kenya. The pfubp1 gene contains 
insertions and deletions. 
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Gene Gene ID Chromosome Gene position Change Coverage 
Variant 
Frequency 
Position Before treatment 
After 
treatment 
1 Pfcrt  MAL7P1.27 7 403,222 to 406,317 G-> T 18 55.60% 74 M74I wt 
     
AT-> GA 17 53.00% 75 N75E wt 
     
A-> C 17 58.80% 76 K76T wt 
     
G-> C 11 45.50% 140 Q140H wt 
     
C-> G 23 43.50% 269 Q269E wt 
     G-> T 30 60.00% 368 R368I wt 
2 PK13  pf3d7_1343700 13 1,724,817-1,726,997 C-> T 49 91.80% 112 G112E G112E 
3 ap2mu   12 717955-719820 T-> A 43 11.60% 233 insertion- N233K wt 
4 pfatpase6 
 
1 265208-269173 A-> T 67 100% 898 I898 (syn) I898 (syn) 
         C-> T 89 100% 431 E431K (syn) E431K 
5 atpase4   12 528999-532792 C-> T 86 50.00% 1128 G1128R wt 
     
G-> T 90 67.78 1081 Q1081K Q1081K 
     A-> C 95 53.68 1045 N1045K N1045K 
 
Table 11: Whole genome sequencing data from P.falciparum isolate Liberia showing single nucleotide polymorphisms (SNPs) present in genes 
Pfcrt, Pfk13, Pfap2mu, Pfatpase6, and Pfatpase4. The variant frequency shows the percentage of the SNPs present relative to the coverage at 
that position. Before treatment and after treatment refers to treatment with atovaquone- proguanil (section 6.3.4) 
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Mutation Mutations New mutations  
6 
Gene Gene ID Chromosome Change Coverage 
Variant 
Frequency 
Position  before treatment 
after 
treatment 
after treatment 
 
pfubp1  PF3D7_0104300 
 
A-> G 93 20.40% 789 N789D N789D N754K 
    
T-> C 90 74.40% 793 D793 (syn) D793 (syn) K779N 
    
G-> A 93 47.30% 795 D795N D795N Q841K 
    
A-> G 85 51.80% 798 N798D N798D N1375K 
    
C-> T 60 45.00% 904 S904 (syn) S904 (syn) K1914N 
    
A-> T 64 40.60% 906 K906N K906N E1915K 
    
G-> C 70 51.40% 1133 R1133S R1133S R2238K 
    
A-> G 60 26.70% 1710 N1710S wt 
 
    
T-> C 25 48% 2236 L2236 (syn) L2236 (syn) 
 
    
G-> A 10 50.00% 3121 V3121I V3121I 
     T-> G 85 64.70% 2817 N2817K N2817K  
7 
pf26-
protsu PF3D7_1466300 
 
C-> T 51 17.60% 427 N427 (syn) wt 
 
    
T-> A 20 25.00% 789 L783 (syn) wt 
 
    
A-> C 78 100% 534 E534A E534A 
     A->G 104 48.08% 711 K711R K711R  
 
Table 12: Whole genome sequencing data from P.falciparum isolate Liberia showing single nucleotide polymorphisms (SNPs) present in genes 
Pfubp1 and Pf26-protsu. The variant frequency shows the percentage of the SNPs present relative to the coverage at that position. Before 
treatment and after treatment refers to treatment with atovaquone- proguanil (section 6.3.4) and new mutations listed show mutations that were 
not present before or after treatment. 
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Mutations  Mutations 
  
Gene Gene ID Chromosome Gene position Change Coverage 
Variant 
Frequency 
Position 
 before 
treatment 
after 
treatment 
8 Pfmrp2 PFL1410c 12 
1,192,888 to 
1,199,214 G-> A 82 46.34% 1643 A1643V A1643V 
     
G-> T 63 27.00% 1531 L1531I wt 
     
A-> T 64 31.25% 1527 S1527T wt 
     
C-> T 36 19.40% 1192 D1192N wt 
     
C-> T 40 22.50% 1188 D1188N wt 
     
C-> T 89 25.80% 1184 D1184N wt 
     
A-> G 73 93.20% 1169 N1169 (syn) N1169 (syn) 
     
T-> A 98 75.51% 714 K714I K714I 
     
T-> C 32 71.86% 646 N646D wt 
     
T-> C 90 27.70% 634 D634 (syn) D634 (syn) 
     
C-> T 32 53.13% 630 D630N Wt 
     
T-> C 85 18.82% 631 D631G Wt 
     
C-> T 84 15.47% 630 D630N D630N 
     G-> C 70 74.30% 199 L199V L199V 
 
       
   
 
Table 13: Whole genome sequencing data from P.falciparum isolate Liberia showing single nucleotide polymorphisms (SNPs) present in the 
pfmrp2 gene.The variant frequency shows the percentage of the SNPs present relative to the coverage at that position. Before treatment and after 
treatment refers to treatment with atovaquone- proguanil (section 6.3.4) 
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Table 14: Whole genome sequencing data from P.falciparum isolate Liberia showing single nucleotide polymorphisms (SNPs) present in the 
pfnhe1 gene.The variant frequency shows the percentage of the SNPs present relative to the coverage at that position. Before treatment and after 
treatment refers to treatment with atovaquone- proguanil (section 6.3.4) 
 
 
         
Mutations  Mutations 
  
Gene Gene ID Chromosome Gene position Change Coverage 
Variant 
Frequency 
Position 
 before 
treatment 
after 
treatment 
9 Pfnhe1 
 
13 169,874-175,789 C-> A 78 70.50% 1380 K1380N K1380N 
     
G-> T 75 44% 1375 H1375N absent 
     
C-> G 76 56.60% 1366 K1366N K1366N 
     
T-> G 77 26.00% 1362 N1362H N1362H 
     
G-> A 76 29.00% 1361 N1361 (syn) wt 
     
C-> G 21 47.62% 1168 E1168Q wt 
     
C-> T 21 19.05% 1168 E1168K wt 
     
T-> C 21 33.33% 1166 K1166E wt 
     
C-> T 17 53.00% 1162 R1162K wt 
     
C-> T 13 30.77% 1159 K1159 (syn) wt 
     
G-> A 63 85.70% 1139 S1139 (syn) S1139 (syn) 
     A-> C 70 100% 950 V950G V950G 
